MCID: HDR003
MIFTS: 50

Hidradenitis

Categories: Endocrine diseases, Skin diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hidradenitis

MalaCards integrated aliases for Hidradenitis:

Name: Hidradenitis 11 43 14 71 75
Hydradenitis 11

Classifications:



External Ids:

Disease Ontology 11 DOID:2282
ICD9CM 34 705.83
MeSH 43 D016575
NCIt 49 C112190
SNOMED-CT 68 267866004
UMLS 71 C0085160

Summaries for Hidradenitis

Disease Ontology: 11 A sweat gland disease that is characterized by inflammation of the apocrine sweat glands and has symptom erythema, edema, papules, plaques, pruritis, and pain.

MalaCards based summary: Hidradenitis, also known as hydradenitis, is related to pyogenic sterile arthritis, pyoderma gangrenosum, and acne and dowling-degos disease, and has symptoms including erythema An important gene associated with Hidradenitis is NCSTN (Nicastrin), and among its related pathways/superpathways are ERK Signaling and Disease. The drugs Triamcinolone and Anesthetics have been mentioned in the context of this disorder. Affiliated tissues include skin, neutrophil and liver, and related phenotypes are no effect and no effect

Wikipedia: 75 Hidradenitis is any disease in which the histologic abnormality is primarily an inflammatory infiltrate... more...

Related Diseases for Hidradenitis

Diseases related to Hidradenitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 901)
# Related Disease Score Top Affiliating Genes
1 pyogenic sterile arthritis, pyoderma gangrenosum, and acne 31.7 PSTPIP1 NLRP3 MEFV IL1B
2 dowling-degos disease 31.1 PSENEN PSEN1 NCSTN
3 inflammatory bowel disease 1 31.0 TNF NOD2 IL1B IL17A
4 folliculitis 31.0 TNF IL17A IFNG
5 spondyloarthropathy 1 30.9 TNF NOD2 IL1B IL17A CRP
6 pyoderma gangrenosum 30.9 TNF PSTPIP1 NOD2 NLRP3 MEFV IL1B
7 cellulitis 30.7 TNF IL1B IL17A CRP CAMP
8 alopecia 30.6 TNF IL1B IL17A IFNG
9 chronic ulcer of skin 30.6 TNF IL1B CRP
10 synovitis 30.5 TNF IL1B IL1A CRP
11 hidradenitis suppurativa 30.5 TNF S100A7 PSTPIP1 PSENEN PSEN1 NOD2
12 sapho syndrome 30.5 TNF PSTPIP1 NOD2 IL17A CRP
13 serum amyloid a amyloidosis 30.5 TNF NLRP3 MEFV CRP
14 arthropathy 30.5 TNF NOD2 NLRP3 IL1B CRP
15 reactive arthritis 30.5 TNF IL17A CRP
16 acne 30.5 TNF S100A7 PSTPIP1 PSENEN PSEN1 NLRP3
17 autoinflammatory syndrome 30.5 NOD2 NLRP3 MEFV
18 amyloidosis 30.5 TNF PSEN1 NLRP3 MEFV IL1B CRP
19 crohn's disease 30.4 TNF NOD2 NLRP3 IL26 IL1B IL17A
20 keratitis, hereditary 30.4 TNF NLRP3 IL1B IL17A GJB2
21 ulcerative colitis 30.4 TNF NOD2 IL1B IL17A IFNG CRP
22 osteoarthritis 30.4 TNF IL1B IL1A IL17A CRP
23 covid-19 30.4 TNF NLRP3 IL1B CRP
24 psoriasis 30.3 TNF S100A7 NOD2 IL1B IL1A IL17A
25 psoriatic arthritis 30.3 TNF NOD2 IL1B IL1A IL17A CRP
26 pyoderma 30.3 TNF PSTPIP1 NOD2 NLRP3 MEFV IL1B
27 fibromyalgia 30.3 TNF IL1B CRP
28 spondylitis 30.3 TNF NOD2 IL1B IL17A IFNG CRP
29 substance abuse 30.2 TNF IL1B CRP
30 rosacea 30.2 TNF IL1B IL17A CRP CAMP
31 histiocytosis 30.2 TNF IL17A IFNG
32 interstitial keratitis 30.2 TNF CRP
33 alopecia areata 30.2 TNF IL1B IL1A IL17A IFNG
34 irritable bowel syndrome 30.2 TNF IL1B IL17A CRP
35 fatty liver disease 30.2 TNF IL1B IL1A CRP
36 exanthem 30.2 TNF NLRP3 IL1B IL17A IFNG CRP
37 pityriasis rubra pilaris 30.2 TNF PSTPIP1 IL17A
38 erythema nodosum 30.1 TNF NOD2 IL1B IL1A IFNG CRP
39 apnea, obstructive sleep 30.1 TNF IL1B CRP
40 alcohol use disorder 30.1 TNF IL1B CRP
41 neutrophilic dermatosis, acute febrile 30.1 TNF PSTPIP1 MEFV IL1B IL17A CRP
42 scleritis 30.1 TNF IFNG CRP
43 spondyloarthropathy 30.1 TNF NOD2 MEFV IL1B IL17A IFNG
44 brucellosis 30.1 TNF NLRP3 MEFV IL17A IFNG CRP
45 lymphangioma 30.1 TNF IL1B IL17A IFNG
46 common cold 30.1 TNF IL1B IL17A CRP
47 acquired immunodeficiency syndrome 30.0 TNF IL1B IFNG CRP
48 allergic disease 30.0 TNF IL1B IL17A IFNG
49 vasculitis 30.0 TNF MEFV LCN2 IL1B IL17A CRP
50 pustulosis of palm and sole 30.0 TNF PSTPIP1 IL17A CRP

Graphical network of the top 20 diseases related to Hidradenitis:



Diseases related to Hidradenitis

Symptoms & Phenotypes for Hidradenitis

Symptoms:

11
  • erythema

GenomeRNAi Phenotypes related to Hidradenitis according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.19 CAMP CRP DSG1 GJB2 IFNG IL12RB1
2 no effect GR00402-S-2 10.19 CAMP CRP DSG1 IFNG IL12RB1 IL1A
3 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 10.07 IL17A IL1A IL1B LCN2 NLRP3 TNF
4 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 10.07 IL17A IL1B LCN2 NLRP3 NOD2 PSEN1

MGI Mouse Phenotypes related to Hidradenitis:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.2 CRP DSG1 GJB2 IFNG IL12RB1 IL17A
2 immune system MP:0005387 10.16 CAMP CRP GJB2 IFNG IL12RB1 IL17A
3 skeleton MP:0005390 9.9 DSG1 GJB2 IFNG IL17A IL1B MEFV
4 hematopoietic system MP:0005397 9.83 CAMP DSG1 IFNG IL12RB1 IL17A IL1A
5 integument MP:0010771 9.4 DSG1 GJB2 IFNG IL12RB1 IL17A IL1A

Drugs & Therapeutics for Hidradenitis

Drugs for Hidradenitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 94)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
2 Anesthetics Phase 4
3 Immunologic Factors Phase 4
4 Immunosuppressive Agents Phase 4
5 glucocorticoids Phase 4
6
Triamcinolone hexacetonide Phase 4
7
Triamcinolone diacetate Phase 4
8
Triamcinolone Acetonide Phase 4 6436
9
Metformin Approved Phase 3 1115-70-4, 657-24-9 4091
10
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
11 Hypoglycemic Agents Phase 3
12 Antibiotics, Antitubercular Phase 3
13
Hydroxychloroquine Approved Phase 1, Phase 2 118-42-3 3652
14
Apremilast Approved, Investigational Phase 2 608141-41-9 10151715 11561674
15
Upadacitinib Approved, Investigational Phase 2 1310726-60-3 76829165 58557659
16
Etanercept Approved, Investigational Phase 2 185243-69-0
17
Infliximab Approved Phase 2 170277-31-3
18
Ustekinumab Approved, Investigational Phase 2 815610-63-0
19
Tofacitinib Approved, Investigational Phase 2 477600-75-2 9926791
20
Benzocaine Approved, Investigational Phase 2 1994-09-7, 94-09-7 2337
21
Tannic acid Approved Phase 2 1401-55-4 16129878 16129778
22
Gentian violet cation Approved Phase 2 14426-25-6, 7438-46-2 3468 11057
23
Methylthioninium Approved, Experimental, Investigational Phase 2 61-73-4, 7060-82-4 6099
24
Glycerin Approved, Investigational Phase 2 56-81-5 753
25
Ethinylestradiol Approved Phase 2 57-63-6 5991
26
Estradiol Approved, Investigational, Vet_approved Phase 2 50-28-2 5757
27
Polyestradiol phosphate Approved Phase 2 28014-46-2
28
Drospirenone Approved Phase 2 67392-87-4 68873
29
Glutamic acid Approved, Nutraceutical Phase 2 56-86-0 33032
30
D-Lysine Approved, Experimental, Nutraceutical Phase 2 923-27-3, 56-87-1 57449 5962
31
PF-06700841 Investigational Phase 2 1883299-62-4 118878093
32
Vilobelimab Investigational Phase 2 2250440-41-4
33 Antimalarials Phase 1, Phase 2
34 Antiprotozoal Agents Phase 1, Phase 2
35 Antiparasitic Agents Phase 1, Phase 2
36 Anti-Inflammatory Agents, Non-Steroidal Phase 2
37 Analgesics, Non-Narcotic Phase 2
38 Analgesics Phase 2
39 Phosphodiesterase Inhibitors Phase 2
40 Phosphodiesterase 4 Inhibitors Phase 2
41 Interleukin 1 Receptor Antagonist Protein Phase 2
42 Complement System Proteins Phase 2
43 Gastrointestinal Agents Phase 2
44 Antibodies, Monoclonal Phase 2
45 Antibodies Phase 2
46 Immunoglobulins Phase 2
47 Protein Kinase Inhibitors Phase 2
48 Janus Kinase Inhibitors Phase 2
49 interferons Phase 2
50 Pharmaceutical Solutions Phase 2

Interventional clinical trials:

(show top 50) (show all 150)
# Name Status NCT ID Phase Drugs
1 Cost-effectiveness of Adalimumab With Adjuvant Surgery Versus Adalimumab Monotherapy in the Treatment of Hidradenitis Suppurativa' Unknown status NCT03221621 Phase 4 Adalimumab Injection
2 A Phase 4, Double-blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Safety and Efficacy of Adalimumab Used in Conjunction With Surgery in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02808975 Phase 4 Placebo;Adalimumab
3 Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa Recruiting NCT04582669 Phase 4 Intralesional Triamcinolone 10 mg/mL;Intralesional Triamcinolone 20 mg/mL;Intralesional Triamcinolone 40 mg/mL;Placebo
4 A Randomized, Controlled Trial Comparing the Use of a Biodegradable Temporizing Matrix to Cadaver Skin in the Reconstruction of Hidradenitis Suppurativa Excisions Not yet recruiting NCT05477225 Phase 4
5 Spironolactone in the Treatment of Hidradenitis Suppurativa: A Prospective, Open-Label Proof-of-Concept and Dose-Ranging Study Withdrawn NCT04100083 Phase 4 Spironolactone 50 MG;Spironolactone 100mg;Spironolactone 200 mg
6 Hidradenitis Suppurativa Patients' Experience of Treatment With Adalimumab Withdrawn NCT04132388 Phase 4 Adalimumab
7 A Phase 3 Multicenter, Open-label, Single Arm Study of the Safety and Efficacy of Adalimumab in Japanese Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT02904902 Phase 3 adalimumab
8 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER II Completed NCT01468233 Phase 3
9 A Phase 3 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER I Completed NCT01468207 Phase 3
10 A Randomized, Double-blind, Multi-center Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNSHINE). Completed NCT03713619 Phase 3 secukinumab;Placebo
11 A Randomized, Double-blind, Multicenter Study Assessing Short (16 Weeks) and Long-term Efficacy (up to 1 Year), Safety, and Tolerability of 2 Subcutaneous Secukinumab Dose Regimens in Adult Patients With Moderate to Severe Hidradenitis Suppurativa (SUNRISE) Completed NCT03713632 Phase 3 Secukinumab;Placebo
12 A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension) Completed NCT01635764 Phase 3
13 A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab to Demonstrate Long-term Efficacy, Safety and Tolerability in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT04179175 Phase 3 secukinumab
14 A Single Center Clinical Trial to Evaluate the Effect of Sclerotherapy on Fistulas and Sinus Tracts in Adult Patients With Hidradenitis Suppurativa Recruiting NCT02805595 Phase 3 23.4% Hypertonic saline;Saline
15 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT04242498 Phase 3 Bimekizumab
16 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Active, not recruiting NCT04242446 Phase 3 Bimekizumab
17 A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa Enrolling by invitation NCT04901195 Phase 3 Bimekizumab
18 Rediscovery of Metformin for the Chronic Disabling Auto-inflammatory Disease Hidradenitis Suppurativa Not yet recruiting NCT04649502 Phase 3
19 To Determine The Efficacy Of A 1320nm Nd: YAG Nonablative Laser For Treatment of Hidradenitis Suppurativa Terminated NCT00367328 Phase 3
20 An Open-label Single Center Study to Evaluate the Efficacy of SILIQ™ (Brodalumab) for the Treatment of Moderate Hidradenitis Suppurativa Unknown status NCT03910803 Phase 2 Brodalumab
21 Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. The HiGUS-trial Unknown status NCT04061395 Phase 2
22 Pilot Study of Hydroxychloroquine for the Treatment of Hidradenitis Suppurativa Completed NCT03275870 Phase 1, Phase 2 Hydroxychloroquine
23 A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04019041 Phase 2 bermekimab;placebo
24 Randomized, Double-blind, Placebo-controlled, Study of Spesolimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT04762277 Phase 2 Spesolimab;Placebo
25 Proof of Concept Study on LTX-109 as Treatment for Hidradenitis Suppurativa Completed NCT04756336 Phase 1, Phase 2 LTX-109 gel, 3% w/w
26 A Phase 2, Dose-Escalation, Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03607487 Phase 2 INCB054707;Placebo
27 A Phase 2 Open-label Single Center Study to Evaluate the Efficacy of Apremilast for the Treatment of Moderate Hidradenitis Suppurativa Completed NCT02695212 Phase 2 Apremilast
28 A Double-blind, Randomised, Placebo-controlled Clinical Trial of the Efficacy of MABp1, a- First-in-class True Human Antibody Targeting Interleukin-1alpha, in Patients With Hidradenitis Suppurativa Not Eligible for antiTNF Therapy Completed NCT02643654 Phase 2 MABp1;Placebo
29 Open Label,Phase Two Study to Assess the Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT00827996 Phase 2 adalimumab
30 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT04430855 Phase 2 Upadacitinib;Placebo Upadacitinib
31 An Open Label Non-randomized Study Assessing the Efficacy and Tolerability of Fixed-dose Regimen Daily Subcutaneous Anakinra for the Treatment of Moderate to Severe Hidradenitis Suppurativa Completed NCT01516749 Phase 2 anakinra
32 A Phase II, Open Label Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03512275 Phase 2 Bermekimab Monoclonal Antibody 400 mg
33 A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 2 Study to Evaluate the Safety and Efficacy of Avacopan in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03852472 Phase 2 Avacopan
34 An Open Label Phase II Trial to Evaluate the Safety of IFX-1 in Patients With Moderate to Severe Hidradenitis Suppurativa Completed NCT03001622 Phase 2
35 A Double-blind, Randomized, Placebo-controlled Clinical Trial of the Safety and Efficacy of Anakinra in Patients With Hidradenitis Suppurativa Completed NCT01558375 Phase 2 Water for injection;Anakinra
36 A Phase 2, Open-Label, Single-Arm Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa Completed NCT03569371 Phase 2 INCB054707
37 Short-term Safety, Efficacy and Mode of Action of Apremilast in Moderate Suppurative Hidradenitis: A Randomised Double-blind Placebo Controlled Trial Completed NCT03049267 Phase 2 Apremilast;Placebo Oral Tablet
38 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety and Efficacy of Risankizumab in Adult Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03926169 Phase 2 Risankizumab;Placebo for risankizumab
39 A Phase 2 Study of the Safety and Efficacy of Etanercept for the Therapy of Hydradenitis Suppurativa Completed NCT00329823 Phase 2 Etanercept sc 50mg per week for 12 weeks
40 A Phase 2 Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa Completed NCT00918255 Phase 2 Placebo
41 A PHASE 2A, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, 16-WEEK STUDY EVALUATING THE SAFETY AND EFFICACY OF PF-06650833, PF-06700841, AND PF-06826647 IN ADULTS WITH MODERATE TO SEVERE HIDRADENITIS SUPPURATIVA Completed NCT04092452 Phase 2 PF-06650833;PF-06700841;PF-06826647;Placebo
42 A Phase II Open Label Clinical Trial of Etanercept for the Treatment of Hidradenitis Suppurativa Completed NCT00107991 Phase 2 etanercept
43 Phase 2 Study to Assess the Safety and Efficacy of Infliximab for the Treatment of Hidradenitis Suppurativa Completed NCT00795574 Phase 2 infliximab;Placebo Comparator
44 A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Proof-of-Concept Study to Evaluate Guselkumab for the Treatment of Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03628924 Phase 2 Guselkumab dose 1;Guselkumab dose 2;Guselkumab dose 3;Placebo
45 A Prospective Proof of Concept Study to Evaluate the Potential Efficacy of Ustekinumab in Patients With Moderate to Severe Hidradenitis Suppurativa (Acne Ectopica) Completed NCT01704534 Phase 2 Ustekinumab
46 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Study to Determine Efficacy and Safety of IFX-1 in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03487276 Phase 2 IFX-1;Placebo
47 A Phase 2 Multicenter, Investigator-Blind, Subject-Blind, Placebo-Controlled Study of the Efficacy, Safety, and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa Completed NCT03248531 Phase 2 Bimekizumab;Adalimumab
48 A Randomized, Double-blind, Placebo Controlled, Multiple Dose Study to Evaluate the Clinical Efficacy, Safety, Tolerability, Dose Relation, Pharmacokinetics and Pharmacodynamics of CJM112 in Moderate to Severe Chronic Hidradenitis Suppurativa Patients Completed NCT02421172 Phase 2 Placebo
49 A Phase 2b Pivotal Study to Evaluate the Efficacy and Safety of Izokibep in Subjects With Moderate to Severe Hidradenitis Suppurativa Recruiting NCT05355805 Phase 2 Izokibep;Placebo to izokibep
50 Exploratory Trial of Ruxolitinib 1.5% Cream for the Treatment of Early Stage Hidradenitis Suppurativa Recruiting NCT04414514 Phase 2 Ruxolitinib 1.5% Cream

Search NIH Clinical Center for Hidradenitis

Cochrane evidence based reviews: hidradenitis

Genetic Tests for Hidradenitis

Anatomical Context for Hidradenitis

Organs/tissues related to Hidradenitis:

MalaCards : Skin, Neutrophil, Liver, Myeloid, Breast, Lymph Node, B Cells

Publications for Hidradenitis

Articles related to Hidradenitis:

(showing 4007, show less)
# Title Authors PMID Year
1
Neighborhood-based analysis of adolescent hidradenitis suppurativa prevalence in a large metropolitan area. 62
36248206 2022
2
Association of hidradenitis suppurativa and liver disease: A systematic review and meta-analysis. 62
36248209 2022
3
A survey of dermatologist perspectives on disease management of patients with hidradenitis suppurativa. 62
36237848 2022
4
Systemic immune inflammation index is a marker of cardiovascular risk and not just disease severity in hidradenitis suppurativa. 62
35694838 2022
5
Disseminated tuberculosis following negative QuantiFERON-TB gold tests during infliximab therapy: Implications for screening of hidradenitis suppurativa. 62
36199671 2022
6
Drug Survival of Oral Retinoids in Hidradenitis Suppurativa: A Real-Life Cohort Study. 62
36070059 2022
7
Treating hidradenitis suppurativa patients with adalimumab: a real-life experience of a tertiary care center in Lisboa, Portugal. 62
36100476 2022
8
Office-based surgical treatment of hidradenitis suppurativa: The unroofing technique. 62
33221463 2022
9
Real-World Considerations of Candidacy for Biologics in Hidradenitis Suppurativa. 62
35930133 2022
10
Global geographic bibliometric analysis of hidradenitis suppurativa publications. 62
34658018 2022
11
Massive squamous cell carcinoma arising from hidradenitis suppurativa with marked hypercalcemia and neutrophilia. 62
36186407 2022
12
Comorbid diseases of hidradenitis suppurativa: a 15-year population-based study in Olmsted County, Minnesota, USA. 62
35485975 2022
13
The Skin and Gut Microbiome in Hidradenitis Suppurativa: Current Understanding and Future Considerations for Research and Treatment. 62
36116091 2022
14
Methylated miRNAs may serve as potential biomarkers and therapeutic targets for hidradenitis suppurativa. 62
35921387 2022
15
Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: 'Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa'. 62
35727206 2022
16
Metabolic syndrome and hidradenitis suppurativa: epidemiological, molecular, and therapeutic aspects. 62
34530487 2022
17
Reconstruction of axillary defects with propeller parascapular flap after resection in patients with advanced hidradenitis suppurativa. 62
36219710 2022
18
Racial and ethnic health disparities in dermatology in the United States. Part 2: Disease-specific epidemiology, characteristics, management, and outcomes. 62
35143915 2022
19
Biomarkers of endothelial dysfunction and atherosclerosis in hidradenitis suppurativa. 62
35661237 2022
20
Hidradenitis Suppurativa: Absence of Hyperhidrosis but Presence of a Proinflammatory Signature in Patients' Sweat. 62
36172698 2022
21
Off-label uses of ustekinumab. 62
36208443 2022
22
Evaluation of Risk in Chronic Cutaneous Inflammatory Conditions for Malignant Transformation. 62
36251409 2022
23
Innate Immunity Protein Markers Are Significantly Elevated in Hidradenitis Suppurativa Skin Than in Psoriasis Vulgaris. 62
36168251 2022
24
Intense pulsed light treatment for inflammatory skin diseases: a review. 62
35913536 2022
25
Development and validation of IHS4-55, an IHS4 dichotomous outcome to assess treatment effect for hidradenitis suppurativa. 62
36184889 2022
26
Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on 'Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?' 62
35699658 2022
27
Long-term secukinumab efficacy in patients with moderate to severe hidradenitis suppurativa: A retrospective single centre case series (23 patients). 62
36268711 2022
28
Step by step surgery for Hidradenitis Suppurativa. 62
36239203 2022
29
Retrospective Cohort Study on Asian Patients with Hidradenitis Suppurativa: Factors Associated with the Efficacy of Antibiotic Treatment. 62
36172700 2022
30
A Practical Guide for Primary Care Providers on Timely Diagnosis and Comprehensive Care Strategies for Hidradenitis Suppurativa. 62
36252715 2022
31
Our Experience in Using Lateral Chest Flap to Treat Axillary Hidradenitis Suppurativa. 62
36246081 2022
32
Perceptions of biologic treatment among hidradenitis suppurativa patients on social media: an analysis of content, engagement, and sentiment. 62
36250292 2022
33
Ultrasonographic railway sign in tunnels as a new independent risk factor of adalimumab failure in hidradenitis suppurativa. 62
36206936 2022
34
Tacrolimus ointment may improve the effectiveness of adalimumab in patients with hidradenitis suppurativa: a novel promising treatment. 62
35699642 2022
35
Optimizing hidradenitis suppurativa clinic visits: Patient perspectives. 62
36000014 2022
36
Complications of hidradenitis suppurativa after surgical management: A systematic review and meta-analysis. 62
36207796 2022
37
Prevalence of Hidradenitis Suppurativa in Berekum, Ghana. 62
35257366 2022
38
The road to biologics in patients with hidradenitis suppurativa: a nationwide drug utilization study. 62
35603888 2022
39
Implementing evidence-based strategies to optimize the journey of patients with hidradenitis suppurativa. 62
35972067 2022
40
Successful treatment of hidradenitis suppurativa and Crohn's disease with combined guselkumab and apremilast. 62
35904888 2022
41
Communicating with health providers and romantic partners: The impact of negative emotions on quality of life for individuals with hidradenitis suppurativa. 62
36225613 2022
42
African American race is a risk factor for severe hidradenitis suppurativa. 62
36183313 2022
43
Hidradenitis Suppurativa: Diagnosis and Management in the Emergency Department. 62
36243614 2022
44
IL-17A is a pertinent therapeutic target for moderate-to-severe hidradenitis suppurativa: Combined results from a pre-clinical and phase II proof-of-concept study. 62
35638561 2022
45
Serum inflammatory markers and leukocyte profiles accurately describe hidradenitis suppurativa disease severity. 62
35543428 2022
46
Infliximab treatment before and after surgery in severe hidradenitis suppurativa: A retrospective study of 10 patients. 62
35738947 2022
47
Effects of the modified excision combined with bidirectional photodynamic therapy on refractory hidradenitis suppurativa: a retrospective study. 62
35389111 2022
48
Trends in the prescribing pattern of spironolactone for acne and hidradenitis suppurativa in adolescents. 62
34896127 2022
49
Topical finasteride: A potential therapeutic option for hidradenitis suppurativa. 62
36114750 2022
50
Hidradenitis suppurativa and suicide risk: a multivariate analysis in a disease with a high psychological burden. 62
36107231 2022
51
Culture-based analyses of skin bacteria in lesional moist, and unaffected dry and sebaceous skin regions of hidradenitis suppurativa patients. 62
35642981 2022
52
Metastatic adenocarcinoma mimicking hidradenitis suppurativa. 62
36039336 2022
53
Erythrocyte sedimentation rate, rather than C-reactive protein, may be the preferred biomarker for hidradenitis suppurativa. 62
35620323 2022
54
Hair removal and deodorants in hidradenitis suppurativa: An online survey on patients' habits. 62
36083700 2022
55
Cytochrome P450 genes mediated by DNA methylation are involved in the resistance to hidradenitis suppurativa. 62
36155054 2022
56
Alexandrite laser as an adjuvant therapy in the management of mild to moderate hidradenitis suppurativa: A controlled prospective clinical study. 62
34774922 2022
57
A complication in a patient with hidradenitis suppurativa taking adalimumab. 62
36051225 2022
58
Intralesional steroid injections to target sinus tract fibrosis in hidradenitis suppurativa: Results from an ultrasound-based retrospective study. 62
35811390 2022
59
Measuring Quality of Life in Hidradenitis Suppurativa: Development and Validation of a Disease-specific Patient-reported Outcome Measure for Practice and Research. 62
36129249 2022
60
Can Ultrasound Examinations Generate Pain in Hidradenitis Suppurativa Patients? Results from a Multicentric Cross-Sectional Study. 62
36122570 2022
61
Five-Year Remission of Hidradenitis Suppurativa Following the Removal of a Levonorgestrel Intrauterine Device and Disease Overview for Obstetrics and Gynecology Providers. 62
36105898 2022
62
Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies. 62
35347705 2022
63
Practical Guidelines for Managing Patients With Hidradenitis Suppurativa: An Update. 62
36000460 2022
64
Understanding the systemic burden of disease in hidradenitis suppurativa from plasma lipidomic analysis. 62
36008225 2022
65
Paradoxical psoriasiform reactions during treatment with adalimumab for hidradenitis suppurativa: Real-life experience and therapeutic response to other biological drugs. 62
36175129 2022
66
Hidradenitis suppurativa. 62
36179144 2022
67
Cigarette smoking precedes the onset of hidradenitis suppurativa. 62
35090045 2022
68
Characterizing the immune checkpoint marker profiles of cutaneous squamous cell carcinomas in patients with hidradenitis suppurativa. 62
36151986 2022
69
Damage in hidradenitis suppurativa: receiving the deserved attention. 62
35508388 2022
70
Unmet clinical needs and burden of disease in hidradenitis suppurativa: real-world experience from EU5 and US. 62
35445469 2022
71
Efficacy and Safety of Risankizumab in Hidradenitis Suppurativa: A Case Series. 62
35971829 2022
72
Hidradenitis suppurativa: a review of current treatment options. 62
35128643 2022
73
Clinical and Epidemiological Characteristics of Hidradenitis Suppurativa Patients with Paradoxical Psoriasiform Reactions following Treatment with Adalimumab. 62
36161088 2022
74
Disease association of anti-CEL autoantibodies in hidradenitis suppurativa. 62
36116506 2022
75
Long-term risk of death in patients with hidradenitis suppurativa. 62
36097962 2022
76
Registries, multicentre and genome-wide association studies in hidradenitis suppurativa. 62
35582836 2022
77
Biomarkers of tissue turnover and systemic inflammation are associated with disease severity and activity in patients with hidradenitis suppurativa. 62
36108804 2022
78
Demographic Gaps and Requirements for Participation: A Systematic Review of Clinical Trial Designs in Hidradenitis Suppurativa. 62
36108592 2022
79
11th European Hidradenitis Suppurativa Foundation (EHSF) e.V. Conference - Innovating the HS future. 62
36059188 2022
80
Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: What's beyond cost-effectiveness? 62
36062429 2022
81
High-dose, high-frequency ustekinumab therapy for patients with severe hidradenitis suppurativa. 62
35192196 2022
82
Closing a gap: an investigator global assessment for use in hidradenitis suppurativa clinical trials. 62
35799469 2022
83
Decreased Arterial Vascular Tone in Small Arteries in Severe Hidradenitis Suppurativa - A Study Using Finger Photopulseplethysmography. 62
36254547 2022
84
Allergic Contact Dermatitis to Topical Clindamycin in a Patient with Hidradenitis Suppurativa. 62
35971837 2022
85
Outcomes and Reliability of Perforator Flaps in the Reconstruction of Hidradenitis Suppurativa Defects: A Systemic Review and Meta-Analysis. 62
36233681 2022
86
Impact of etiology leading to abdominoperineal resection with anterolateral thigh flap reconstruction: A retrospective cohort study. 62
36112361 2022
87
This Month in JAAD Case Reports: December 2022. Hidradenitis suppurative and malignancy. 62
36152695 2022
88
Infliximab in hidradenitis suppurativa: A systematic review and meta-analysis. 62
35790062 2022
89
Damage in hidradenitis suppurativa: a narrative review emphasizing the need for a novel outcome measure. 62
35104363 2022
90
Identification of clinical features affecting diagnostic delay in paediatric hidradenitis suppurativa: results from a multicentre observational study. 62
35292964 2022
91
New treatments and new assessment instruments for Hidradenitis suppurativa. 62
35582833 2022
92
An Open-Label, Prospective, Pilot Study of Hypertonic Saline for Hidradenitis Suppurativa. 62
36054049 2022
93
A cross-sectional study of pediatric hidradenitis suppurativa and the value of the International Hidradenitis Suppurativa Severity Score System (IHS4) as a pediatric clinical trial inclusion criteria. 62
35766518 2022
94
Reconstruction of the male external genitalia in diverse disease processes: Our reconstructive algorithm, techniques, and experience. 62
36204359 2022
95
Does SAPHO syndrome exist in dermatology? 62
35462435 2022
96
Coexistence of pachyonychia congenita and hidradenitis suppurativa: more than a coincidence. 62
35606927 2022
97
Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab-induced hidradenitis suppurativa and secukinumab-induced alopecia areata. 62
36151938 2022
98
Incidence, prevalence, and predictors of inflammatory arthritis in patients with hidradenitis suppurativa: a systematic review and meta-analysis. 62
34432308 2022
99
Which hidradenitis suppurativa comorbidities should I take into account? 62
35737874 2022
100
Skin and gut microbiota dysbiosis in autoimmune and inflammatory skin diseases. 62
36149040 2022
101
Microbiome in Hidradenitis Suppurativa-What We Know and Where We Are Heading. 62
36232581 2022
102
ALA-iPDT for follicular occlusion tetrad concomitant with pachyonychia congenital type Ⅱ and ankylosing spondylitis. 62
35490959 2022
103
Complete blood collection-based systemic inflammation biomarkers for patients with hidradenitis suppurativa. 62
35462426 2022
104
Neutrophilic eccrine hidradenitis in a pediatric patient with acute myeloid leukemia. 62
36112359 2022
105
A severe case of hidradenitis suppurativa with chronic anemia treated with adalimumab. 62
36074661 2022
106
Successfully and safety use of dupilumab in the management of severe atopic dermatitis and concomitant moderate-to-severe hidradenitis suppurativa. 62
35716015 2022
107
Severe atopic dermatitis and concurrent severe hidradenitis suppurativa successfully treated with dupilumab. 62
36006169 2022
108
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications. 62
36012744 2022
109
The impact of hidradenitis suppurativa on quality of life is worse than inflammatory bowel disease and myocardial infarction. 62
35932467 2022
110
Improving hidradenitis suppurativa patient education using written action plan: a randomized controlled trial. 62
34579620 2022
111
Evolving utility of apremilast in dermatological disorders for off-label indications. 62
35974705 2022
112
Neutralizing Anti‒DNase 1 and ‒DNase 1L3 Antibodies Impair Neutrophil Extracellular Traps Degradation in Hidradenitis Suppurativa. 62
35934056 2022
113
Does weight loss lead to improvement of dermatological conditions: what is the evidence? 62
35384013 2022
114
Dissecting cellulitis of the scalp associated with peripheral and axial spondyloarthritis: report of a case and review of the literature. 62
35460009 2022
115
Use of granulocyte and monocyte adsorption apheresis in dermatology (Review). 62
35837066 2022
116
International Dermatology Outcome Measures (IDEOM): Report from the 2021 Annual Meeting. 62
35946973 2022
117
Modulation of keratin deposition and pathogenesis of hidradenitis suppurativa: evidence coming from pachyonychia congenita. 62
35996837 2022
118
Hidradenitis Suppurativa Leads to Increased Risk of Wound-Related Complications following Total Joint Arthroplasty. 62
35789782 2022
119
Alternative uses of ustekinumab for non-indicated dermatological conditions: a systematic review. 62
34156549 2022
120
Hidradenitis suppurativa and Down syndrome in a single-centre sample: A cross-sectional study. 62
35567765 2022
121
Angiotensin-converting enzyme 2 expression is elevated in tissue of hidradenitis suppurativa and pyoderma gangrenousm and demonstrates a different pattern of expression to psoriasis vulgaris. 62
35986694 2022
122
Role of IL-36 cytokines in psoriasis and other inflammatory skin conditions. 62
35679693 2022
123
Perceived stress in four inflammatory skin diseases: an analysis of data taken from 7273 adult subjects with acne, atopic dermatitis, psoriasis or hidradenitis suppurativa. 62
35181931 2022
124
Psoriasis and hidradenitis suppurativa are associated with inflammatory bowel disease: a growing body of evidence. 62
35975655 2022
125
The role of TNF-β in psoriasis and hidradenitis suppurativa. 62
35916183 2022
126
The age of onset of hidradenitis suppurativa correlates with the age of onset of smoking. Comment on "cigarette smoking precedes the onset of hidradenitis suppurativa". 62
35933682 2022
127
The Incidence and Risk of Respiratory Tract Infections in Patients Using Biologics for Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. 62
35946977 2022
128
Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. 62
35191018 2022
129
A novel mutation of the NCSTN gene in a Chinese hidradenitis suppurativa family with familial comedones as the main clinical manifestation. 62
34860362 2022
130
Development and initial validation of the HS-IGA: a novel hidradenitis suppurativa-specific investigator global assessment for use in interventional trials. 62
35599448 2022
131
Advances in molecular pathogenesis of hidradenitis suppurativa: Dysregulated keratins and ECM signaling. 62
35131152 2022
132
Magnetic Resonance Imaging of Hidradenitis Suppurativa: A Focus on the Anoperineal Location. 62
35914743 2022
133
Circulating microRNAs in Hidradenitis Suppurativa. 62
36140712 2022
134
Increased risk of renal diseases in people with hidradenitis suppurativa: a systematic review and meta-analysis. 62
36040416 2022
135
Co-Graft of Acellular Dermal Matrix and Split Thickness Skin Graft-A New Reconstructive Surgical Method in the Treatment of Hidradenitis Suppurativa. 62
36004913 2022
136
Hidradenitis Suppurativa: A Perspective on Genetic Factors Involved in the Disease. 62
36009585 2022
137
Validity and Reliability of Two Digital Wound Measurement Tools after Surgery in Patients with Hidradenitis Suppurativa. 62
35998557 2022
138
Effectiveness and Safety of Acitretin for the Treatment of Hidradenitis Suppurativa, Predictors of Clinical Response: A Cohort Study. 62
35998603 2022
139
Exploring the role of systemic immune-inflammation index and neutrophil-lymphocyte ratio in cardiovascular risk stratification for patients with hidradenitis suppurativa: A cross-sectional study. 62
36000267 2022
140
Hidradenitis suppurativa: Evaluating activity patterns and predictors of recalcitrant course-A population-based study. 62
35510316 2022
141
Zinc in dermatology. 62
35437093 2022
142
Hidradenitis-suppurativa-bedingte Kosten, ein Plädoyer für Aufmerksamkeit: eine systematische Literaturübersicht. 62
35971574 2022
143
Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa? 62
35437813 2022
144
Quality of life in patients with early- and late-onset hidradenitis suppurativa. 62
35997825 2022
145
The impact of Janus kinase 1 inhibitors on quality of life in patients with hidradenitis suppurativa. 62
35122235 2022
146
Hidradenitis suppurativa may impact clothing patterns even in patients with mild disease and symptoms: an observational study. 62
35084746 2022
147
Hidradenitis suppurativa surgery: patient perspectives and barriers. 62
35933652 2022
148
Extensive genomic copy number alterations are common in squamous cell carcinoma arising in hidradenitis suppurativa with moderate histological differentiation. 62
35561841 2022
149
Cross-sectional survey-based study reveals self-diagnosis of hidradenitis suppurativa via Internet search in over 10% of patients. 62
35605153 2022
150
No increased incidence of Clostridium difficile infection among patients with hidradenitis suppurativa treated with systemic clindamycin. 62
34428535 2022
151
Pain and Late-Onset of Hidradenitis Suppurativa Can Have a Negative Influence on Occupational Status and Educational Level. A Cross-Sectional Study. 62
36030826 2022
152
Certolizumab pegol in the treatment of severe hidradenitis suppurativa after adalimumab failure: A real-life experience. 62
35996992 2022
153
Teledermatology in the management of hidradenitis suppurativa: Should we improve this service? 62
35951634 2022
154
Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa. 62
36054650 2022
155
Pain measurement in painful skin conditions and rheumatoid arthritis randomized controlled trials: a scoping review to inform pain measurement in hidradenitis suppurativa. 62
35962565 2022
156
Phytotherapeuthics Affecting the IL-1/IL-17/G-CSF Axis: A Complementary Treatment Option for Hidradenitis Suppurativa? 62
36012322 2022
157
Hidradenitis suppurativa-Pitfalls of long-term immunosuppressive treatment with tumor necrosis factor (TNF)-α inhibitors. 62
35614570 2022
158
Shear wave elastography as a potential tool for quantitative assessment of sinus tracts fibrosis in hidradenitis suppurativa. 62
35353931 2022
159
Hidradenitis suppurativa-related expenditure, a call for awareness: systematic review of literature. 62
35821567 2022
160
Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. 62
35531874 2022
161
Real-world safety and clinical response of Janus kinase inhibitor upadacitinib in the treatment of hidradenitis suppurativa: A retrospective cohort study. 62
35934210 2022
162
Immunomodulatory Drugs in the Treatment of Hidradenitis Suppurativa-Possibilities and Limitations. 62
36077114 2022
163
Biopsychosocial Complexity in Patients With Hidradenitis Suppurativa: A Pilot Study of a Psychodermatology Assessment Scale. 62
35963338 2022
164
Real-World Moderate-to-Severe Hidradenitis Suppurativa: Decrease in Disease Burden With Adalimumab. 62
35322692 2022
165
Low predictive value of questionnaire-based diagnosis of hidradenitis suppurativa. 62
35870150 2022
166
Author's Reply to Pestana et al. Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?" 62
35665909 2022
167
Comment on: "Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors?" 62
35665908 2022
168
Considerable improvement in hidradenitis suppurativa with oral roflumilast therapy. 62
35791762 2022
169
Response to Martora et al's "Hidradenitis suppurativa flares following COVID-19 vaccination: a case series". 62
35571456 2022
170
Factors associated with treatment satisfaction in patients with hidradenitis suppurativa: results from the Global VOICE project. 62
36056741 2022
171
Response to the article by Kwak et al entitled "No increased incidence of Clostridium difficile infection among patients with hidradenitis suppurativa treated with systemic clindamycin". 62
35257791 2022
172
At 180 days hidradenitis suppurativa readmission rate is comparable to heart failure: Analysis of the nationwide readmissions database. 62
34314742 2022
173
Amplicon sequencing demonstrates comparable follicular mycobiomes in patients with hidradenitis suppurativa compared with healthy controls. 62
35285081 2022
174
Treatment of severe hidradenitis Suppurativa and Fistulizing Crohn's disease with Guselkumab. 62
35224787 2022
175
Interviewing Women with Hidradenitis Suppurativa-Thematic and Content Analysis. 62
35723957 2022
176
Radiofrequency Epilation Using Acupuncture Needles to Decrease the Disease Burden in Hidradenitis Suppurativa. 62
35778252 2022
177
Internalized skin bias: validation study to explore the impact of the internalization of social stigma on those with hidradenitis suppurativa. 62
35170818 2022
178
A systematic review and meta-analysis of sexual dysfunction in patients with hidradenitis suppurativa. 62
35781695 2022
179
Clinical Features and Treatment Outcomes in Hidradenitis Suppurativa With Fistulizing Crohn's Disease: A Systematic Review. 62
35220795 2022
180
Cervicofacial hidradenitis suppurativa: A case report and literature review. 62
36241598 2022
181
Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa. 62
35887799 2022
182
Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience. 62
35510581 2022
183
Hidradenitis suppurativa associated with immunoglobulin A-dominant infection-related glomerulonephritis. 62
35246857 2022
184
Biologic use in hidradenitis suppurativa: patient perspectives and barriers. 62
35737883 2022
185
An Anti-Interleukin-17A Monoclonal Antibody, Ixekizumab, in the Treatment of Resistant Hidradenitis Suppurativa: A Case Series. 62
35983467 2022
186
Intermammary Hidradenitis Suppurativa. 62
35983474 2022
187
Guidance on COVID-19 Vaccination in Hidradenitis Suppurativa Patients: A Modified Delphi Consensus of Experts. 62
35979524 2022
188
Histopathology of Hidradenitis Suppurativa: A Systematic Review. 62
35892482 2022
189
Effects of NCSTN Mutation on Hair Follicle Components in Mice. 62
35843211 2022
190
Outcomes and cost of medical and surgical treatments of pilonidal disease: A single institution's 10-year review. 62
35647503 2022
191
Ultrasonography in dermatologic surgery: revealing the unseen for improved surgical planning. 62
35616215 2022
192
Hidradenitis suppurativa: Morphologic and vascular study of nodular inflammatory lesions by means of optical coherence tomography. 62
35263469 2022
193
Impact of Hidradenitis Suppurativa Surgical Treatment on Health-Related Life Quality. 62
35893421 2022
194
Mechanism of anti-inflammatory effects of rifampicin in an ex vivo culture system of hidradenitis suppurativa. 62
35048417 2022
195
Stress signalling and STAT1 activation characterize the keratinocytic gene expression pattern in Hidradenitis suppurativa. 62
35881108 2022
196
An Up-to-Date Approach to the Management of Dissecting Cellulitis. 62
35816064 2022
197
Interpretation of comorbidity risk in hidradenitis suppurativa: comparing odds ratio and 'number needed to be exposed'. 62
35793407 2022
198
Secukinumab for PASS syndrome: A new choice for therapeutic challenge? 62
35419914 2022
199
Hidradenitis supparativa complicated by penoscrotal lymphedema and renal amyloidosis. 62
35830985 2022
200
Body dysmorphia in common skin diseases: results of an observational, cross-sectional multicentre study among dermatological outpatients in 17 European countries. 62
35041211 2022
201
Alterations in mental health and quality of life in patients with skin disorders: a narrative review. 62
34403497 2022
202
Neutrophilic dermatoses. 62
35870984 2022
203
Variations in Genetics, Biology, and Phenotype of Cutaneous Disorders in Skin of Color. Part II: Differences in Clinical Presentation and Disparities in Cutaneous Disorders in Skin of Color. 62
35817332 2022
204
Variations in Genetics, Biology, and Phenotype of Cutaneous Disorders in Skin of Color. Part I: Genetic, Biological, and Structural Differences in Skin of Color. 62
35809800 2022
205
Hidradenitis suppurativa and the risk of myocardial infarction, cerebrovascular accident, and peripheral vascular disease: a population-based study. 62
35871185 2022
206
Neutrophilic Dermatoses in a Clinical Practice of Wound Care Professionals. 62
35703854 2022
207
Risk factors associated with hidradenitis suppurativa comorbid with inflammatory bowel disease and clinical phenotypes: a pilot case-control study. 62
35722935 2022
208
Immuno-Pathogenesis of Chronic Inflammatory Skin Diseases: Novel Molecular Targets and Biomarkers. 62
35743922 2022
209
[The role of metformin in the treatment of dermatological diseases: A narrative review]. 62
35569426 2022
210
Impact of psychiatric comorbidities in psoriasis, hidradenitis suppurativa and atopic dermatitis: The importance of a psychodermatological approach. 62
35285091 2022
211
Occurrence of inflammatory bowel disease in patients with chronic inflammatory skin diseases: a cohort study. 62
35718888 2022
212
Biologics and Small Molecule Inhibitors for Treating Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. 62
35740325 2022
213
Efficacy of non-surgical monotherapies for hidradenitis suppurativa: a systematic review and network meta-analyses of randomized trials. 62
33961535 2022
214
Psychosocial impact of hidradenitis suppurativa: a practical guide for clinicians. 62
34060964 2022
215
Single use negative-pressure wound therapy compared to standard care in patients after carbon dioxide laser surgery for hidradenitis suppurativa. 62
35373495 2022
216
Efficacy and safety of topical resorcinol 15% versus topical clindamycin 1% in the management of mild-to-moderate hidradenitis suppurativa: A retrospective study. 62
35278025 2022
217
Clostridium difficile infection risk in patients with hidradenitis suppurativa. 62
35700148 2022
218
Potential use of microwave technology in dermatology. 62
35699665 2022
219
Celebrating 20 years of the UK Dermatology Clinical Trials Network. Part 1: Developing and delivering high-quality independent clinical trials. 62
35199857 2022
220
Menopause, skin and common dermatosis: part 2. 62
35727900 2022
221
Cutaneous Body Image: How the Mental Health Benefits of Treating Dermatologic Disease Support Military Readiness in Service Members. 62
35960965 2022
222
Therapeutic potential of targeting interleukin-1 family cytokines in chronic inflammatory skin diseases. 62
34990008 2022
223
Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa. 62
35179254 2022
224
Educational attainment is inversely correlated with hidradenitis suppurativa severity. 62
36259813 2022
225
Hidradenitis suppurativa and association with stroke: systematic review and meta-analysis. 62
34289795 2022
226
Fear of negative evaluation in patients with hidradenitis suppurativa is correlated with worse quality of life: an observational study. 62
35656721 2022
227
Pediatric hidradenitis suppurativa: epidemiology, disease presentation, and treatments. 62
34057384 2022
228
International Classification of Diseases codes do not capture all cases of hidradenitis suppurativa in the electronic health record: a retrospective cohort. 62
35656711 2022
229
Itch in Hidradenitis Suppurativa/Acne Inversa: A Systematic Review. 62
35807098 2022
230
Systematic review of photodynamic therapy for the treatment of hidradenitis suppurativa. 62
35713108 2022
231
LAight® Therapy Is an Effective Treatment Option to Maintain Long-Term Remission of Hurley I and II Hidradenitis Suppurativa: Results from Period B of RELIEVE, a Multicenter Randomized, Controlled Trial. 62
35679831 2022
232
Seven years-experience of adalimumab therapy for Hidradenitis Suppurativa in a real-life dermatologic setting. 62
33843413 2022
233
Can Adalimumab Reduce the Extent of Hidradenitis Suppurativa Surgery? 62
35262636 2022
234
Recommendations to Optimize Patient Care in Hidradenitis Suppurativa Clinics: Our Experience. 62
35691279 2022
235
[Translated article] RF - Usefulness of Zinc Gluconate and Other Nondrug Treatments for Managing Hidradenitis Suppurativa. 62
35748008 2022
236
Advances in biologic and small molecule therapies for hidradenitis suppurativa. 62
35470765 2022
237
RF - Usefulness of Zinc Gluconate and Other Nondrug Treatments for Managing Hidradenitis Suppurativa. 62
35728916 2022
238
Seasonal burden of National Emergency Department visits due to hidradenitis suppurativa. 62
34051317 2022
239
A report of 1290 pediatric hidradenitis suppurativa hospitalizations: A nationwide analysis from the Kids' Inpatient Database. 62
34216721 2022
240
Ex Vivo Culture Models of Hidradenitis Suppurativa for Defining Molecular Pathogenesis and Treatment Efficacy of Novel Drugs. 62
35301634 2022
241
New onset lesion in patient with hidradenitis suppurativa. 62
35078632 2022
242
Flares as dynamic predictive factor of response to adalimumab in hidradenitis suppurativa: real-life data. 62
34159775 2022
243
Arthritis in patients with hidradenitis suppurativa. 62
34897827 2022
244
Management of genital hidradenitis suppurativa and lymphoedema with the restoration of erectile function. 62
35138636 2022
245
When staged surgical treatment can solve bilateral axillary and inguinal severe hidradenitis suppurativa. 62
35546020 2022
246
Hidradenitis Suppurativa: A Comparison of Institutional Experience and the Tracking Operations and Outcomes for Plastic Surgeons Registry. 62
35311802 2022
247
Janus kinase inhibitors for hidradenitis suppurativa: expanding the therapeutic toolbox. 62
35415896 2022
248
Certolizumab pegol and its role in pregnancy-age hidradenitis suppurativa. 62
34270087 2022
249
Psychosocial impact and treatment trends of hidradenitis suppurativa in Singapore. 62
35658158 2022
250
Prevalence and perceptions towards hidradenitis suppurativa: a cross-sectional study in a non-dermatological outpatient population. 62
35034401 2022
251
Surgical deroofing in pediatric patients with hidradenitis suppurativa. 62
35178762 2022
252
Incidence of self-reported hidradenitis suppurativa - a commentary. 62
35416362 2022
253
Successful treatment of early-onset hidradenitis suppurativa with acitretin in an infant with a novel mutation in PSENEN gene. 62
35146980 2022
254
Hidradenitis Suppurativa in the United States: Insights From the National Inpatient Sample (2008-2017) on Contemporary Trends in Demographics, Hospitalization Rates, Chronic Comorbid Conditions, and Mortality. 62
35686277 2022
255
Acne Fulminans Induced by Lymecycline in a Patient with Hidradenitis Suppurativa: A Case Report. 62
35702372 2022
256
Certolizumab pegol as an alternative treatment in patients with coexisting hidradenitis suppurativa and other inflammatory immune-mediated diseases: Report of two cases. 62
35199899 2022
257
Holistic health record for Hidradenitis suppurativa patients. 62
35589750 2022
258
Adalimumab Effect on Pain in Hidradenitis Suppurativa Patients: Systematic Review and Meta-Analysis. 62
35646432 2022
259
Microbial Isolates and Association with Disease Severity and Quality of Life in Individuals with Hidradenitis Suppurativa: An Observational Study. 62
35707293 2022
260
International consensus definition of disease flare in hidradenitis suppurativa. 62
35531746 2022
261
The prevalence of hidradenitis suppurativa outside the hospital setting: the impact of the undiagnosed. 62
35428975 2022
262
Uncovering a prominent association between pyoderma gangrenosum and hidradenitis suppurativa. 62
35415857 2022
263
Understanding the zebras of wound care: an overview of atypical wounds. 62
35839157 2022
264
Hidradenitis Suppurativa's Impact on Social Activities: An Observational Study. 62
35637919 2022
265
A Case of Overlapping Clinical Features of Idiopathic Granulomatous Mastitis, Hidradenitis Suppurativa, and Pyoderma Gangrenosum Successfully Treated with Adalimumab. 62
35702373 2022
266
Bilateral Phlyctenular Keratoconjunctivitis in the Context of Hidradenitis Suppurativa: A Case Report and Literature Review. 62
33226311 2022
267
Severe recalcitrant hidradenitis suppurativa in a 2-year-old boy with partial trisomy 13. 62
35229889 2022
268
Pain management modalities for hidradenitis suppurativa: a patient survey. 62
32914659 2022
269
Hidradenitis suppurativa flares following COVID-19 vaccination: A case series. 62
35308064 2022
270
Incidence and remission rates of self-reported hidradenitis suppurativa - A prospective cohort study conducted in Danish blood donors. 62
34862994 2022
271
New insights in hidradenitis suppurativa from a population-based Dutch cohort: prevalence, smoking behaviour, socioeconomic status and comorbidities. 62
34921556 2022
272
Patient satisfaction with hidradenitis suppurativa televisits correlates with less severe disease. 62
33901569 2022
273
The role of negative-pressure wound therapy in the management of axillary hidradenitis suppurativa. 62
34590422 2022
274
Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. 62
34978076 2022
275
Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art. 62
35630620 2022
276
An assessment of current practices in the treatment of hidradenitis suppurativa: the rise of biologic therapy. 62
32940551 2022
277
A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa? 62
35707292 2022
278
Comorbidity screening in hidradenitis suppurativa: Evidence-based recommendations from the US and Canadian Hidradenitis Suppurativa Foundations. 62
33493574 2022
279
Spironolactone in dermatology. 62
35038224 2022
280
Ischemia-Modified Albumin-A Potential New Marker of Oxidative Stress in Dermatological Diseases. 62
35630086 2022
281
Immunobiologicals in dermatology. 62
35314083 2022
282
Findings from a survey about hidradenitis suppurativa in the Netherlands. 62
35501937 2022
283
Alexithymia and Cutaneous Disease Morbidity: A Systematic Review. 62
35636409 2022
284
Patients with Hidradenitis Suppurativa Suffer from Low Health-Related Quality of Life as Measured by the Generic 15D Instrument. 62
35702276 2022
285
Spectrum of diseases associated with pyoderma gangrenosum and correlation with effectiveness of therapy: New insights on the diagnosis and therapy of comorbid hidradenitis suppurativa. 62
35385180 2022
286
Delayed drug hypersensitivity reaction to secukinumab in a patient with hidradenitis suppurativa. 62
35580946 2022
287
Dermatologic Health Disparities. 62
35557168 2022
288
Hepcidin levels can distinguish anemia of chronic disease from iron deficiency anemia in a cross-sectional study of patients with hidradenitis suppurativa. 62
33812958 2022
289
Interleukin-17E, inducible nitric oxide synthase and arginase1 as new biomarkers in the identification of neutrophilic dermatoses. 62
34669971 2022
290
A review of IL-36: an emerging therapeutic target for inflammatory dermatoses. 62
35470744 2022
291
Large-scale serum analysis identifies unique systemic biomarkers in psoriasis and hidradenitis suppurativa. 62
34254293 2022
292
A case of moderate hidradenitis suppurativa and psoriasis successfully treated with risankizumab. 62
34151438 2022
293
Factors related to the onset and recurrence of flares in hidradenitis suppurativa patients treated with adalimumab. 62
33982548 2022
294
Insights into hidradenitis suppurativa. 62
35189127 2022
295
Use of thermal imaging and a dedicated wound-imaging smartphone app as an adjunct to staging hidradenitis suppurativa. 62
34748648 2022
296
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study. 62
33629618 2022
297
Two novel mutations of the γ-secretase genes in Chinese acne inversa (hidradenitis suppurativa). 62
34748240 2022
298
Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12-week interim analysis of post-marketing surveillance in Japan. 62
35040156 2022
299
Lifestyle modifications associated with symptom improvement in hidradenitis suppurativa patients. 62
33893517 2022
300
Hidradenitis Suppurativa International Online Community: Patient Characteristics and a Novel Model of Treatment Effectiveness. 62
35312027 2022
301
Infectious eccrine hidradenitis: sweat glands as the portal of entry for cellulitis. 62
35379684 2022
302
Pyoderma gangrenosum: A systematic review of the molecular characteristics of disease. 62
35114021 2022
303
Self-Reported Hidradenitis Suppurativa Severity: Is It Useful for Clinical Practice? 62
35274220 2022
304
Histopathological progression of hidradenitis suppurativa/acne inversa : A morphological study with a closer look on the early changes of the folliculosebaceous apocrine apparatus. 62
34185217 2022
305
Effectiveness and safety of topical 15% resorcinol in the management of mild-to-moderate hidradenitis suppurativa: A cohort study. 62
34984726 2022
306
Treatment of Hidradenitis Suppurativa Evaluation Study (THESEUS): protocol for a prospective cohort study. 62
35450918 2022
307
Safety and Efficacy of Intense Pulsed Light With Radiofrequency in United States Hidradenitis Suppurativa Patients. 62
35389583 2022
308
Botulinum Toxin in Hidradenitis Suppurativa: A Systematic Review. 62
35389587 2022
309
Treatment strategies for hidradenitis suppurativa: real-life data from a tertiary Greek hospital. 62
33094412 2022
310
Hormonal Treatment of Acne and Hidradenitis Suppurativa in Adolescent Patients. 62
35366970 2022
311
Assessment of the generalizability of hidradenitis suppurativa microbiome studies: The minimal inclusion of racial and ethnic populations. 62
34757150 2022
312
[Translated article] RF - Usefulness of Zinc Gluconate and Other Nondrug Treatments for Managing Hidradenitis Suppurativa. 62
35487277 2022
313
Hidradenitis suppurativa and relapsing polychondritis: An uncommon association. 62
35092648 2022
314
Intralesional Treatments in Hidradenitis Suppurativa: A Systematic Review. 62
35477143 2022
315
Fast-growing mass in a patient with hidradenitis suppurativa. 62
35470548 2022
316
Associations of Internalized Skin Bias With Age, Adverse Psychopathology, and Health-Related Quality of Life Among Patients With Hidradenitis Suppurativa: A Cross-sectional Analysis. 62
35293961 2022
317
Use of Patient-Reported Outcome Measures in the Surgical Treatment of Hidradenitis Suppurativa: A Systematic Review. 62
35333200 2022
318
Surgical Treatment in Hidradenitis Suppurativa. 62
35566438 2022
319
Hidradenitis suppurativa publication trends from Latin America from 2009 to 2019: A bibliometric analysis. 62
35620024 2022
320
Primary alterations during the development of hidradenitis suppurativa. 62
34724272 2022
321
Medical Management of Hidradenitis Suppurativa with Non-Biologic Therapy: What's New? 62
34990004 2022
322
Inpatient burden of hidradenitis suppurativa in the United States: analysis of the 2016 National Inpatient Sample. 62
32436763 2022
323
Chronic Vulvar Plaque in a Patient With Severe Hidradenitis Suppurativa. 62
35659130 2022
324
The Temporal Evolution of Distinct Skin Surface Microbiome in Asian Patients with Severe Hidradenitis Suppurativa during Effective Adalimumab Treatment. 62
34461127 2022
325
Autoantibody-Mediated Macrophage Responses Provide the Missing Link between Innate and Adaptive Immune Dysfunction in Hidradenitis Suppurativa. 62
34716008 2022
326
Clinical and psychosocial factors affecting work productivity among patients with hidradenitis suppurativa: A cluster analytical investigation. 62
33662462 2022
327
MicroRNA Cross-Involvement in Acne Vulgaris and Hidradenitis Suppurativa: A Literature Review. 62
35328662 2022
328
Radiation therapy in chronic hidradenitis suppurativa: case report. 62
35368203 2022
329
Characteristics and Outcomes of Patients Undergoing Surgical Management of Hidradenitis Suppurativa: An ACS-NSQIP Data Analysis. 62
35152778 2022
330
A visit guide for adolescent hidradenitis suppurativa: Bridging the divide between pediatric and adult care. 62
35243400 2022
331
Hidradenitis suppurativa: racial and socioeconomic considerations in management. 62
35333408 2022
332
Severe anemia and copper deficiency in a patient treated with supplemental zinc for hidradenitis suppurativa. 62
33950518 2022
333
Hidradenitis Suppurativa in Sexual and Gender Minorities: A Review and Considerations for Providers. 62
35283243 2022
334
Decreased glomerular function is associated with disease severity in patients with hidradenitis suppurativa. 62
35284649 2022
335
Comparison of Artificial Intelligence with a Conventional Search in Dermatology: A Case Study of Systematic Review of Apremilast in Hidradenitis Suppurativa Performed by Both Methods. 62
35287422 2022
336
Biologic Use in Pediatric Patients With Hidradenitis Suppurativa: A Systematic Review. 62
34587768 2022
337
Management Landscape of Pediatric Hidradenitis Suppurativa. 62
35419424 2022
338
Diagnosing and Managing Hidradenitis Suppurativa in Pediatrics. 62
35293815 2022
339
Ustekinumab in the Management of Hidradenitis Suppurativa: A Retrospective Study. 62
35254749 2022
340
The Impact of Racial Differences on Treatment Strategies in Hidradenitis Suppurativa: A Retrospective Review. 62
35254766 2022
341
Treatment of hidradenitis suppurativa resolves associated hematologic abnormalities. 62
35620032 2022
342
Low incidence of COVID-19 in hidradenitis suppurativa: How to interpret it? 62
34679208 2022
343
Acellular dermal substitute use in the reconstruction of axillary hidradenitis suppurativa. 62
35079618 2022
344
Dermatologic Management of Hidradenitis Suppurativa and Impact on Pregnancy and Breastfeeding. 62
35659142 2022
345
A Controversial Relationship Between Crohn's Disease and Hidradenitis Suppurativa: A Case Series and Literature Review. 62
35481292 2022
346
The role of nutrition in acne vulgaris and hidradenitis suppurativa. 62
35398509 2022
347
The versatility of azelaic acid in dermatology. 62
32730109 2022
348
Identification of Biomarkers and Critical Evaluation of Biomarker Validation in Hidradenitis Suppurativa: A Systematic Review. 62
35044423 2022
349
New and Emerging Targeted Therapies for Hidradenitis Suppurativa. 62
35409118 2022
350
Pediatric Hidradenitis Suppurativa: A Cross-Sectional Study on Clinical Features and Treatment Approaches. 62
34615396 2022
351
Effectiveness of ustekinumab for moderate-to-severe hidradenitis suppurativa: a case series. 62
32502365 2022
352
Consulting 'Dr YouTube': a content analysis of YouTube® videos related to hidradenitis suppurativa treatments. 62
34767665 2022
353
Treating hidradenitis suppurativa during the COVID-19 pandemic: teledermatology exams of sensitive body areas. 62
32643464 2022
354
Golimumab, as an alternative treatment in patients with coexisting hidradenitis suppurativa and arthritis after adalimumab failure: Report of two cases. 62
34913547 2022
355
Sub-classification of Hidradenitis suppurativa: a cross-sectional study. 62
33089403 2022
356
Identifying Unmet Care Needs and Important Treatment Attributes in the Management of Hidradenitis Suppurativa: A Qualitative Interview Study. 62
34368925 2022
357
Peripheral ulcerative keratitis secondary to severe hidradenitis suppurativa. 62
35198822 2022
358
A rare case of axillary keratoacanthoma arising in hidradenitis suppurativa. 62
35146101 2022
359
Association of Spironolactone Use With Risk of Cancer: A Systematic Review and Meta-analysis. 62
35138351 2022
360
Neutrophils as Drivers of Immune Dysregulation in Autoimmune Diseases with Skin Manifestations. 62
34253374 2022
361
Hidradenitis Suppurativa: Estimated Prevalence, Clinical Features, and Risk Factors in Riyadh, Saudi Arabia. 62
35419230 2022
362
Autoantibodies Present in Hidradenitis Suppurativa Correlate with Disease Severity and Promote the Release of Proinflammatory Cytokines in Macrophages. 62
34606886 2022
363
Unraveling the Role of Sex Hormones on Keratinocyte Functions in Human Inflammatory Skin Diseases. 62
35328552 2022
364
Disease-Specific Health Disparities: A Targeted Review Focusing on Race and Ethnicity. 62
35455781 2022
365
Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. 62
35329838 2022
366
Dowling-Degos Disease Presenting With Associated Epidermal Inclusion Cysts: A Case Report and Review of the Literature. 62
34816802 2022
367
Refractory Dissecting Cellulitis of the Scalp Treated With Risankizumab. 62
35254754 2022
368
Evolutionary distinct roles of γ-secretase subunit nicastrin in zebrafish and humans. 62
35016821 2022
369
Altered Skin and Gut Microbiome in Hidradenitis Suppurativa. 62
34364884 2022
370
Off-label dermatologic uses of IL-17 inhibitors. 62
32116066 2022
371
Prevalence of Marfan syndrome, Ehlers-Danlos syndrome, and osteogenesis imperfecta in patients with hidradenitis suppurativa. 62
34592380 2022
372
Self-disgust in Patients with Dermatological Diseases. 62
35113320 2022
373
Obsessive-compulsive disorder and the associated risk of autoimmune skin diseases: a nationwide population-based cohort study. 62
35147076 2022
374
The inflammatory proteome of hidradenitis suppurativa skin is more expansive than that of psoriasis vulgaris. 62
34339761 2022
375
Is biologic treatment of hidradenitis suppurativa during the COVID-19 pandemic different from psoriasis biologic treatment? 62
32432955 2022
376
Off-Label studies on anakinra in dermatology: a review. 62
32279586 2022
377
Outcome comparison between thoracodorsal artery perforator flap and muscle-sparing latissimus dorsi flap in axillary reconstruction after hidradenitis suppurativa excision. 62
34783373 2022
378
Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review. 62
35203664 2022
379
Simultaneous Bilateral Reconstruction of the Axilla with Posterior Arm Flap in Recurrent Hidradenitis Suppurativa. 62
35444744 2022
380
Impact of the COVID-19 pandemic on patients with hidradenitis suppurativa. 62
35128802 2022
381
Antimicrobial peptides in hidradenitis suppurativa: a systematic review. 62
34498267 2022
382
Patient Impressions and Outcomes After Clinic-Based Hidradenitis Suppurativa Surgery. 62
34985494 2022
383
Secukinumab-induced paradoxical hidradenitis suppurativa successfully treated with adalimumab. 62
34258759 2022
384
Are antimicrobial peptides a double-edged sword in hidradenitis suppurativa pathophysiology? 62
34787309 2022
385
Online crowdfunding for medical expenses related to hidradenitis suppurativa. 62
34614227 2022
386
Assessment of inter-rater reliability of clinical hidradenitis suppurativa outcome measures using ultrasonography. 62
34388853 2022
387
Biologics for patients affected by hidradenitis suppurativa in the COVID-19 era: data from a referral center of Southern Italy. 62
32403954 2022
388
Ustekinumab in the treatment of patients with hidradenitis suppurativa: multicenter case series and systematic review. 62
32279593 2022
389
Effect of hidradenitis suppurativa on obstetric and neonatal outcomes. 62
35135394 2022
390
Vulvar cancer in hidradenitis suppurativa. 62
35106355 2022
391
Wound Closure with Transcutaneous Absorbable Polyglactin Sutures after Hidradenitis Suppurativa Excision. 62
35050922 2022
392
The relationship between hidradenitis suppurativa and irritable bowel syndrome: a cross-sectional study. 62
36161595 2022
393
The challenges of wound management for hidradenitis suppurativa. 62
35220746 2022
394
Pilot study of fractional microneedling radiofrequency for hidradenitis suppurativa assessed by clinical response and histology. 62
34431555 2022
395
Squamous cell carcinoma in hidradenitis suppurativa: Case report of a novel surgical treatment for an aggressive tumour. 62
34928501 2022
396
Facial pyoderma gangrenosum triggered by leishmaniasis in a patient with hidradenitis suppurativa. 62
34554592 2022
397
Dapsone in Hidradenitis Suppurativa: A Systematic Review. 62
34997914 2022
398
Switching from Adalimumab Originator to Biosimilar: Clinical Experience in Patients with Hidradenitis Suppurativa. 62
35207280 2022
399
Response to: "Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial". 62
34293391 2022
400
Wound dressings improve quality of life for hidradenitis suppurativa patients. 62
34610381 2022
401
Drug Survival of Biologics in Patients With Hidradenitis Suppurativa. 62
34851360 2022
402
Management of mild hidradenitis suppurativa: our greatest challenge yet. 62
34608630 2022
403
Axillary hidradenitis reconstruction using a dermal regeneration template. 62
35801979 2022
404
Surgical View of Morphological and Pathogenetic Identity of Pilonidal Cysts and Acne Inversa. 62
36047363 2022
405
A Novel NCSTN Mutation in a Three-Generation Chinese Family with Hidradenitis Suppurative. 62
35368949 2022
406
The Utility of Frequent Laboratory Monitoring for Patients on Tumor Necrosis Factor-Alpha Inhibitors in Dermatology. 62
35761997 2022
407
Comprehensive Treatment of Severe Follicular Occlusion Triad: A Case Report. 62
35387202 2022
408
Investigation of thiol-disulfide homeostasis and ischemia-modified albumin levels in patients with hidradenitis supurativa. 62
35653419 2022
409
Bibliometric Analysis of Hidradenitis Suppurativa Publication Trends from Asia and Australasia. 62
35118124 2022
410
Therapies for hidradenitis suppurativa: a systematic review with a focus on Brazil. 62
35145556 2022
411
What's Race Got to Do With It? CRP Levels in Immune Mediated Skin Diseases: Considerations for Hidradenitis Suppurativa. 62
35432388 2022
412
LAight® Therapy Significantly Enhances Treatment Efficacy of 16 Weeks of Topical Clindamycin Solution in Hurley I and II Hidradenitis Suppurativa: Results from Period A of RELIEVE, a Multicenter Randomized, Controlled Trial. 62
34535610 2022
413
Recent advances in hidradenitis suppurativa: Role of race, genetics, and immunology. 62
36092908 2022
414
The surgical management of hidradenitis suppurativa in the United Kingdom: a national survey of care pathways informing the THESEUS study. 62
34674976 2022
415
JAAD Game Changers∗: The role of wide local excision for the treatment of severe hidradenitis suppurativa (Hurley grade III): Retrospective analysis of 74 patients. 62
33894326 2022
416
A case of scrofuloderma of the axilla presenting as hidradenitis suppurativa: A case report. 62
36225223 2022
417
Efficacy and Toxicity of Classical Immunosuppressants, Retinoids and Biologics in Hidradenitis Suppurativa. 62
35160122 2022
418
Clinical Trials and Skin of Color: The Example of Hidradenitis Suppurativa. 62
34107480 2022
419
Surgical Management of Hidradenitis Suppurativa: A Narrative Review. 62
35309275 2022
420
Long-Term Follow-Up after Radiotherapy of Hidradenitis Suppurativa. 62
34134120 2022
421
Patient experiences with hidradenitis suppurativa: the Hidradenitis Patient Experience survey. 62
34235774 2022
422
The expected missing heritability of hidradenitis suppurativa in perspective. 62
34726766 2022
423
The Value of Negative-Pressure Wound Therapy and Flap Surgery in Hidradenitis Suppurativa - A Single Center Analysis of Different Treatment Options. 62
35836613 2022
424
Impact of Pregnancy on Hidradenitis Suppurativa Disease Course: A Systematic Review and Meta-Analysis. 62
34515085 2022
425
Antiandrogen therapy in hidradenitis suppurativa: finasteride for females. 62
34260109 2022
426
How to Define Mild to Severe Hidradenitis Suppurativa? A Simple New Tool Based on Latent Class Analysis of EPIVER Data Study. 62
35734147 2022
427
Top 100 most-cited publications in hidradenitis suppurativa: An updated bibliometric analysis. 62
36160144 2022
428
Interpreting the spectrum of gamma-secretase complex missense variation in the context of hidradenitis suppurativa-An in-silico study. 62
36118898 2022
429
Innate immunity and microbial dysbiosis in hidradenitis suppurativa - vicious cycle of chronic inflammation. 62
35967376 2022
430
Ultrasound-guided photodynamic therapy with intralesional methylene blue and a 635 nm light-emitting diode lamp in hidradenitis suppurativa: A retrospective study of 41 patients. 62
34157160 2022
431
Fractionated microneedle radiofrequency as a potential novel procedure for treatment of hidradenitis suppurativa: A medical hypothesis. 62
34837442 2022
432
Readability of online materials for hidradenitis suppurativa. 62
35073415 2022
433
Possible beneficial impact of surgical deroofing procedure to cover the disadvantage of adalimumab treatment for hidradenitis suppurativa. 62
34514647 2022
434
Overall Impairment of Quality of Life in Japanese Patients with Hidradenitis Suppurativa: Comparison with National Standard. 62
34935991 2022
435
Cardiovascular Disease-Associated Skin Conditions. 62
35210782 2022
436
Adverse pregnancy and maternal outcomes in women with hidradenitis suppurativa. 62
34126093 2022
437
Prevalence of low vitamin D levels in patients with Hidradenitis suppurativa in Jordan: A comparative cross-sectional study. 62
35303020 2022
438
Probiotics in hidradenitis suppurativa: a potential treatment option? 62
34236727 2022
439
High inflammation in hidradenitis suppurativa extends to perilesional skin and can be subdivided by lipocalin-2 expression. 62
34081946 2022
440
Evidence of gene-gene interaction in hidradenitis suppurativa: a nationwide registry study of Danish twins. 62
34289077 2022
441
Clinical translation of hidradenitis suppurativa genetic studies requires global collaboration. 62
34498254 2022
442
Prevalence and Clinical Characteristics of Hidradenitis Suppurativa Phenotypes in a Large Dutch Cohort. 62
34649257 2022
443
The Bacteriology of Skin Lesions in Patients with Hidradenitis Suppurativa Is Associated with Previous Antibiotic Treatment in the Community Setting: A Referral Center Experience. 62
35086093 2022
444
Hidradenitis Suppurativa in a Large Cohort of Italian Patients: Evaluation of the Burden of Disease. 62
34474409 2022
445
Hidradenitis suppurativa successfully treated with two-stage surgery under disease control with adalimumab. 62
34505716 2022
446
Modified Posterior Arm Flap for Axillary Hidradenitis Suppurativa. 62
33833171 2022
447
Prevalence of depression among children, adolescents, and adults with hidradenitis suppurativa. 62
34144081 2022
448
Potential Benefits of the Mediterranean Diet and Physical Activity in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study in a Spanish Population. 62
35276909 2022
449
Metabolic Disorders/Obesity Is a Primary Risk Factor in Hidradenitis Suppurativa: An Immunohistochemical Real-World Approach. 62
34293747 2022
450
Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa. 62
33887735 2022
451
Hidradenitis suppurativa in pediatric patients. 62
32822788 2022
452
3D-SeboSkin Model for Human ex vivo Studies of Hidradenitis Suppurativa/Acne Inversa. 62
34077928 2022
453
The Personal Impact of Daily Wound Care for Hidradenitis Suppurativa. 62
34929704 2022
454
Outcome Comparison of Different Reconstructive Approaches for Axillary Defects Secondary to Radical Excision of Hidradenitis Suppurativa. 62
35086097 2022
455
Treatment Outcomes of IL-17 Inhibitors in Hidradenitis Suppurativa: A Systematic Review. 62
34365863 2022
456
The Genomic Architecture of Hidradenitis Suppurativa-A Systematic Review. 62
35401657 2022
457
Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. 62
35755063 2022
458
Outcomes of pregnancy and childbirth in women with hidradenitis suppurativa. 62
34153386 2022
459
Hepatitis B and C among patients with hidradenitis suppurativa: a population-based study. 62
33998670 2022
460
Systematic Review of Safety and Efficacy of IL-1-Targeted Biologics in Treating Immune-Mediated Disorders. 62
35874710 2022
461
Neutrophilic Dermatoses: a Clinical Update. 62
35310367 2022
462
Photodynamic therapy in pediatric age: Current applications and future trends. 62
36052131 2022
463
Avacopan: First Approval. 62
34826105 2022
464
Association of hidradenitis suppurativa with autoimmune disease and autoantibodies. 62
35531048 2022
465
Paraneoplastic Syndromes in Patients with Keratinocyte Skin Cancer. 62
35008413 2022
466
Modified Keystone Perforator Island Flap for Tension-Reducing Coverage of Axillary Defects Secondary to Radical Excision of Chronic Inflammatory Skin Lesions: A Retrospective Case Series. 62
36212718 2022
467
Pyoderma Gangrenosum, Acne, and Hidradenitis Suppurativa Syndrome: A Case Report and Literature Review. 62
35402426 2022
468
International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. 62
34537770 2022
469
Clinical Treatment Study of Secondary Multiple Squamous Cell Carcinoma with Psoriasis Vulgaris. 62
35035485 2022
470
Successful treatment of hidradenitis suppurativa with secukinumab in a patient with ankylosing spondylitis and Familial Mediterranean Fever. 62
34508267 2022
471
Complement activation in Hidradenitis suppurativa: Covert low-grade inflammation or innocent bystander? 62
36211440 2022
472
Disfiguring Hidradenitis Suppurativa of the Face. 62
35118134 2022
473
Hidradenitis suppurativa in acute myeloid leukemia: Review of disease course and management. 62
34917723 2022
474
Relationships of Serum Homocysteine, Vitamin B12, and Folic Acid Levels with Papulopustular Rosacea Severity: A Case-Control Study. 62
35832851 2022
475
Impact of gut microbiome on skin health: gut-skin axis observed through the lenses of therapeutics and skin diseases. 62
35866234 2022
476
Case Report: Comorbid Hyper-IgD Syndrome and Hidradenitis Suppurativa - A New Syndromic Form of HS? A Report of Two Cases. 62
35720358 2022
477
Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. 62
35924080 2022
478
The Role of Nutrition in Immune-Mediated, Inflammatory Skin Disease: A Narrative Review. 62
35276950 2022
479
Intermammary Hidradenitis Suppurativa: A Case Report. 62
35431584 2022
480
Neutrophilic Dermatosis and Management Strategies for the Inpatient Dermatologist. 62
35873076 2022
481
Hyperhidrosis treatments in hidradenitis suppurativa: A systematic review. 62
34796606 2022
482
Whole-Exome Sequencing in 10 Unrelated Patients with Syndromic Hidradenitis Suppurativa: A Preliminary Step for a Genotype-Phenotype Correlation. 62
35034021 2022
483
Biologic therapy is not associated with increased COVID-19 severity in patients with hidradenitis suppurativa: Initial findings from the Global Hidradenitis Suppurativa COVID-19 Registry. 62
34537252 2022
484
Colchicine in Managing Skin Conditions: A Systematic Review. 62
35214027 2022
485
Paradoxical hidradenitis suppurativa in Crohn's disease patients receiving infliximab: a case report and review of literature. 62
33905217 2021
486
RAEB II type of myelodysplastic syndrome associated with axillary abscesses - Case Report. 62
34969238 2021
487
A Patient-Centered Guide to Hidradenitis Suppurativa Flare Prevention. 62
34898157 2021
488
Dressings management of chronic wounds in patients with hidradenitis suppurativa. 62
34048093 2021
489
Hidradenitis suppurativa is associated with iron deficiency anemia, anemia of chronic disease, and sickle cell anemia-A single-center retrospective cohort study. 62
35028363 2021
490
Role of Aryl Hydrocarbon Receptor Activation in Inflammatory Chronic Skin Diseases. 62
34944067 2021
491
Hidradenitis suppurativa in a female adolescent with Rett Syndrome: a fortuitous association? 62
32163043 2021
492
Reply to: Comments on "Hidradenitis suppurativa and atopic dermatitis: A two-way association". 62
34044104 2021
493
Atopic dermatitis and hidradenitis suppurativa: An under-recognized pair. 62
34214619 2021
494
Single-center survey of biologic use for inflammatory skin diseases during the coronavirus disease 2019 pandemic. 62
34549456 2021
495
Contribution of mycobiota to the pathogenesis of spondyloarthritis. 62
34166798 2021
496
A case of hidradenitis suppurativa and Darier disease in a patient treated with acitretin: how to kill two birds with one stone. 62
32163048 2021
497
A Rare Case of Job Syndrome With Autism: Complicated With Hidradenitis Suppurativa and Chronic Deep Vein Thrombosis. 62
35141085 2021
498
Pleomorphic Appearance of Breast Cancer Cutaneous Metastases. 62
35028206 2021
499
Vulvar Fordyce adenitis: A cohort of 45 women. 62
34217527 2021
500
Hidradenitis suppurativa and atopic dermatitis: A 2-way association. 62
33378660 2021
501
Hidradenitis suppurativa associated with systemic lupus erythematosus and psoriasis: a therapeutical challenge. 62
30924627 2021
502
Impact of Psoriasis and Hidradenitis Suppurativa in Pregnancy, a Systematic Review. 62
34945189 2021
503
No Evident Systemic Terminal Complement Pathway Activation in Hidradenitis Suppurativa. 62
34252397 2021
504
Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study. 62
34378812 2021
505
Hidradenitis Suppurativa and Comorbid Disorder Biomarkers, Druggable Genes, New Drugs and Drug Repurposing-A Molecular Meta-Analysis. 62
35056940 2021
506
A cross-sectional analysis of popular hidradenitis suppurativa content on TikTok. 62
34693364 2021
507
NOD2 signalling in hidradenitis suppurativa. 62
34056759 2021
508
Clinical considerations in the management of hidradenitis suppurativa in women. 62
35028361 2021
509
Facial hidradenitis suppurativa: A potential mimicker of acne vulgaris. 62
31103567 2021
510
Assessing the responsiveness of sonographic biomarkers to Brodalumab therapy in Hidradenitis Suppurativa. 62
34310761 2021
511
Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association. 62
34409549 2021
512
In response: Overall and subgroup prevalence of acne vulgaris among patients with hidradenitis suppurativa. 62
31103569 2021
513
Gender differences in hidradenitis suppurativa characteristics: A retrospective cohort analysis. 62
35028362 2021
514
Shedding light on the impact of hidradenitis suppurativa on women and their families: A focus of the International Journal of Women's Dermatology. 62
35028360 2021
515
Improvement in Quality of Life and Pain in Patients With Hidradenitis Suppurativa After Wide Local Excision: A Prospective Study. 62
34537785 2021
516
Quality of Life of Patients With Hidradenitis Suppurativa in Jeddah, Saudi Arabia. 62
34909350 2021
517
Hidradenitis suppurativa and socioeconomic status. 62
34242407 2021
518
Golimumab for the Treatment of Hidradenitis Suppurativa in Patients with Previous TNF-α Treatment Failure. 62
34097922 2021
519
Hidradenitis Suppurativa Quality of Life (HiSQOL): creation and validation of the Polish language version. 62
35126002 2021
520
Clindamycin Mono-Therapy of Hidradenitis Suppurativa Patients: A Single-Center Retrospective Study. 62
34858002 2021
521
Efficacy of short-term intravenous clindamycin prior to oral clindamycin-rifampicin treatment in hidradenitis suppurativa: a retrospective case series. 62
34270785 2021
522
Hidradenitis suppurativa with perifolliculitis capitis abscedens et suffodiens successfully treated with a human anti-tumour necrosis factor monoclonal antibody. 62
34096639 2021
523
Dermatological knowledge survey: US medical students' perception of hidradenitis suppurativa. 62
34236701 2021
524
Management of adolescents with hidradenitis suppurativa. 62
31933397 2021
525
Human skin microbiota in health and disease: The cutaneous communities' interplay in equilibrium and dysbiosis: The cutaneous communities' interplay in equilibrium and dysbiosis. 62
34919288 2021
526
Refining how we measure as we test: new insights using adalimumab in patients with hidradenitis suppurativa. 62
34773662 2021
527
Palmoplantar eccrine hidradenitis. 62
31104462 2021
528
Skin Manifestations in Psoriatic and HS Patients in Treatment with Biologicals during the COVID-19 Pandemic. 62
34945136 2021
529
Plasma Radiofrequency Ablation for Scar Treatment. 62
35011879 2021
530
A Novel Technique for Securing a Bolster For Skin Grafting after Extensive Vulvar Resection. 62
34796090 2021
531
Hidradenitis Suppurativa From a Patient Perspective Including Symptoms and Self-Treatment. 62
34137667 2021
532
Characterization of comorbidity heterogeneity among 13,667 patients with hidradenitis suppurativa. 62
34546979 2021
533
Hidradenitis suppurativa; classification, remedies, etiology, and comorbidities; a narrative review. 62
35136760 2021
534
[Chilean clinical guideline for the management of hidradenitis suppurativa - executive summary]. 62
35735325 2021
535
Trends in the management of hidradenitis suppurativa in the Middle East region: a systematic review. 62
33615455 2021
536
Neoplastic Implications in Patients Suffering from Hidradenitis Suppurativa under Systemic Treatments. 62
34829823 2021
537
Hidradenitis suppurativa: Disease pathophysiology and sex hormones. 62
34975118 2021
538
Hidradenitis suppurativa disease course during pregnancy and postpartum: a retrospective survey study. 62
33760224 2021
539
Hidradenitis suppurativa: redirecting a life trajectory. 62
34468981 2021
540
Management of Acute and Chronic Pain Associated With Hidradenitis Suppurativa: A Comprehensive Review of Pharmacologic and Therapeutic Considerations in Clinical Practice. 62
35100536 2021
541
Global data analysis supports smoking as the fundamental element associated with geographical sex disparities in hidradenitis suppurativa. 62
34128538 2021
542
Dapsone in hidradenitis suppurativa: A case series of 56 patients. 62
34665504 2021
543
JAAD Game Changers∗: Intralesional triamcinolone for flares of hidradenitis suppurativa (HS): A case series. 62
33848600 2021
544
The effect of age on self-rated skin pain in patients with hidradenitis suppurativa. 62
34789451 2021
545
Hidradenitis suppurativa among patients with HIV: investigating patient and disease characteristics and misdiagnosis. 62
34155629 2021
546
Vitamin D deficiency and hidradenitis suppurativa: the impact on clinical severity and therapeutic responsivity. 62
31994944 2021
547
Efficacy and Safety of Adalimumab in Conjunction With Surgery in Moderate to Severe Hidradenitis Suppurativa: The SHARPS Randomized Clinical Trial. 62
34406349 2021
548
Squamous cell carcinoma arising within hidradenitis suppurativa: a literature review. 62
34075588 2021
549
Development of a Patient-Reported Outcome Questionnaire to Assess Signs and Symptoms of Hidradenitis Suppurativa: The Hidradenitis Suppurativa Symptom Diary (HSSD). 62
34808326 2021
550
Analysis of hidradenitis suppurativa hospitalizations: A report from the National Inpatient Sample database. 62
33152368 2021
551
Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial. 62
34406364 2021
552
Misdiagnoses and barriers to care in hidradenitis suppurativa: A patient survey. 62
34314017 2021
553
Thematic synthesis of the experiences of people with hidradenitis suppurativa: a systematic review. 62
34050935 2021
554
Hidradenitis suppurativa: pathogenesis, clinical presentation, epidemiology, and comorbid associations. 62
33890304 2021
555
The Use of HSQoL-24 in an Assessment of Quality-of-Life Impairment among Hidradenitis Suppurativa Patients: First Look at Real-Life Data. 62
34830727 2021
556
Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real-world results from the HARMONY Study. 62
34320249 2021
557
Risankizumab effectiveness in a recalcitrant case of hidradenitis suppurativa after anti-TNF and anti-interleukin-17 failures. 62
34459075 2021
558
Adalimumab Induces a Wound Healing Profile in Patients with Hidradenitis Suppurativa by Regulating Macrophage Differentiation and Matrix Metalloproteinase Expression. 62
33965402 2021
559
Hidradenitis suppurativa in East and Southeast Asian populations: a systematic review and meta-analysis. 62
34075575 2021
560
Cumulative Inflammation and HbA1c Levels Correlate with Increased Intima-Media Thickness in Patients with Severe Hidradenitis Suppurativa. 62
34830503 2021
561
Increased Serum Levels of S100A4 and S100A15 in Individuals Suffering from Hidradenitis Suppurativa. 62
34830597 2021
562
A systematic review on shared biological mechanisms of depression and anxiety in comorbidity with psoriasis, atopic dermatitis, and hidradenitis suppurativa. 62
34819201 2021
563
Coexistence of Hidradenitis Suppurativa and Steatocystoma Multiplex: Is It a New Variant of Hidradenitis Suppurativa? 62
33908804 2021
564
Characterization and Management of Inflammatory Eye Disease in Patients with Hidradenitis Suppurativa. 62
32255701 2021
565
TNF-α inhibition in the setting of undiagnosed HIV infection: a call for enhanced screening guidelines. 62
34115645 2021
566
Clinical background of patients with psoriasiform skin lesions due to tumor necrosis factor antagonist administration at a single center. 62
34409641 2021
567
Omacetaxine added to a standard acute myeloid leukaemia chemotherapy regimen reduces cellular FLIP levels, markedly increasing the incidence of eccrine hidradenitis. 62
34490614 2021
568
Mapping risk factors for cumulative life course impairment in patients with chronic skin diseases - a systematic review. 62
33988873 2021
569
Angiogenesis in Chronic Inflammatory Skin Disorders. 62
34769465 2021
570
Off-label uses of TNF-a inhibitors and IL-12/23 inhibitors in dermatology. 62
35130397 2021
571
Mediterranean diet, lifestyle and quality of life in Sardinian patients affected with Hidradenitis suppurativa. 62
34850622 2021
572
Prevalence and Associated Factors of Alexithymia in Patients with Hidradenitis Suppurativa: A Cross-sectional Study. 62
34724071 2021
573
The Use of Biologics During the COVID-19 Pandemic. 62
34556244 2021
574
Inflammatory skin diseases and the risk of chronic kidney disease: population-based case-control and cohort analyses. 62
33730366 2021
575
Care for Adolescents With Polycystic Ovary Syndrome: Development and Prescribing Patterns of a Multidisciplinary Clinic. 62
33794340 2021
576
Prevalence of Central Sensitization in Patients With Hidradenitis Suppurativa. 62
34406352 2021
577
A systematic review and critical appraisal of metagenomic and culture studies in hidradenitis suppurativa. 62
32614993 2021
578
Coronavirus disease 2019 complications in patients with hidradenitis suppurativa: A multicenter analysis. 62
34405434 2021
579
A novel c.671_682del NCSTN variant in a family with hidradenitis suppurativa: a pilot study. 62
33852739 2021
580
May COVID-19 infection induce a paradoxical improvement of a non-responsive case of hidradenitis suppurativa? 62
34282868 2021
581
Intralesional anti-biofilm therapy for tunnels in patients with hidradenitis suppurativa. 62
33890735 2021
582
Adalimumab dose intensification in hidradenitis suppurativa: effectiveness and safety results of a multicentre study. 62
34050921 2021
583
Yin and Yang: A disrupted skin microbiome and an aberrant host immune response in hidradenitis suppurativa. 62
34018644 2021
584
Potential predictive biomarkers of adalimumab response in patients with hidradenitis suppurativa. 62
33811319 2021
585
Hidradenitis Suppurativa at an Uncommon Site: A Review of Its Clinical Features, Diagnostic Difficulties, and Management. 62
34790460 2021
586
Colchicine Improves Clinical Outcomes and Quality of Life in Hidradenitis Suppurativa Patients: A Retrospective Study. 62
34682864 2021
587
Primary care management of hidradenitis suppurativa: a cross-sectional survey of UK GPs. 62
34326099 2021
588
Duration of Adalimumab Therapy in Hidradenitis Suppurativa With and Without Oral Immunosuppressants. 62
34846999 2021
589
Hidradenitis suppurativa in a transgender man. 62
33852750 2021
590
Treatment Stacking: Optimizing Therapeutic Regimens for Hidradenitis Suppurativa. 62
34846994 2021
591
Novel evidence of androgen receptor immunoreactivity in skin tunnels of hidradenitis suppurativa: assessment of sex and individual variability. 62
34047363 2021
592
Severe ulcerative proctitis, pyoderma gangrenosum, hidradenitis suppurativa and fever in a patient with a rare variant of the PSTPIP1 gene. 62
34273117 2021
593
Hidradenitis suppurativa: A folliculotropic disease of innate immune barrier dysfunction? 62
34418166 2021
594
A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs. 62
33910441 2021
595
Therapeutic biomarkers in hidradenitis suppurativa: one step closer to the clinic. 62
34131898 2021
596
Perspectives on the Twitter presence of hidradenitis suppurativa. 62
33909289 2021
597
[Differences in anatomical area-specific wound healing in hidradenitis suppurativa/acne inversa after surgery]. 62
34789440 2021
598
Patient satisfaction and quality of life after surgery combined with 5-aminolevulinic acid-based photodynamic therapy for hidradenitis suppurativa. 62
33440214 2021
599
Vulvoperineal Hidradenitis Suppurativa: Diagnosis, Treatment, and Management of Deformities. 62
34724076 2021
600
Hidradenitis suppurativa research from Africa: a bibliometric analysis. 62
33844314 2021
601
A Comparison of Alternative Medicine Users and Non-Users in Patients With Hidradenitis Suppurativa. 62
34636524 2021
602
Insights into the Pathogenesis of HS and Therapeutical Approaches. 62
34572354 2021
603
Patients With Hidradenitis Suppurativa Negatively Perceive Both Medical and Euphemistic Appellations of Their Disease: A Study From Turkey. 62
34631262 2021
604
Ultrasound-guided injection of intralesional steroids in acute hidradenitis suppurativa lesions: A prospective study. 62
34297465 2021
605
Differential profiles of gamma secretase Notch signalling in hidradenitis suppurativa: the need for genotype-endotype-phenotype analysis. 62
33421094 2021
606
Quality and engagement of online hidradenitis suppurativa information. 62
34621966 2021
607
[Erratum to: Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa]. 62
34424353 2021
608
Decreased Serum Level of Interleukin-22 Correlates with Hepcidin in Patients with Hidradenitis Suppurativa. 62
34515804 2021
609
In-Depth Analysis of the Hidradenitis Suppurativa Serum Proteome Identifies Distinct Inflammatory Subtypes. 62
33766512 2021
610
Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: A retrospective analysis. 62
34463372 2021
611
Lymphangioma circumscriptum as an untoward consequence of hidradenitis suppurativa surgery. 62
34621964 2021
612
Indirect Self-Destructiveness in Hidradenitis Suppurativa Patients. 62
34575300 2021
613
The Clinical Relevance of the Microbiome in Hidradenitis Suppurativa: A Systematic Review. 62
34696185 2021
614
Racial and Ethnic Distribution of Patients Hospitalized With Hidradenitis Suppurativa, 2008-2018. 62
34379078 2021
615
Outcomes of patients with chronic plaque psoriasis and hidradenitis suppurativa on biologic therapy during the Covid-19 pandemic: A UK dermatology tertiary centre experience. 62
34235510 2021
616
Follicular Dowling-Degos Disease with Hidradenitis Suppurativa: A Case Report and Review of the Literature. 62
35082614 2021
617
Diabetes Detection and Prevention in Dermatology. 62
34631273 2021
618
Atopic dermatitis is associated with hidradenitis suppurativa diagnosis: A single institution retrospective cohort study. 62
34409385 2021
619
Clinical Application of Pharmacogenetic Markers in the Treatment of Dermatologic Pathologies. 62
34577605 2021
620
Differences Between Children and Adults With Hidradenitis Suppurativa. 62
34379074 2021
621
Not all that glitters is COVID-19: a case series demonstrating the need for histopathology when skin findings accompany SARS-CoV-2 infection. 62
34013600 2021
622
Liver enzyme levels are associated with markers of systemic inflammation, disease severity, and metabolic syndrome in patients with hidradenitis suppurativa. 62
34553080 2021
623
Sexual Dysfunction in Patients with Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. 62
34840661 2021
624
Risk Factors for Developing Hidradenitis Suppurativa in Patients With Inflammatory Bowel Disease: A Retrospective Case-Control Study. 62
34337316 2021
625
International Classification of Diseases-based analysis is inaccurate in assessing the prevalence of inflammatory bowel disease in patients with hidradenitis suppurativa. 62
34092407 2021
626
Proceedings Report of the Fifth Symposium on Hidradenitis Suppurativa Advances (SHSA) 2020. 62
34397198 2021
627
Oral isotretinoin for the treatment of dermatologic conditions other than acne: a systematic review and discussion of future directions. 62
33151346 2021
628
Dowling-Degos disease: a review. 62
33368260 2021
629
[Pathogenesis of hidradenitis suppurativa/acne inversa]. 62
34228138 2021
630
Corrigendum: Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. 62
34755972 2021
631
Insights from γ-Secretase: Functional Genetics of Hidradenitis Suppurativa. 62
33836848 2021
632
Pain as Defining Feature of Health Status and Prominent Therapeutic Target in Patients with Hidradenitis Suppurativa. 62
34441944 2021
633
Serum high-sensitivity C-reactive protein, tumor necrosis factor-α, interleukin (IL)-1β, IL-17A and IL-23 levels in patients with hidradenitis suppurativa. 62
34034145 2021
634
Clinical Implementation of Biologics and Small Molecules in the Treatment of Hidradenitis Suppurativa. 62
34283386 2021
635
Quality of Life in Hidradenitis Suppurativa: validation of the HSQoL-24. 62
34427316 2021
636
Hidradenitis suppurativa: Basic considerations for its approach: A narrative review. 62
34401142 2021
637
Hidradenitis Suppurativa: Where We Are and Where We Are Going. 62
34440863 2021
638
Combined treatment of hidradenitis suppurativa with intense pulsed light (IPL) and radiofrequency (RF). 62
31609667 2021
639
Prevalence of Hidradenitis Suppurativa: A Systematic Review and Meta-regression Analysis. 62
34037678 2021
640
The efficacy and tolerability of tetracyclines and clindamycin plus rifampicin for the treatment of hidradenitis suppurativa: Results of a prospective European cohort study. 62
33484766 2021
641
Recycled Split-Thickness Skin Grafting: A Novel Treatment for Axillary Hidradenitis Suppurativa. 62
33587371 2021
642
[Clinical, pathology-associated and molecular biomarkers of hidradenitis suppurativa/acne inversa]. 62
34213572 2021
643
[Topical and novel device-based therapies for mild hidradenitis suppurativa]. 62
34223936 2021
644
[Need for real-world data studies on hidradenitis suppurativa/acne inversa treatment]. 62
34223938 2021
645
'Hidradenitis suppurativa and amyloidosis: a possible association with the pyrin inflammasome': reply from authors. 62
33908073 2021
646
[Hidradenitis suppurativa/acne inversa: From "orphan disease" to a curable inflammatory skin disorder]. 62
34324067 2021
647
Ultrasound-guided de-roofing of epithelialised tunnels of hidradenitis suppurativa. 62
34028797 2021
648
[Systemic treatment of moderate/severe hidradenitis suppurativa]. 62
34189590 2021
649
[Perforator based flaps of lateral thoracic artery (LTAP) and thoracodorsal artery (TDAP) for axillary reconstruction in patients with hidradenitis suppurativa]. 62
32820484 2021
650
Remote consultations for patients with hidradenitis suppurativa during the COVID-19 pandemic: a single-centre experience. 62
33864282 2021
651
[Hidradenitis suppurativa /acne inversa-surgical options, reconstruction and combinations with drug therapies-an update]. 62
34228137 2021
652
[Epidemiology, patient quality of life, and treatment costs of hidradenitis suppurativa/acne inversa]. 62
34223939 2021
653
[Hidradenitis suppurativa/acne inversa in daily practice]. 62
34223937 2021
654
Development of In-Situ Spray for Local Delivery of Antibacterial Drug for Hidradenitis Suppurativa: Investigation of Alternative Formulation. 62
34451309 2021
655
Hidradenitis Suppurativa Specialty Clinics in the USA. 62
34604323 2021
656
Perifolliculitis capitis abscedens et suffodiens with hidradenitis suppurativa and nodulocystic acne treated with adalimumab. 62
33960498 2021
657
British Association of Dermatologists National Clinical Audit on the Management of Hidradenitis Suppurativa in the UK. 62
33577133 2021
658
Topography of lesion progression in hidradenitis suppurativa. 62
33369730 2021
659
High-fat diet induces a predisposition to follicular hyperkeratosis and neutrophilic folliculitis in mice. 62
33713763 2021
660
Hidradenitis suppurativa and sleep disorders: a population-based study. 62
33893667 2021
661
[Acne inversa: A rare disease with far-reaching consequences for those affected : Experiences and wishes of patients]. 62
34259898 2021
662
Neutrophilic Eccrine Hidradenitis. 62
34347955 2021
663
Successful treatment of pyoderma gangrenosum, acne, and suppurative hidradenitis syndrome with granulocyte and monocyte adsorption apheresis. 62
33991008 2021
664
A Novel Technique for the Treatment of a Case of Verneuil's Disease of Perineum and Axillary Regions. 62
34295976 2021
665
A Case of Neutrophilic Eccrine Hidradenitis in a Patient with Crohn's Disease. 62
34759403 2021
666
Neutrophil trafficking: the missing link in the pathogenesis of hidradenitis suppurativa. 62
33885149 2021
667
Split-thickness skin graft in one-stage procedure for severe axillary hidradenitis suppurativa. 62
34076328 2021
668
Identifying triggers for hidradenitis suppurativa flare: a patient survey. 62
33665807 2021
669
Biologic survival in hidradenitis suppurativa: much done, more to do. 62
34121174 2021
670
Should We Scan Hidradenitis Suppurativa Patients? A Systematic Review of Radiologic Findings. 62
34125731 2021
671
Clinico-Epidemiological Characteristics of Hidradenitis Suppurativa: A Retrospective Cohort Study from a Tertiary Care Centre in Northern India. 62
34430460 2021
672
[Impact of LAight therapy on hidradenitis suppurativa care]. 62
34125251 2021
673
Oral clindamycin and rifampicin in the treatment of hidradenitis suppurativa-acne inversa in patients of paediatric age: a pilot prospective study. 62
33544882 2021
674
The Role of Oral Contraceptive Pills in Hidradenitis Suppurativa: A Cohort Study. 62
34357069 2021
675
mTORC1 - a potential player in the pathogenesis of hidradenitis suppurativa? 62
33656206 2021
676
MCPIP1/Regnase-1 Expression in Keratinocytes of Patients with Hidradenitis Suppurativa: Preliminary Results. 62
34298861 2021
677
Intermittent low-dose corticosteroid therapy for hidradenitis suppurativa: A case series. 62
34189222 2021
678
Hidradenitis suppurativa and amyloidosis: a possible association with the pyrin inflammasome. 62
33577081 2021
679
Smoking cessation outcomes in patients with hidradenitis suppurativa: a retrospective analysis. 62
33576526 2021
680
Evaluation of barriers to therapeutic drug monitoring in the management of hidradenitis suppurativa. 62
33576504 2021
681
Pain management in hidradenitis suppurativa and a proposed treatment algorithm. 62
32950543 2021
682
Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa. 62
33400270 2021
683
Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. 62
33594790 2021
684
Severe hidradenitis suppurativa (acne inversa) associated with focal segmental glomerulosclerosis and gout partially responsive to canakinumab. 62
34036700 2021
685
Hidradenitis suppurativa-specific, patient-reported outcome measures. 62
34139050 2021
686
Long-term treatment with apremilast in hidradenitis suppurativa: A 2-year follow-up of initial responders. 62
32891782 2021
687
Erythrasma in 4 skin of color patients with hidradenitis suppurativa. 62
34195323 2021
688
Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine during Ixekizumab treatment for hidradenitis suppurativa. 62
34809775 2021
689
Adalimumab and infliximab survival in patients with hidradenitis suppurativa: a daily practice cohort study. 62
33544917 2021
690
Treatment of hidradenitis suppurativa with tetracycline, doxycycline, or lymecycline: a prospective study. 62
33660281 2021
691
Hidradenitis suppurativa is associated with acne keloidalis nuchae: a population-based study. 62
32676745 2021
692
Late-onset hidradenitis suppurativa: A cluster analysis of the National Italian Registry IRHIS. 62
33677001 2021
693
Convergent Validity of Suffering and Quality of Life as Measured by The Hidradenitis Suppurativa Quality of Life. 62
33539563 2021
694
Intralesional Triamcinolone for Hidradenitis Suppurativa-How Much Is Needed? 62
33625152 2021
695
Impact of Treatment With TNF-α Inhibitors for Hidradenitis Suppurativa During the COVID-19 Pandemic. 62
33625899 2021
696
Incidence of Venous Thromboembolism in Patients With Dermatologist-Diagnosed Chronic Inflammatory Skin Diseases. 62
34037662 2021
697
Cross-sectional study reveals reduced odds of allergies in people with hidradenitis suppurativa. 62
32781187 2021
698
A case of myeloperoxidase-antineutrophil cytoplasmic antibody and anticardiolipin antibody-positive pyogenic arthritis, pyoderma gangrenosum, acne and hidradenitis suppurativa (PAPASH) syndrome with colitis. 62
33560194 2021
699
Two Cases of Hidradenitis Suppurativa Treated with Adalimumab at the Department of Dermatology and Venereology, Clinical Hospital Mostar. 62
34477078 2021
700
Recurrent myocarditis in the context of Behçet's disease: a case report. 62
34345764 2021
701
Family physicians' awareness and general knowledge of hidradenitis suppurativa: A survey research. 62
33780110 2021
702
Mammary Hidradenitis Suppurativa Lesions - A Suggestion for Phenotyping. 62
34477072 2021
703
Unilateral Breast Skin Changes in Patient With Hidradenitis Suppurativa: Malignancy Versus Lymphedema. 62
34367830 2021
704
Trends in body mass index before and after diagnosis of hidradenitis suppurativa. 62
33300131 2021
705
Elevated body mass index, a risk factor or consequence of hidradenitis suppurativa? 62
33755195 2021
706
Analysis of prior authorization success and timeliness at a community-based specialty care pharmacy. 62
33618986 2021
707
The Burden of Hidradenitis Suppurativa Signs and Symptoms in Quality of Life: Systematic Review and Meta-Analysis. 62
34206415 2021
708
The concealed morbidity of buried penis: a narrative review of our progress in understanding adult-acquired buried penis as a surgical condition. 62
34295741 2021
709
Gender differences in sexual health impairment in hidradenitis suppurativa: A systematic review. 62
34222580 2021
710
Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. 62
33548397 2021
711
Dapsone as an Effective Treatment for Arthritis Secondary to Hidradenitis Suppurativa. 62
34081891 2021
712
Autoinflammatory keratinitzation diseases (AIKDs. 62
34118208 2021
713
Intermammary Hidradenitis Suppurativa: Considerations on a Unique Presentation. 62
34307482 2021
714
Multifocal myositis and elevated creatine phosphokinase associated with the use of ustekinumab for hidradenitis suppurativa. 62
33370450 2021
715
Obstructive sleep apnoea in psoriasis and hidradenitis suppurativa. 62
33404093 2021
716
Long-standing refractory hidradenitis suppurativa responded to a brodalumab monotherapy in a patient with psoriasis: A possible involvement of Th17 across the spectrum of both diseases. 62
33609416 2021
717
Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment. 62
34043022 2021
718
Investigation of gamma secretase gene complex mutations in German population with Hidradenitis suppurativa designate a complex polygenic heritage. 62
33559291 2021
719
Hidradenitis suppurativa in South-East Asia and East Asia. 62
34085331 2021
720
Efficacy and safety of adalimumab in hidradenitis suppurativa: A systematic review and meta-analysis of randomized controlled trials. 62
34087885 2021
721
Comparing the Effectiveness and Safety Associated With Infliximab vs Infliximab-abda Therapy for Patients With Hidradenitis Suppurativa. 62
33825849 2021
722
Quality of Life in Hidradenitis Suppurativa: An Update. 62
34204126 2021
723
Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. 62
32893875 2021
724
Successful Treatment of Coexistent Acne Fulminans and Severe Hidradenitis Suppurativa with Adalimumab. 62
34307485 2021
725
Provider perspectives on the management of hidradenitis suppurativa in pregnancy - A survey study. 62
34222596 2021
726
Isotretinoin in the treatment of hidradenitis suppurativa: a retrospective study. 62
31535587 2021
727
Corticosteroid rescue therapy in relapsing hidradenitis suppurativa treated with adalimumab. 62
33539633 2021
728
Hidradenitis suppurativa in patients of color is associated with increased disease severity and healthcare utilization: A retrospective analysis of 2 U.S. cohorts. 62
34409370 2021
729
Association of Trimethylamine N-Oxide (TMAO) with the Clinical Severity of Hidradenitis Suppurativa (Acne Inversa). 62
34200594 2021
730
Histologic progression of acne inversa/hidradenitis suppurativa: Implications for future investigations and therapeutic intervention. 62
33377546 2021
731
Hidradenitis suppurativa in skin of colour. 62
34085333 2021
732
Pain Index: a new prospective hidradenitis suppurativa patient-reported outcome measure instrument. 62
33492666 2021
733
Anti-COVID-19 measurements for hidradenitis suppurativa patients. 62
34085330 2021
734
Association of clinical severity scores with psychosocial impact in patients with hidradenitis suppurativa. 62
32781189 2021
735
Novel use of Asopa technique for penile urethrocutaneous fistula repair. 62
33387231 2021
736
Target molecules for future hidradenitis suppurativa treatment. 62
34085329 2021
737
Impact of Bariatric Surgery on Hidradenitis Suppurativa. 62
34003299 2021
738
Frequency of allergic contact dermatitis in hidradenitis suppurativa patients. 62
33070570 2021
739
Do collagen-related diseases represent a risk factor for hidradenitis suppurativa? 62
33492758 2021
740
10th European Hidradenitis Suppurativa (EHSF) e.V. Conference: A jubilee scientific event. 62
34085335 2021
741
10th European Hidradenitis Suppurativa (EHSF) e.V. Conference. 62
34085334 2021
742
Reply to: Comment on "Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa". 62
32800873 2021
743
Comment on "Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa". 62
32800872 2021
744
Development or exacerbation of hidradenitis suppurativa in two transgender men after initiation of testosterone therapy. 62
33448331 2021
745
Evaluation of serum omentin-1 and apelin concentrations in patients with hidradenitis suppurativa. 62
34377127 2021
746
A survey of clinicians regarding preferred severity assessment tools for hidradenitis suppurativa. 62
33179770 2021
747
Intralesional photodynamic therapy in hidradenitis suppurativa: Getting closer to the target. 62
33992813 2021
748
[CME Dermatology 23/Answers: Hidradenitis suppurativa]. 62
34107755 2021
749
Caring for Pediatric Hidradenitis Suppurativa Patients in the Emergency Department. 62
34038926 2021
750
Caring for Pediatric Hidradenitis Suppurativa Patients in the Emergency Department. 62
34038925 2021
751
Hidradenitis suppurativa lesions are associated with decreased collagen, decreased elastin, and increased neovascularization. 62
33757414 2021
752
Efficacy and tolerability of long-pulse Alexandrite laser hair removal for hidradenitis suppurativa. 62
34106051 2021
753
Does smoking affect your skin? 62
34377115 2021
754
Vulval squamous cell carcinoma arising from hidradenitis suppurrativa. 62
34130973 2021
755
Pseudomonas-Contaminated Pool Triggering an Episode of Idiopathic Palmoplantar Hidradenitis. 62
34594199 2021
756
Exploring the human hair follicle microbiome. 62
32762039 2021
757
Hidradenitis Suppurativa Treated With Apremilast: A Case Series. 62
33984314 2021
758
Hidradenitis suppurativa through the lens of YouTube: A cross-sectional analysis. 62
32522514 2021
759
Genetic variations in gamma-secretase and PSTPIP1 in hidradenitis suppurativa in Singaporean Chinese. 62
33460495 2021
760
Hidradenitis suppurativa: A retrospective analysis of an Australian multidisciplinary service. 62
32951199 2021
761
Facklamia hominis in hidradenitis suppurativa. 62
33898677 2021
762
Metronidazole for Hidradenitis Suppurativa: future potential treatment applications. 62
33393693 2021
763
Characterization of Hidradenitis Suppurativa Phenotypes: A Multidimensional Latent Class Analysis of the National Italian Registry IRHIS. 62
33098826 2021
764
Opportunities for better outcomes in patients with hidradenitis suppurativa. 62
32771541 2021
765
Low prescription of tumor necrosis alpha inhibitors in hidradenitis suppurativa: A cross-sectional analysis. 62
32758630 2021
766
[Anakinra therapy in a patient with multifocal pyoderma gangrenosum and hidradenitis suppurativa]. 62
33095334 2021
767
A growing family of outcome measurement proposals for hidradenitis suppurativa. 62
33398878 2021
768
The association between hidradenitis suppurativa and male and female infertility: A population-based study. 62
33399222 2021
769
The measurement performance of the EQ-5D-5L versus EQ-5D-3L in patients with hidradenitis suppurativa. 62
33534032 2021
770
The link between hidradenitis suppurativa and phylloid hypomelanosis in partial trisomy-13 mosaicism: New evidences and further genetic/pathogenetic insights. 62
33715178 2021
771
Disease severity and poor mental health are the main predictors of stigmatization in patients with hidradenitis suppurativa. 62
33619860 2021
772
Hidradenitis Suppurativa Area and Severity Index Revised (HASI-R): psychometric property assessment. 62
32969027 2021
773
Serum cytokine levels in patients with hidradenitis suppurativa vary with race. 62
32860911 2021
774
Impact of hidradenitis suppurativa on work productivity and associated risk factors. 62
32763324 2021
775
25-Hydroxyvitamin D serum levels inversely correlate to disease severity and serum C-reactive protein levels in patients with hidradenitis suppurativa. 62
33624897 2021
776
Epidemiology of hidradenitis suppurativa in Taiwan: A 14-year nationwide population-based study. 62
33626195 2021
777
Full exome sequencing of 11 families with Hidradenitis suppurativa. 62
33336462 2021
778
Successful treatment of recalcitrant hidradenitis suppurativa with risankizumab after failure of anti-tumour necrosis factor alpha. 62
33301601 2021
779
Intralesional corticosteroid injection for the treatment of hidradenitis suppurativa: a multicenter retrospective clinical study. 62
31402725 2021
780
Tildrakizumab as a potential long-term therapeutic agent for severe Hidradenitis Suppurativa: A 15 months experience of an Australian institution. 62
33729553 2021
781
Guidelines for the management of hidradenitis suppurativa: recommendations supported by the Centre of Evidence of the French Society of Dermatology. 62
33278829 2021
782
Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? 62
33665949 2021
783
Unraveling the Heterogeneity of Hidradenitis Suppurativa with Phenotype Schema. 62
33888215 2021
784
Real-world experience of adalimumab in the treatment of hidradenitis suppurativa. 62
33316329 2021
785
Association of inflammatory skin diseases with venous thromboembolism in US adults. 62
32642810 2021
786
Are dissecting cellulitis and hidradenitis suppurativa different diseases? 62
34518010 2021
787
The impact of autoimmune systemic inflammation and associated medications on male reproductive health in patients with chronic rheumatological, dermatological, and gastroenterological diseases: A systematic review. 62
33420722 2021
788
[Psychiatric comorbidities in hidradenitis suppurativa/acne inversa]. 62
33398389 2021
789
Chronic Systemic Inflammatory Skin Disease as a Risk Factor for Cardiovascular Disease. 62
33607473 2021
790
Association of hidradenitis suppurativa with Crohn's disease. 62
34046451 2021
791
Surgical reconstruction of massive scrotal lymphedema associated with hidradenitis suppurativa: a case report. 62
34164324 2021
792
Systemic antibiotics in hidradenitis suppurativa: efficacy and effects of body mass index and smoking pack-year on the response to therapy. 62
33634552 2021
793
COVID-19: The Italian experience. 62
34517999 2021
794
The Association among Pyoderma Gangrenosum, Ulcerative Colitis, and Hidradenitis Suppurativa and the Syndromic Hidradenitis Suppurativa Network: A Case Report. 62
34055914 2021
795
Hidradenitis suppurativa - The role of interleukin-17, the aryl hydrocarbon receptor and the link to a possible fungal aetiology. 62
33607406 2021
796
Severe hidradenitis suppurativa in a patient affected by Hermansky-Pudlak Syndrome type 9: possible shared pathogenetic aspects. 62
33423449 2021
797
Case of bullous pemphigoid under treatment with adalimumab for hidradenitis suppurativa. 62
33502014 2021
798
Case of neutrophilic eccrine hidradenitis resembling acanthosis nigricans in a patient with acute myeloid leukemia associated with azacitidine and sorafenib. 62
33543504 2021
799
Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. 62
33910945 2021
800
Clinical and demographic features of hidradenitis suppurativa: a multicentre study of 1221 patients with an analysis of risk factors associated with disease severity. 62
33030217 2021
801
Hidradenitis suppurativa associated with a novel NCSTN mutation and concomitant Klippel-Trenaunay syndrome. 62
33814361 2021
802
Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. 62
33608949 2021
803
Screening for cardiovascular comorbidity in United States outpatients with psoriasis, hidradenitis, and atopic dermatitis. 62
32393987 2021
804
Global Harmonization of Morphological Definitions in Hidradenitis Suppurativa for a Proposed Glossary. 62
33688910 2021
805
Long-term antibiotic use for the treatment of hidradenitis suppurativa consistent with guideline recommendations. 62
33202036 2021
806
Doppler ultrasound-based noninvasive biomarkers in hidradenitis suppurativa: evaluation of analytical and clinical validity. 62
32602132 2021
807
Hidradenitis Suppurativa in the Pediatric Population: An International, Multicenter, Retrospective, Cross-sectional Study of 481 Pediatric Patients. 62
33625473 2021
808
Treatment of hidradenitis suppurativa with certolizumab pegol during pregnancy. 62
33247833 2021
809
Assessment of familial risk in patients with hidradenitis suppurativa. 62
33152101 2021
810
Comparison of clinical and sonographic scores in hidradenitis suppurativa and proposal of a novel ultrasound scoring system. 62
30298709 2021
811
Bibliometric Analysis of the 50 Most Cited Publications in Hidradenitis Suppurativa. 62
34055904 2021
812
Outcomes of Routine Diabetes Screening for Patients with Hidradenitis Suppurativa. 62
32910937 2021
813
Recurrence Rates Following Reconstruction Strategies After Wide Excision of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. 62
33795566 2021
814
Drug repurposing through drug-gene interaction profiles for hidradenitis suppurativa/acne inversa treatment. 62
33007126 2021
815
An additional drug repurposing study for hidradenitis suppurativa/acne inversa. 62
33095911 2021
816
Hidradenitis suppurativa odour and drainage scale: a novel method for evaluating odour and drainage in patients with hidradenitis suppurativa. 62
33205398 2021
817
Validation of global item for assessing impact on quality of life of patients with hidradenitis suppurativa. 62
32602129 2021
818
Vulvar hidradenitis suppurativa: Clinical cross-sectional study of 25 patients. 62
33547675 2021
819
HIDRADENITIS SUPPURATIVA IN POSTMENOPAUSE. 62
34925580 2021
820
Squamous Cell Carcinoma in Hidradenitis Suppurativa Lesions Following Tumor Necrosis Factor α Inhibitors. 62
34096852 2021
821
Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa. 62
34094734 2021
822
Expert Knowledge, Attitudes, and Practices in Management of Hidradenitis Suppurativa Pain. 62
33625467 2021
823
Clinical Epidemiology and Management of Hidradenitis Suppurativa. 62
33706337 2021
824
Comment on "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa". 62
33253840 2021
825
Authors' reply to the comment "High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa". 62
33253838 2021
826
Metascoring Hidradenitis suppurativa. 62
33131129 2021
827
Superficial fungal infections and patients with hidradenitis suppurativa: a study under the Danish Blood Donor Study. 62
33006774 2021
828
Strong validation of ultrasound as an imaging biomarker in hidradenitis suppurativa. 62
32869312 2021
829
European registry for hidradenitis suppurativa: state of play. 62
33135255 2021
830
Recognizing the Effects and Disparities of Pediatric Hidradenitis Suppurativa. 62
33625471 2021
831
Importance of Standardized Nomenclature to Advance Hidradenitis Suppurativa Research and Clinical Care. 62
33688911 2021
832
The management of hidradenitis suppurativa degenerating into squamous cell carcinoma: About three case reports. 62
33868679 2021
833
Impact of 970 nm photobiomodulation therapy on wound healing in cellular models of hidradenitis suppurativa. 62
32647934 2021
834
Hidradenitis suppurativa associated with actinomycosis owing to Actinomyces meyeri. 62
33140414 2021
835
Pain Control in Dermatologic Conditions. 62
33821364 2021
836
Lymph Node Involvement in Axillary Hidradenitis Suppurativa: A Clinical, Ultrasonographic and Bacteriological Study Conducted during Radical Surgery. 62
33916058 2021
837
Preparing the hair follicle canal for hair shaft emergence. 62
33025661 2021
838
Obesity is Not Associated With Need for Skin Grafting After Hidradenitis Excision. 62
33047967 2021
839
Assessing Psychological Interventions for Hidradenitis Suppurativa as a First Step Toward Patient-Centered Practice. 62
33956602 2021
840
Cutaneous Squamous Cell Carcinoma in Patients with Hidradenitis Suppurativa. 62
33800250 2021
841
Crystallized phenol for sacral hidradenitis suppurativa. 62
31259621 2021
842
Use of primary care services among patients with chronic skin disease seen by dermatologists. 62
34409351 2021
843
Hidradenitis suppurativa and perceived stigmatization in a diverse Canadian clinic population: a pilot study. 62
33095910 2021
844
Hidradenitis suppurativa and major adverse cardiac events: A systematic review and meta-analysis. 62
33038472 2021
845
Interventions in case of acute exacerbation of hidradenitis suppurativa. 62
33754667 2021
846
High-frequency ultrasound as a non-invasive tool in predicting early hidradenitis suppurativa fistulization in comparison with the Hurley system. 62
33111357 2021
847
Abscess Management: An Evidence-Based Review for Emergency Medicine Clinicians. 62
33298356 2021
848
Current Surgical Management of Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. 62
33481433 2021
849
Cryptic deep dermatophytosis in a renal transplant recipient with hidradenitis suppurativa. 62
33665286 2021
850
New insights into hidradenitis suppurativa diagnosis via salivary infrared biosignatures: A pilot study. 62
33231348 2021
851
Antidrug antibodies to tumour necrosis factor inhibitors in hidradenitis suppurativa: a systematic review. 62
33006769 2021
852
Clinical and Power-Doppler ultrasound features related with persistence of fistulous tracts under treatment with adalimumab in hidradenitis suppurativa: 4 years of follow-up. 62
33486868 2021
853
A microbiome study to explore the gut-skin axis in hidradenitis suppurativa. 62
33423845 2021
854
Candida Esophagitis Associated With Adalimumab for Hidradenitis Suppurativa. 62
33956612 2021
855
Severe hidradenitis suppurativa with herpes simplex virus 1 superinfection and clinical responsiveness to ixekizumab. 62
33598516 2021
856
PASH, PAPASH, PsAPASH, and PASS: The autoinflammatory syndromes of hidradenitis suppurativa. 62
34272017 2021
857
Effectiveness of clindamycin and rifampicin combination therapy in hidradenitis suppurativa: a 6-month prospective study. 62
33000461 2021
858
Plastic Surgical Management of Hidradenitis Suppurativa. 62
33620946 2021
859
Prevalence and cutaneous comorbidities of hidradenitis suppurativa in the German working population. 62
32322958 2021
860
Quality of life in hidradenitis suppurativa: A cross-sectional study of a pediatric population. 62
33011326 2021
861
Evaluation of the laboratory parameters in hidradenitis suppurativa: Can we use new inflammatory biomarkers? 62
33527638 2021
862
Reproductive Potential and Outcomes in Patients with Hidradenitis Suppurativa: Clinical Profile and Therapeutic Implications. 62
33810294 2021
863
Hidradenitis Suppurativa: Host-Microbe and Immune Pathogenesis Underlie Important Future Directions. 62
34909706 2021
864
A visit guide for hidradenitis suppurativa-Managing a complex disease in a busy clinic. 62
33010310 2021
865
Race-Specific Prevalence of Hidradenitis Suppurativa. 62
33174482 2021
866
Hidradenitis suppurativa: A review of post-operative outcomes. 62
32868233 2021
867
Is There a Role for Therapeutic Drug Monitoring in Patients with Hidradenitis Suppurativa on Tumor Necrosis Factor-α Inhibitors? 62
33398848 2021
868
Physician perspectives on complementary and alternative medicine in hidradenitis suppurativa. 62
33547869 2021
869
Dermal tunnels influence time to clinical response and family history influences time to loss of clinical response in patients with hidradenitis suppurativa treated with adalimumab. 62
32931599 2021
870
Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease. 62
31389737 2021
871
Concomitant psoriasis and hidradenitis suppurativa responsive to adalimumab therapy: A case series. 62
31389375 2021
872
Hidradenitis suppurativa and chromosomal abnormalities: a case report and systematic review of the literature. 62
33599294 2021
873
Human cutaneous B cells: what do we really know? 62
33842661 2021
874
Surgical Excision of a Pilonidal Sinus at the Neck Region. 62
33889456 2021
875
Dynamic Leukocyte Populations Are Associated With Early- and Late-stage Lesions in Hidradenitis Suppurativa. 62
33238789 2021
876
Co-occurrence of Ichthyosis Vulgaris, Dowling-Degos Disease, and Hidradenitis Suppuritiva in Same Patient: An Association or Coincidence? 62
34188288 2021
877
Specific urogenital disease information-revealing male genital votive offerings dedicated to gods in ancient age sanctuary medicine. 62
33650539 2021
878
Body mass index at the onset of hidradenitis suppurativa. 62
33569917 2021
879
Hidradenitis suppurativa - Body-Mass-Index zu Beginn der Erkrankung. 62
33709574 2021
880
Analyzing the Efficacy of Isotretinoin in Treating Dissecting Cellulitis: A Literature Review and Meta-Analysis. 62
33387328 2021
881
The role of biologic treatment in special scenarios in hidradenitis suppurativa: Facial and nape phenotype, dissecting cellulitis of the scalp, and lymphedema. 62
33527618 2021
882
Hidradenitis suppurativa is associated with hypothyroidism and hyperthyroidism: a large-scale population-based study. 62
33241580 2021
883
Therapeutic Drug Monitoring in Patients with Suboptimal Response to Adalimumab for Hidradenitis Suppurativa: A Retrospective Case Series. 62
33242185 2021
884
Pruritus as a Distinctive Feature of Type 2 Inflammation. 62
33807098 2021
885
Clinical Research after COVID-19: Embracing a New Normal. 62
32890628 2021
886
The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. 62
33810197 2021
887
Multiomics Integration in Skin Diseases with Alterations in Notch Signaling Pathway: PlatOMICs Phase 1 Deployment. 62
33546374 2021
888
Acneiform Presentations of Folliculotropic Mycosis Fungoides. 62
33492839 2021
889
Mechanical forces and Hidradenitis Suppurativa. 62
33155312 2021
890
Fatal New-Onset Congestive Heart Failure Related to Adalimumab Use in a Patient with Relapsing Hidradenitis Suppurativa: A Case Report. 62
33563886 2021
891
Discovery of LYS006, a Potent and Highly Selective Inhibitor of Leukotriene A4 Hydrolase. 62
33592148 2021
892
Anti-PD-1-Induced Hidradenitis Suppurativa. 62
33668724 2021
893
A Multicenter Analysis of Wide Excision and Reconstruction for Severe Anogenital Hidradenitis Suppurativa. 62
33449465 2021
894
Sexual impairment in patients with hidradenitis suppurativa: a systematic review. 62
32531099 2021
895
Therapeutic Use of Botulinum Neurotoxins in Dermatology: Systematic Review. 62
33562846 2021
896
Lichen sclerosus and hidradenitis suppurativa: Two case reports of a new possible association. 62
32815154 2021
897
Low Incidence of Inflammatory Bowel Disease Adverse Events in Adalimumab Clinical Trials Across Nine Different Diseases. 62
32100944 2021
898
Adult Acquired Buried Penis: A Hidden Problem in Obese Men. 62
33680609 2021
899
The Microbiome in Hidradenitis Suppurativa: A Review. 62
33244661 2021
900
Itch and pain by lesion morphology in hidradenitis suppurativa patients. 62
32662883 2021
901
Interactive, Proof of Concept Clinical Trial Design in Hidradenitis Suppurativa. 62
32585209 2021
902
Self-Reported Pain Alleviating Methods in Patients with Hidradenitis Suppurativa. 62
33232705 2021
903
Burden of Ocular Comorbidities in Patients With Hidradenitis Suppurativa. 62
33404588 2021
904
Non-pharmacologic approaches for hidradenitis suppurativa - a systematic review. 62
31106609 2021
905
Pregnancy in Hidradenitis Suppurativa-Patient Perspectives and Practice Gaps. 62
33439230 2021
906
Efficacy of high-dose intralesional triamcinolone for hidradenitis suppurativa. 62
32808305 2021
907
Hidradenitis suppurativa patient perspectives during the COVID-19 pandemic. 62
33818992 2021
908
Noninvasive assessment of cytokine and antimicrobial peptide levels in hidradenitis suppurativa using transdermal analysis patches. 62
32767746 2021
909
Weekly administration of brodalumab in hidradenitis suppurativa: an open-label cohort study. 62
32974912 2021
910
A Systematic Review of Promising Therapeutic Targets in Hidradenitis Suppurativa: A Critical Evaluation of Mechanistic and Clinical Relevance. 62
32919760 2021
911
Improved Psychosocial Status after Surgery for Genital Elephantiasis due to Hidradenitis Suppurativa: A Prospective Study of a Case Series. 62
33470416 2021
912
Wide Local Excisions and Pedicled Perforator Flaps in Hidradenitis Suppurativa: A Study of Quality of Life. 62
32881748 2021
913
Postoperative Quality of Life in Patients with Hidradenitis Suppurativa Utilizing the Hidradenitis Suppurativa Burden of Disease Tool. 62
33575157 2021
914
Factors Determining Affected Sites in Hidradenitis Suppurativa. 62
33524978 2021
915
Long-term efficacy and safety of adalimumab on a severe case of hidradenitis suppurativa. 62
30350561 2021
916
Invasive Cutaneous Squamous Cell Carcinoma Arising from Chronic Hidradenitis Suppurativa: A Case Report of Treatment by Slow Mohs Micrographic Surgery. 62
33911814 2021
917
Tattooing in Hidradenitis Suppurativa. 62
33540404 2021
918
The Importance of Methodological Rigor in Proof-of-Concept Clinical Trials: A Lesson from Hidradenitis Suppurativa. 62
32585210 2021
919
Management of Severe Hidradenitis Suppurativa. 62
33777570 2021
920
Medical infrared thermography as hidradenitis suppurativa diagnostic tool: literature review. 62
34408563 2021
921
A study of biophysical profile of inguinal skin: An implication for health and disease. 62
34765931 2021
922
First real-world data provide evidence for a 'window of opportunity' in treatment of hidradenitis suppurativa/acne inversa. 62
32476130 2021
923
Characterizing physical symptoms of flare in hidradenitis suppurativa: a patient survey. 62
32702152 2021
924
Characteristics of patients with hidradenitis suppurativa seen at a tertiary care facility from 2009-2019: a retrospective chart review study. 62
33560801 2021
925
Ectopic Hidradenitis Suppurativa: Case Report and Review of Literature. 62
33659117 2021
926
Vascularization and fibrosis are important ultrasonographic tools for assessing response to adalimumab in hidradenitis suppurativa: Prospective study of 32 patients. 62
33368976 2021
927
A case report about adalimumab-induced radiologically isolated syndrome: A significant side effect of tumour necrosis factor inhibitors. 62
33796317 2021
928
Treatment of hidradenitis suppurativa using a long-pulsed hair removal neodymium:yttrium-aluminium-garnet laser: A multicenter, prospective, randomized, intraindividual, comparative trial. 62
32348825 2021
929
Conceivable Differences between the Sexes for the Associations of Patient Characteristics with Locations Affected by Hidradenitis Suppurativa. 62
32316016 2021
930
Sonographic Evaluation of Hidradenitis Suppurativa with Smartphone-Linked Portable Ultrasound. 62
33684921 2021
931
Real-Time Confocal Imaging for Hidradenitis Suppurativa: Description of Morphological Aspects and Focus on the Role of Follicular Ostia. 62
33588411 2021
932
[CME Dermatology 23: Hidradenitis suppurativa]. 62
34019444 2021
933
Botulinum toxin type A for the management of hidradenitis suppurativa. 62
35035756 2021
934
Nicotine Dependency and Readiness to Quit Smoking among Patients with Hidradenitis Suppurativa. 62
33535209 2021
935
Radiotherapy for Hidradenitis Suppurativa: A Systematic Review. 62
33535201 2021
936
Hidradenitis suppurativa in surgeons' practice: Prevalence and treatment approach according to the Hurley stage in Latvia. 62
33331018 2021
937
A petition for all patients with hidradenitis suppurativa to receive the HPV vaccine. 62
32975480 2021
938
Multidisciplinary Management of Adolescents with Hidradenitis Suppurativa - Series of Cases and Literature Review. 62
34429610 2021
939
Correction: Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital. 62
34506609 2021
940
Pediatric Hidradenitis Suppurativa with Concomitant Bipolar Disorder: An Underrepresented Population. 62
33361701 2021
941
Prevalence of Hidradenitis Suppurativa in Colombia According to Data from the National Health Registry. 62
34861917 2021
942
Plant Antimicrobial Peptides as Potential Tool for Topic Treatment of Hidradenitis Suppurativa. 62
34966375 2021
943
Hidradenitis Suppurativa Caused by Vedolizumab. 62
33208632 2021
944
Potential role of human allogeneic mesenchymal cells in the treatment of refractory fistulas in patients with hidradenitis suppurativa. 62
33191614 2021
945
Pregnancy and breastfeeding in hidradenitis suppurativa: A review of medication safety. 62
33320387 2021
946
Economic analysis of the costs associated with Hidradenitis suppurativa at a German University Hospital. 62
34347845 2021
947
Proceeding report of the Fourth Symposium on Hidradenitis Suppurativa Advances 2019. 62
32497690 2021
948
The P2X7 Receptor Is Overexpressed in the Lesional Skin of Subjects Affected by Hidradenitis Suppurativa: A Preliminary Study. 62
31454821 2021
949
Risk of Hidradenitis Suppurativa Comorbidities Over Time: A Prospective Cohort Study of Danish Blood Donors. 62
33372684 2021
950
Age-specific physical and mental health status in Italian patients with hidradenitis suppurativa: a comparison with the general population. 62
32270321 2021
951
Thyroid Disease and Active Smoking May Be Associated with More Severe Hidradenitis Suppurativa: Data from a Prospective Cross Sectional Single-Center Study. 62
32966979 2021
952
Increased expression profile of NCSTN, Notch and PI3K/AKT3 in hidradenitis suppurativa. 62
32978818 2021
953
Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts. 62
33503635 2021
954
COVID-19 in patients with hidradenitis suppurativa. 62
32880904 2021
955
Rapid Response to Certolizumab Pegol in Hidradenitis Suppurativa: A Case Report. 62
33614722 2021
956
γ-Secretase Genetics of Hidradenitis Suppurativa: A Systematic Literature Review. 62
33333507 2021
957
Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study. 62
32119111 2021
958
Race and Ethnicity Gaps in Global Hidradenitis Suppurativa Clinical Trials. 62
31865334 2021
959
A Comparison of International Management Guidelines for Hidradenitis Suppurativa. 62
31645040 2021
960
Hidradenitis suppurativa - prevalence analyses of German statutory health insurance data. 62
32580237 2021
961
Undergarment and Fabric Selection in the Management of Hidradenitis Suppurativa. 62
31466052 2021
962
Single-Cell RNA Sequencing Reveals Cellular and Transcriptional Changes Associated With M1 Macrophage Polarization in Hidradenitis Suppurativa. 62
34504848 2021
963
Diagnosis and management of hidradenitis suppurativa in women. 62
32980357 2021
964
Features Associated With Quality of Life Impairment in Hidradenitis Suppurativa Patients. 62
33987196 2021
965
Pain Severity and Management of Hidradenitis Suppurativa at US Emergency Department Visits. 62
33206135 2021
966
Irrelevance of Panton-Valentine leukocidin in hidradenitis suppurativa: results from a pilot, observational study. 62
32767177 2021
967
Staphylococcus aureus Carriage in Hidradenitis Suppurativa: Impact on Response to Adalimumab. 62
33401280 2021
968
Implications of Hidradenitis Suppurativa Phenotypes in Cardiovascular Risk and Treatment Decisions: A Retrospective Cohort Study. 62
33477150 2021
969
Combining Deroofing with LAight® Therapy for Long-Term Disease Control of Hurley Stage II Hidradenitis Suppurativa: Case Report. 62
33506816 2021
970
Gut Microbiome Perturbations in Patients with Hidradenitis Suppurativa: A Case Series. 62
32422215 2021
971
Lymecycline vs. clindamycin plus rifampicin in hidradenitis suppurativa treatment: clinical and ultrasonography evaluation. 62
32683727 2021
972
Real life data on the biopsychosocial effects of Adalimumab in the management of hidradenitis suppurativa: A multicenter cross sectional analysis and consideration of a multisystem monitoring approach to follow up. 62
33296539 2021
973
New perspectives on the treatment of hidradenitis suppurativa. 62
34840709 2021
974
Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa. 62
32368973 2021
975
Pain in Hidradenitis Suppurativa: A Cross-sectional Study of 1,795 Patients. 62
33320274 2021
976
MABp1 targeting interleukin-1α in hidradenitis suppurativa ineligible for adalimumab treatment: results of the open-label extension period. 62
32516832 2021
977
Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: Open-label phase 3 results. 62
33029861 2021
978
Nanostructured lipid carriers for hair follicle-targeted delivery of clindamycin and rifampicin to hidradenitis suppurativa treatment. 62
33181388 2021
979
Serum Concentration and Skin Expression of S100A7 (Psoriasin) in Patients Suffering from Hidradenitis Suppurativa. 62
33202403 2021
980
Implementing Medical Chatbots: An Application on Hidradenitis Suppurativa. 62
33744903 2021
981
KID Syndrome and Hidradenitis Suppurativa: A Rare Association Responding to Surgical Treatment. 62
33614714 2021
982
Contrast-enhanced ultrasound with peroxide hydrogen for hidradenitis suppurativa and pilonidal sinus presurgical mapping. 62
33428974 2021
983
Hidradenitis Suppurativa: Proposal of Classification in Two Endotypes with Two-Step Cluster Analysis. 62
33171462 2021
984
Risk of connective tissue disease, morphoea and systemic vasculitis in patients with hidradenitis suppurativa. 62
32531094 2021
985
Development and Validation of HSCAPS-1: A Clinical Decision Support Tool for Diagnosis of Hidradenitis Suppurativa over Cutaneous Abscess. 62
33099547 2021
986
The findings of 18F-fluorodeoxyglucose positron emission tomography-computed tomography scan in patients with hidradenitis suppurativa in Malaysia: A multicenter study. 62
33850487 2021
987
Hidradenitis Suppurativa is Associated with Symptoms of Keratoconjunctivitis Sicca. 62
32506959 2021
988
PSENEN Mutation in Coexistent Hidradenitis Suppurativa and Dowling-Degos Disease. 62
33768038 2021
989
Phenotypes and Pathophysiology of Syndromic Hidradenitis Suppurativa: Different Faces of the Same Disease? A Systematic Review. 62
32942279 2021
990
Association between Hidradenitis Suppurativa and Inflammatory Arthritis: A Systematic Review and Meta-Analysis. 62
33774640 2021
991
Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab. 62
34540202 2021
992
Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern. 62
33326954 2021
993
Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies. 62
34150655 2021
994
Hormonal Contraceptives and Dermatology. 62
32894455 2021
995
Cutaneous Metastatic Breast Cancer Masked by Hidradenitis Suppurativa. 62
33633892 2021
996
Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients. 62
33429896 2021
997
Sexuality in Persons With Hidradenitis Suppurativa: Factors Associated With Sexual Desire and Functioning Impairment. 62
34690835 2021
998
Alexithymia, Psychological Distress, and Social Impairment in Patients with Hidradenitis Suppurativa. 62
31743903 2021
999
Prevalence of inflammatory bowel disease among pediatric patients with hidradenitis suppurativa and the potential role of screening with fecal calprotectin. 62
33099810 2021
1000
Hidradenitis suppurativa: an update on epidemiology, phenotypes, diagnosis, pathogenesis, comorbidities and quality of life. 62
32460374 2021
1001
The Relationship Between Alzheimer's Disease and Skin Diseases: A Review. 62
34729018 2021
1002
NAFLD and Infection, a Nuanced Relationship. 62
33977096 2021
1003
The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa. 62
34239882 2021
1004
Outcomes and adverse effects of ablative vs nonablative lasers for skin resurfacing: A systematic review of 1093 patients. 62
33084193 2021
1005
Anemia in Patients with Hidradenitis Suppurativa: Prevalence and Risk Factors in a Hospital-Based Cohort. 62
35022114 2021
1006
Intellectual Disability and Hidradenitis Suppurativa. 62
33040054 2021
1007
Impact of the COVID-19 pandemic on the course and management of chronic inflammatory immune-mediated skin diseases: What's the evidence? 62
33972053 2021
1008
The utility of PROMIS domain measures in dermatologic care. 62
32270322 2021
1009
A novel mutation in POFUT1 gene associated with Dowling-Degos disease and hidradenitis suppurativa. 62
32767357 2021
1010
Case report of hidradenitis suppurativa localized to the face in an HIV patient. 62
34777812 2021
1011
Hidradenitis Suppurativa Associated with Galli-Galli Disease: Extending the Link with Dowling-Degos Disease. 62
33488918 2020
1012
Prevalence and Risk Factors for Anemia in a Population With Hidradenitis Suppurativa. 62
33457122 2020
1013
Contribution of Genetics to the Susceptibility to Hidradenitis Suppurativa in a Large, Cross-sectional Dutch Twin Cohort. 62
33052394 2020
1014
Coping with Psoriasis or Hidradenitis Suppurativa: A Qualitative Study. 62
33208663 2020
1015
T-cell/histiocyte-rich large B-cell lymphoma in a 27-year-old with hidradenitis suppurativa, psoriasis, and vitiligo: Implications for screening. 62
33294556 2020
1016
Recent advances in hidradenitis suppurativa in pediatrics. 62
33423411 2020
1017
The epidemiology of hidradenitis suppurativa. 62
32880911 2020
1018
Gastrointestinal involvement of primary skin diseases. 62
32455473 2020
1019
Alternative Clinical Indications of Botulinum Toxin. 62
32651806 2020
1020
Efficacy and safety of topical resorcinol 15% as long-term treatment of mild-to-moderate hidradenitis suppurativa: a valid alternative to clindamycin in the panorama of antibiotic resistance. 62
32579711 2020
1021
Surgical management of hidradenitis suppurativa with keystone perforator island flap. 62
32173078 2020
1022
Metformin as Adjunctive Therapy for Pediatric Patients With Hidradenitis Suppurativa. 62
33346525 2020
1023
Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn's disease: Report and systematic literature review of effectiveness and safety. 62
33363841 2020
1024
Clinical characteristics of pediatric hidradenitis suppurativa: a cross-sectional multicenter study of 140 patients. 62
32166376 2020
1025
Menses, pregnancy, delivery, and menopause in hidradenitis suppurativa: A patient survey. 62
33898700 2020
1026
Current and future treatment of hidradenitis suppurativa. 62
29981245 2020
1027
Profound consequences of hidradenitis suppurativa: a review. 62
29744872 2020
1028
What causes hidradenitis suppurativa ?-15 years after. 62
33058306 2020
1029
Ixekizumab in hidradenitis suppurativa in a psoriatic patient. 62
30636397 2020
1030
Hidradenitis suppurativa and adalimumab in the COVID-19 era. 62
33337329 2020
1031
Lipidomics Profiling of Hidradenitis Suppurativa Skin Lesions Reveals Lipoxygenase Pathway Dysregulation and Accumulation of Proinflammatory Leukotriene B4. 62
32387270 2020
1032
Characterizing perimenstrual flares of hidradenitis suppurativa. 62
33898701 2020
1033
Endocrinological disorders and inflammatory skin diseases during COVID-19 outbreak: a review of the literature. 62
32969629 2020
1034
Aetiology and pathogenesis of hidradenitis suppurativa. 62
33048349 2020
1035
Patients with a familial predisposition to hidradenitis suppurativa have a distinct clinical phenotype. 62
32289402 2020
1036
Profile of smoking dependency in hidradenitis suppurativa patients and smoking cessation outcomes. 62
32311802 2020
1037
Hidradenitis suppurativa is associated with childhood and lifetime traumatic events: a case-control study. 62
32692875 2020
1038
Concomitant Hidradenitis Suppurativa and Eruptive Xanthomas Presenting with Phimosis - The Importance of Timely Diagnosis. 62
33422169 2020
1039
Surgical management of advanced hidradenitis suppurativa via a one-stage procedure: A single-center experience. 62
33051068 2020
1040
[Intense pulsed light treatment for hidradenitis suppurativa: a within-person randomized controlled trial]. 62
33300880 2020
1041
Quantifying the natural variation in lesion counts over time in untreated hidradenitis suppurativa: Implications for outcome measures and trial design. 62
34409342 2020
1042
Tumescent triamcinolone infiltration: A new approach for the management of recalcitrant hidradenitis suppurativa. 62
33294572 2020
1043
Systemic Steroids in the Management of Moderate-to-severe Hidradenitis Suppurativa. 62
32663444 2020
1044
Early health economic modelling for a treatment candidate in hidradenitis suppurativa. 62
33084453 2020
1045
An oral supplementation based on myo-inositol, folic acid and liposomal magnesium may act synergistically with antibiotic therapy and can improve metabolic profile in patients affected by Hidradenitis suppurativa: our experience. 62
30249083 2020
1046
Prevalence of Neuropathic Pain and Related Characteristics in Hidradenitis Suppurativa: A Cross-Sectional Study. 62
33333779 2020
1047
Further evidence for the immediate knowledge improvement through EADV Schools on hidradenitis suppurativa/acne inversa. 62
32535980 2020
1048
Impact of a hidradenitis suppurativa patient decision aid on treatment decision making: A randomized controlled trial. 62
34409339 2020
1049
Formulation, long-term physicochemical and microbiological stability of 15% topical resorcinol for hidradenitis suppurativa. 62
33328205 2020
1050
Assessing the risk of adalimumab use for hidradenitis suppurativa during the COVID-19 pandemic. 62
32735966 2020
1051
What counts? The relationship between patient estimated numbers of painful hidradenitis suppurativa lesions over 4 weeks compared with clinician's lesion count at the time of examination. 62
32488900 2020
1052
[Impact of an educational campaign by WhatsAppⓇ on hidradenitis suppurativa among the walk-in clinic physicians of a University Hospital]. 62
33351392 2020
1053
Clinical pearl: Expanding knowledge of emergency contraception among dermatologists. 62
33898718 2020
1054
Spironolactone in dermatology: uses in acne and beyond. 62
32844462 2020
1055
MRSA septic pulmonary emboli presenting as isolated focal chest pain in an adolescent. 62
32994851 2020
1056
Report from the International Dermatology Outcome Measures Initiative. 62
33099394 2020
1057
Skin scars and wrinkles temporary camouflage in dermatology and oncoesthetics: focus on acetyl hexapeptide-8 62
33151254 2020
1058
Topical antibiotics in the dermatological clinical practice: Indications, efficacy, and adverse effects. 62
32531105 2020
1059
Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1. 62
32880206 2020
1060
Risk of keratinocyte carcinoma among patients with hidradenitis suppurativa. 62
32473027 2020
1061
Occurrence and risk factors of depression in patients with hidradenitis suppurativa. 62
32707258 2020
1062
Inframammary Hidradenitis Suppurativa: An optimal surgical approach to a challenging region. 62
32761658 2020
1063
Delivery of high-dose radiation for recurrence of breast cancer in a patient with hidradenitis suppurativa. 62
33257394 2020
1064
Emergency Doctor's ability to diagnose Hidradenitis Suppurativa. 62
32330318 2020
1065
Cortexolone 17α-propionate for hidradenitis suppurativa. 62
32761708 2020
1066
Surgical Treatment of Intermammary Hidradenitis Suppurativa With a 3-Point Advancement Flap (Mercedes Closure). 62
31453909 2020
1067
Intralesional therapy under ultrasound guidance in hidradenitis suppurativa: The importance of ultrasound evaluation. 62
32737957 2020
1068
What has changed in the UK management of hidradenitis suppurativa from 2014 to 2019? 62
32510572 2020
1069
Commentary on "Surgical and postsurgical wound care in hidradenitis suppurativa". 62
32713124 2020
1070
Reply to: ''Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis". 62
32682024 2020
1071
Non-contrast-enhanced 3-Tesla Magnetic Resonance Imaging Using Surface-coil and Sonography for Assessment of Hidradenitis Suppurativa Lesions. 62
32945342 2020
1072
Development of a hidradenitis suppurativa patient decision aid. 62
33342169 2020
1073
A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS. 62
32677247 2020
1074
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic. 62
32558071 2020
1075
New-onset depression among children, adolescents, and adults with hidradenitis suppurativa. 62
32446831 2020
1076
Alleviating and exacerbating foods in hidradenitis suppurativa. 62
32860476 2020
1077
Validity of EQ-5D-5L, Skindex-16, DLQI and DLQI-R in patients with hidradenitis suppurativa. 62
32618022 2020
1078
Coverage losses of substance in the shoulder. 62
32807532 2020
1079
Secukinumab may be remedy for systemic amyloidosis findings secondary to hidradenitis suppurativa. 62
32829493 2020
1080
SAPHO syndrome: the supposed trigger by isotretinoin, the efficacy of adalimumab and the specter of depressive disorder: a case report. 62
33187546 2020
1081
Biologic Therapy for Hidradenitis Suppurativa Plus Conglobate Acne Associated with SAPHO Syndrome: A Case Report. 62
33074337 2020
1082
Cytokine Pathways and Investigational Target Therapies in Hidradenitis Suppurativa. 62
33182701 2020
1083
The effect of subcutaneous brodalumab on clinical disease activity in hidradenitis suppurativa: An open-label cohort study. 62
32416208 2020
1084
"Hidradenitis Suppurativa" Is a Historical Term That Does Not Reflect the Current Understanding of Disease Pathogenesis. 62
32628519 2020
1085
Retrospective cohort study of pregnancy outcomes in hidradenitis suppurativa. 62
32333790 2020
1086
Sirolimus as combination rescue therapy with tumor necrosis alpha inhibitors for severe, refractory hidradenitis suppurativa. 62
32565204 2020
1087
Lymph node involvement in hidradenitis suppurativa: Ultrasound and color Doppler study of 85 patients. 62
32585058 2020
1088
Clinical selection criteria in new clinical trials of hidradenitis suppurativa: External validity and implications on the daily clinical practice. 62
32860480 2020
1089
Certolizumab pegol for hidradenitis suppurativa: Case report and literature review. 62
33135826 2020
1090
Metabolic, pharmacokinetic, and toxicological issues of biologic therapies currently used in the treatment of hidradenitis suppurativa. 62
32896186 2020
1091
Immunomodulatory drugs alone and adjuvant to surgery for hidradenitis suppurativa/acne inversa-A narrative review. 62
32558202 2020
1092
Physician severity scores correlate poorly with health-related quality of life in patients with Hidradenitis Suppurativa. 62
32348584 2020
1093
Sexuality in Patients with Hidradenitis Suppurativa: Beliefs, Behaviors and Needs. 62
33260862 2020
1094
Severe hidradenitis suppurativa successfully treated with secukinumab. 62
32544258 2020
1095
Increased prevalence of family history of Alzheimer's disease in hidradenitis suppurativa: Cross-sectional analysis of 192 HS patients. 62
32820841 2020
1096
Sequential paradoxical psoriasiform reaction and sacroiliitis following adalimumab treatment of hidradenitis suppurativa, successfully treated with guselkumab. 62
32790040 2020
1097
Tildrakizumab in the treatment of moderate-to-severe hidradenitis suppurativa. 62
32627843 2020
1098
The prevalence of hidradenitis suppurativa is shown by the Secure Anonymised Information Linkage (SAIL) Databank to be one per cent of the population of Wales. 62
32433788 2020
1099
Effectiveness of secukinumab in hidradenitis suppurativa: an open study (20 cases). 62
32401354 2020
1100
Extracellular matrix graft for the surgical management of Hurley stage III hidradenitis suppurativa: a pilot case series. 62
33175626 2020
1101
Effectiveness and safety of ustekinumab in patients with hidradenitis suppurativa using intravenous induction. 62
32700796 2020
1102
Intralesional ultrasound-guided combined treatment with triamcinolone plus lincomycin in hidradenitis suppurativa: A pilot study. 62
32589335 2020
1103
Clinical experience with adalimumab biosimilar imraldi in hidradenitis suppurativa. 62
33030281 2020
1104
Infliximab-induced neutrophilic eccrine hidradenitis in a patient with hidradenitis suppurativa. 62
32589317 2020
1105
Efficacy of topical ichthammol 10% for hidradenitis suppurativa: Case series and systematic review of its use in dermatology. 62
32558051 2020
1106
COVID-19 occurrence in one secukinumab-treated patient affected by hidradenitis suppurativa and systemic lupus erythematosus. 62
32966593 2020
1107
Hidradenitis suppurativa and Down syndrome: A systematic review and meta-analysis. 62
32892406 2020
1108
Fluorine-18 Fluorodeoxyglucose PET/CT Images of Hidradenitis Suppurativa Mimicking Metastasis in a Patient With Small Cell Lung Carcinoma. 62
33409018 2020
1109
Ultrasound Morphologic Features of Steatocystoma Multiplex With Clinical Correlation. 62
32356597 2020
1110
The deregulation of NOTCH pathway, inflammatory cytokines, and keratinization genes in two Dowling-Degos disease patients with hidradenitis suppurativa. 62
33200913 2020
1111
Serum irisin level, insulin resistance, and lipid profiles in patients with hidradenitis suppurativa: a case-control study. 62
33008659 2020
1112
Notch Signaling Regulation in Autoinflammatory Diseases. 62
33238371 2020
1113
Apremilast in dermatology: A review of literature. 62
32876993 2020
1114
A Molecular Perspective on the Potential Benefits of Metformin for the Treatment of Inflammatory Skin Disorders. 62
33255783 2020
1115
Correlation between Depression, Quality of Life and Clinical Severity in Patients with Hidradenitis Suppurativa. 62
32985674 2020
1116
Cellulitis-like Sweet Syndrome caused by adalimumab therapy for severe hidradenitis suppurativa. 62
32567672 2020
1117
Management of patients with hidradenitis suppurativa during the COVID-19 pandemic: Risk and benefit of immunomodulatory therapy. 62
32860474 2020
1118
Hidradenitis Suppurativa in a Patient Affected by Mayer-Rokitansky-Küster-Hauser Syndrome: Insight into the Role of Hormones in HS. 62
33313053 2020
1119
Six cases of Solobacterium moorei isolated alone or in mixed culture in Hungary and comparison with previously published cases. 62
32777291 2020
1120
Novel nicastrin mutation in hidradenitis suppurativa-Dowling-Degos disease clinical phenotype: more than just clinical overlap? 62
32282940 2020
1121
Circulating levels of adiponectin, leptin, resistin and visfatin in non-diabetics patients with hidradenitis suppurativa. 62
31786710 2020
1122
A Novel NCSTN Gene Mutation in a Japanese Family with Hidradenitis Suppurativa. 62
32926179 2020
1123
PAPA spectrum disorders. 62
32618443 2020
1124
Spironolactone in Dermatology: Uses in Acne, Hidradenitis Suppurativa, Female Pattern Baldness, and Hirsutism. 62
32571540 2020
1125
A novel nicastrin mutation in a three-generation Dutch family with hidradenitis suppurativa: a search for functional significance. 62
32078194 2020
1126
Updates on treatment guidelines for psoriasis, atopic dermatitis (eczema), hidradenitis suppurativa, and acne/rosacea during the COVID-19 pandemic. 62
33147660 2020
1127
Botulinum Toxin Type B for Hidradenitis Suppurativa: A Randomised, Double-Blind, Placebo-Controlled Pilot Study. 62
32761500 2020
1128
Pre-operative ultrasound planning in the surgical management of patients with hidradenitis suppurativa. 62
32267015 2020
1129
Transcriptomic analysis of hidradenitis suppurativa skin suggests roles for multiple inflammatory pathways in disease pathogenesis. 62
32661800 2020
1130
Malignancy and infection risk during adalimumab therapy in hidradenitis suppurativa. 62
32358868 2020
1131
[Endocrinological mechanisms in the pathophysiology of hidradenitis suppurativa]. 62
32886132 2020
1132
Global Hidradenitis Suppurativa COVID-19 Registry: a registry to inform data-driven management practices. 62
32597495 2020
1133
Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. 62
32853177 2020
1134
Low Prevalence of GSC Gene Mutations in a Large Cohort of Predominantly Caucasian Patients with Hidradenitis Suppurativa. 62
32142795 2020
1135
Dysregulation of tryptophan catabolism at the host-skin microbiota interface in hidradenitis suppurativa. 62
32970636 2020
1136
Experience in patients with hidradenitis suppurativa and COVID-19 symptoms. 62
32603717 2020
1137
Immunopathogenesis of hidradenitis suppurativa and response to anti-TNF-α therapy. 62
32841223 2020
1138
Male granulomatous mastitis with hidradenitis suppurativa, a rarely encountered disorder. 62
32515519 2020
1139
Hidradenitis suppurativa publications are sparse in frontline specialties. 62
32294228 2020
1140
Disease characteristics in female and male patients with hidradenitis suppurativa. 62
32294242 2020
1141
Multidisciplinary Update on Genital Hidradenitis Suppurativa: A Review. 62
32838413 2020
1142
Hidradenitis Suppurativa in the Military. 62
33186426 2020
1143
Dapsone therapy for hidradenitis suppurativa. 62
32294243 2020
1144
Color Doppler ultrasound: a standard of care in hidradenitis suppurativa. 62
32314414 2020
1145
A Giant Squamous Cell Carcinoma Arising in a Patient with Hidradenitis Suppurativa. 62
32773439 2020
1146
Development of inflammatory nodules and scarring mimicking hidradenitis suppurativa after treatment of axillary hyperhidrosis using a microwave-based energy device. 62
32995428 2020
1147
Moderate to Severe Hidradenitis Suppurativa Successfully Treated With Secukinumab. 62
32553985 2020
1148
Publisher Correction: Ultrasound-assisted intralesional corticosteroid infiltrations for patients with hidradenitis suppurativa. 62
33051509 2020
1149
May COVID-19 outbreaks lead to a worsening of skin chronic inflammatory conditions? 62
32492559 2020
1150
High and discordant prevalences of clinical and sonographic enthesitis in patients with hidradenitis suppurativa. 62
32294241 2020
1151
Medical therapy is the optimal treatment for hidradenitis suppurativa. 62
32171810 2020
1152
Hidradenitis suppurativa: New drugs, old challenges. 62
32413451 2020
1153
Validation of the Three-Item Skindex-Mini Among Hidradenitis Suppurativa Patients With Diverse Racial Backgrounds. 62
32469259 2020
1154
Giant escrotal hidradenitis suppurativa. 62
32648437 2020
1155
Association of Human Leukocyte Antigens Class II Variants with Susceptibility to Hidradenitis Suppurativa in a Caucasian Spanish Population. 62
32992947 2020
1156
Food allergy-exacerbated atypical hidradenitis suppurativa. 62
32389796 2020
1157
Publication trends in hidradenitis suppurativa from 2008 to 2018. 62
31968146 2020
1158
Epicardial fat thickness is ıncreased and associated with disease severity in hidradenitis suppurativa. 62
31894390 2020
1159
Neoadjuvant Biologic Therapy in the Surgical Management of Patients with Hidradenitis Suppurativa: A Cohort Study. 62
32830282 2020
1160
An Internet-based survey study of patients with hidradenitis suppurativa: Use of the Internet for disease-related information. 62
31857107 2020
1161
Hidradenitis suppurativa and risk of suicide - systematic review and meta-analysis. 62
31063002 2020
1162
Work impairment in a woman with severe hidradenitis suppurativa after delayed diagnosis: A call for action. 62
33015296 2020
1163
Surgery is an essential aspect of managing patients with hidradenitis suppurativa. 62
32171813 2020
1164
The Surface Microbiome of Clinically Unaffected Skinfolds in Hidradenitis Suppurativa: A Cross-Sectional Culture-Based and 16S rRNA Gene Amplicon Sequencing Study in 60 Patients. 62
32339539 2020
1165
Remote management of hidradenitis suppurativa in a pandemic era of COVID-19. 62
32578210 2020
1166
Emerging drugs for the treatment of hidradenitis suppurativa. 62
32667213 2020
1167
Hidradenitis suppurativa in paediatric patients: a retrospective monocentric study in Germany and review of the literature. 62
32324936 2020
1168
Physical symptoms and psychosocial problems associated with hidradenitis suppurativa: correlation with Hurley stage. 62
33054933 2020
1169
Anger, Emotional Fragility, Self-esteem, and Psychiatric Comorbidity in Patients with Hidradenitis Suppurativa/Acne Inversa. 62
31222671 2020
1170
Standardizing Hidradenitis Suppurativa Skin Microbiome Research: The Methods Matter. 62
32800181 2020
1171
Hidradenitis suppurativa and pemphigus: a cross-sectional study. 62
32034471 2020
1172
Association between major depressive disorder and subsequent autoimmune skin diseases: A nationwide population-based cohort study. 62
32469824 2020
1173
Dermatologic conditions in Down syndrome: A single-center retrospective chart review. 62
32519435 2020
1174
Association between hidradenitis suppurativa, depression, anxiety, and suicidality: A systematic review and meta-analysis. 62
31862404 2020
1175
Association of retinol binding protein4 (RBP4) and ghrelin plasma levels with insulin resistance and disease severity in non-diabetic patients with hidradenitis suppurativa. 62
32564394 2020
1176
Presentation of a Large and Debilitating Fungating Anogenital Lesion. 62
32531464 2020
1177
Mucinous adenocarcinoma of the buttock associated with hidradenitis: A case report. 62
33024779 2020
1178
Multimorbidity and mortality risk in hospitalized adults with chronic inflammatory skin disease in the United States. 62
32047999 2020
1179
Trends and Perspectives for Dermatological Research in Europe: An Abstract Title Analysis of ESDR and IID Congresses 2010-2019. 62
32800177 2020
1180
Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa. 62
32459291 2020
1181
Cutaneous Manifestations in a Patient With Reactive Hemophagocytic Lymphohistiocytosis. 62
32874817 2020
1182
Dissecting Cellulitis of the Scalp: A Review and Case Studies of Surgical Reconstruction. 62
32983774 2020
1183
The impact of hidradenitis suppurativa on general health is higher than that of hypertension, congestive heart failure, type 2 diabetes, myocardial infarction and depression. 62
32043666 2020
1184
Oral Metformin for Treating Dermatological Diseases: A Systematic Review. 62
32845585 2020
1185
Hidradenitis Suppurativa is Associated with Non-alcoholic Fatty Liver Disease: A Cross-sectional Study. 62
32725250 2020
1186
The prevalence and odds of anxiety and depression in children and adults with hidradenitis suppurativa: Systematic review and meta-analysis. 62
32222447 2020
1187
Kyrle disease associated with hidradenitis suppurativa successfully treated with tumour necrosis factor inhibition. 62
32058641 2020
1188
Renbök phenomenon in a Down syndrome patient with hidradenitis suppurativa and alopecia areata. 62
32969807 2020
1189
Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors. 62
32500484 2020
1190
IL-17 in inflammatory skin diseases psoriasis and hidradenitis suppurativa. 62
32379344 2020
1191
Quality of Life in Cohabitants of Patients with Hidradenitis Suppurativa: A Cross-sectional Study. 62
32824800 2020
1192
New insights into mechanism of Notch signaling in hidradenitis suppurativa. 62
29998713 2020
1193
Ultrasound-assisted intralesional corticosteroid infiltrations for patients with hidradenitis suppurativa. 62
32770058 2020
1194
Recurrence Rates Following Excision of Hidradenitis Suppurativa: A Systematic Review and Meta-analysis. 62
32235148 2020
1195
Expression of koebnerisin (S100A15) and calgranulin A (S100A8) in lesional and perilesional skin in patients suffering from hidradenitis suppurativa. 62
32119136 2020
1196
Clinical characteristics of hidradenitis suppurativa patients in Okinawa, Japan: Differences between East Asia and Western countries. 62
32458466 2020
1197
Emerging medical treatments for hidradenitis suppurativa. 62
32289386 2020
1198
The Asia Pacific Hidradenitis Suppurativa (APHiS) foundation: promoting hidradenitis suppurativa research in the Asia Pacific. 62
32436230 2020
1199
Hidradenitis suppurativa on Facebook: thematic and content analyses of patient support group. 62
31845011 2020
1200
Anti-Saccharomyces cervisiae antibodies in hidradenitis suppurativa: More than a gut feeling. 62
32362531 2020
1201
Anti-Saccharomyces cerevisiae antibodies could reflect distinct phenotypes in hidradenitis suppurativa. 62
32482529 2020
1202
Anti-Saccharomyces cerevisiae IgG and IgA antibodies are associated with systemic inflammation and advanced disease in hidradenitis suppurativa. 62
32061710 2020
1203
Factors affecting quality of life in patients with hidradenitis suppurativa. 62
31848682 2020
1204
Exploring the risk of severe COVID-19 infection in patients with hidradenitis suppurativa. 62
32389715 2020
1205
Baseline Characteristics from UNITE: An Observational, International, Multicentre Registry to Evaluate Hidradenitis Suppurativa (Acne Inversa) in Clinical Practice. 62
32077014 2020
1206
A Phase II Open-Label Study of Bermekimab in Patients with Hidradenitis Suppurativa Shows Resolution of Inflammatory Lesions and Pain. 62
32004568 2020
1207
The Hidradenitis Suppurativa Quality of Life (HiSQOL) score: development and validation of a measure for clinical trials. 62
31705538 2020
1208
Hidradenitis suppurativa/acne inversa: a prospective bacteriological study and review of the literature. 62
29683279 2020
1209
Psychosocial burden of Hidradenitis Suppurativa patients' partners. 62
32003871 2020
1210
Cross-sectional study identifies lower risk of Staphylococcus aureus nasal colonization in Danish blood donors with hidradenitis suppurativa symptoms. 62
32078163 2020
1211
The patient experience of pain in hidradenitis suppurativa. 62
32134499 2020
1212
Faecal calprotectin in hidradenitis suppurativa: a study of 55 patients. 62
32969802 2020
1213
Ultrasound: an indispensable tool to evaluate the outcome of surgical approaches in patients affected by hidradenitis suppurativa. 62
32180267 2020
1214
Prevalence of hidradenitis suppurativa in Malta: comparison with established epidemiological data. 62
32367586 2020
1215
Office-Based Surgical Intervention for Hidradenitis Suppurativa (HS): A Focused Review for Dermatologists. 62
32435998 2020
1216
Efficacy of oral zinc and nicotinamide as maintenance therapy for mild/moderate hidradenitis suppurativa: A controlled retrospective clinical study. 62
32339699 2020
1217
Atherogenic index of plasma is associated with the severity of Hidradenitis Suppurativa: a case-control study. 62
32861241 2020
1218
Primary imputation methods impact efficacy results in hidradenitis suppurativa clinical trials. 62
32247874 2020
1219
Response to Raschi E et al. 'Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction'. 62
32189381 2020
1220
Reduced reporting of neuropsychiatric adverse events with tumor necrosis factor alpha inhibitors for hidradenitis suppurativa: caution before concluding for risk reduction. 62
32191362 2020
1221
Creation of a severity index for hidradenitis suppurativa that includes a validated quality-of-life measure: the HIDRAscore. 62
32119143 2020
1222
Measuring treatment response to adalimumab in hidradenitis suppurativa patients: An observational study. 62
32065658 2020
1223
Hidradenitis suppurativa: The importance of virtual outpatient care during COVID-19 pandemic. 62
32360857 2020
1224
Hidradenitis suppurativa prevalence in Berekum, Ghana: A cross-sectional study and initial validation of a questionnaire in an African setting. 62
34409310 2020
1225
Ex Vivo Models and Interpretation of Mechanistic Studies in Hidradenitis Suppurativa. 62
32571498 2020
1226
9th Conference of the European Hidradenitis Suppurativa Foundation, 5-7 February 2020, Athens, Greece. 62
32691940 2020
1227
Hidradenitis Suppurativa: Surgical and Postsurgical Management. 62
32903939 2020
1228
Effect of Hidradenitis Suppurativa Disease Duration on Psychiatric Comorbidity. 62
32556339 2020
1229
Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications. 62
31940465 2020
1230
Amyloidosis in hidradenitis suppurativa: a cross-sectional study and review of the literature. 62
31989656 2020
1231
Description of a disease activity proforma for documentation of hidradenitis suppurativa severity and distribution, and suggestions for use as a patient-reported outcome measure. 62
31885089 2020
1232
Identification of Hidradenitis Suppurativa-Related mRNA Expression Patterns Through Analysis of Gene Expression Omnibus. 62
32782449 2020
1233
Increased risk of permanent stoma in Crohn's disease associated with hidradenitis suppurativa: a case-control study. 62
32525586 2020
1234
Smart wound closure: A novel technique for the surgical treatment of hidradenitis suppurativa. 62
32484585 2020
1235
Hidradenitis suppurativa for the nondermatology clinician. 62
33100533 2020
1236
Response to Ring et al.: In Silico Predictive Metagenomic Analyses Highlight Key Metabolic Pathways Impacted in the Hidradenitis Suppurativa Skin Microbiome. 62
32088206 2020
1237
Advanced evaluation of hidradenitis suppurativa with ultra-high frequency ultrasound: A promising tool for the diagnosis and monitoring of disease progression. 62
31825113 2020
1238
Quality of life in people living with patients suffering from hidradenitis suppurativa. 62
32118320 2020
1239
Moderate-to-severe hidradenitis suppurativa under systemic therapy during the COVID-19 outbreak. 62
32447800 2020
1240
Successful use of guselkumab in the treatment of severe hidradenitis suppurativa. 62
32068912 2020
1241
Hidradenitis suppurativa is an autoinflammatory keratinization disease: A review of the clinical, histologic, and molecular evidence. 62
34409324 2020
1242
Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab. 62
31954061 2020
1243
Hair follicle stem cell replication stress drives IFI16/STING-dependent inflammation in hidradenitis suppurativa. 62
32240121 2020
1244
Adalimumab for treatment of hidradenitis suppurativa during the COVID-19 pandemic: Safety considerations. 62
32283230 2020
1245
Altered keratinization and vitamin D metabolism may be key pathogenetic pathways in syndromic hidradenitis suppurativa: a novel whole exome sequencing approach. 62
32518053 2020
1246
Hidradenitis suppurativa and psychiatric comorbidities, suicides and substance abuse: systematic review and meta-analysis. 62
32793666 2020
1247
Predictive Metagenomic Analysis Reveals a Role of Cutaneous Dysbiosis in the Development of Hidradenitis Suppurativa. 62
31838125 2020
1248
Reduced risk of suicidal behaviours associated with the treatment of hidradenitis suppurativa with tumour necrosis factor alpha antagonists: results from the US FDA Adverse Events Reporting System pharmacovigilance database. 62
31981260 2020
1249
Questionnaire-based epidemiological study of hidradenitis suppurativa in Japan revealing characteristics different from those in Western countries. 62
32441411 2020
1250
Psychiatric comorbidities in patients with hidradenitis suppurativa. 62
32385861 2020
1251
Understanding the Relationship Between Smoking and Hidradenitis Suppurativa. 62
32650845 2020
1252
Systematic Review of Complications and Recurrences After Surgical Interventions in Hidradenitis Suppurativa. 62
32049703 2020
1253
Lesional Inflammatory Profile in Hidradenitis Suppurativa Is Not Solely Driven by IL-1. 62
32081612 2020
1254
Support group utilization and impact for patients with hidradenitis suppurativa. 62
31541749 2020
1255
Endpoints of clinical trials for Hidradenitis Suppurativa: Proceedings of a round-table session. 62
32691939 2020
1256
Hidradenitis suppurativa at the knees. 62
32898405 2020
1257
Hidradenitis suppurativa management using tumor necrosis factor inhibitors in patients younger than 18 years: A series of 12 cases. 62
32151626 2020
1258
Ixekizumab: An efficacious treatment for both psoriasis and hidradenitis suppurativa. 62
32495491 2020
1259
Pyoderma gangrenosum and suppurative hidradenitis association, overlap or spectrum of the same disease? Case report and discussion. 62
32508990 2020
1260
Teledermatologic monitoring for chronic cutaneous autoimmune diseases with smartworking during COVID-19 emergency in a tertiary center in Italy. 62
32458588 2020
1261
Apocrine glands are bystanders in hidradenitis suppurativa and their involvement is gender specific. 62
32031713 2020
1262
COVID-19 knowledge prevents biologics discontinuation: Data from an Italian multicenter survey during RED-ZONE declaration. 62
32415727 2020
1263
Dowling-Degos Disease with Follicular Involvement Associated with Hidradenitis Suppurativa: A Manifestation of Follicular Occlusion Phenomenon? 62
32831371 2020
1264
Association of Birth Weight, Childhood Body Mass Index, and Height With Risk of Hidradenitis Suppurativa. 62
32347905 2020
1265
Disease Trajectories for Hidradenitis Suppurativa in the Danish Population. 62
32432647 2020
1266
Nevus Comedonicus Suppurativa: A Report of a Novel Entity. 62
32884617 2020
1267
Hidradenitis suppurativa and risk for development of Clostridium difficile colitis. 62
32010962 2020
1268
A case of Atopic dermatitis and Hidradenitis Suppurativa successfully treated with Dupilumab. 62
32034813 2020
1269
The Association Between Oral Health and Skin Disease. 62
32884621 2020
1270
Managing Cutaneous Immune-Mediated Diseases During the COVID-19 Pandemic. 62
32277351 2020
1271
The Use of TNFα Inhibitors in Treating Pediatric Skin Disorders. 62
32350817 2020
1272
Dermatology Resident Training on Depression Screening: A Cross-Sectional Survey. 62
32754401 2020
1273
Pleiotropic Role of Notch Signaling in Human Skin Diseases. 62
32545758 2020
1274
Hidradenitis Suppurativa and Crohn Disease: A Rare Association. 62
32304573 2020
1275
Polyclonal gammopathy in an adolescent affected by Dent disease 2 and hidradenitis suppurativa. 62
31971248 2020
1276
Treatment of hidradenitis suppurativa: Surgery and yeast (Saccharomyces cerevisiae)-exclusion diet. Results after 6 years. 62
32098690 2020
1277
Anti-TNFα-induced psoriasis under treatment of hidradenitis suppurativa: report of 2 cases. 62
30014684 2020
1278
Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study. 62
30295448 2020
1279
Vulvar and perineal verrucous changes complicating hidradenitis suppurativa after wide excision: a case and literature review. 62
32898403 2020
1280
Baseline patient-reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice. 62
31800124 2020
1281
The role of virtual support groups for patients with hidradenitis suppurativa during the COVID-19 pandemic. 62
32352025 2020
1282
Defining hidradenitis suppurativa phenotypes based on the elementary lesion pattern: results of a prospective study. 62
31919904 2020
1283
Multimodal management of hidradenitis suppurativa. 62
32637538 2020
1284
Methotrexate shows benefit in a subset of patients with severe hidradenitis suppurativa. 62
32637536 2020
1285
Biologic therapies for the treatment of hidradenitis suppurativa. 62
32077334 2020
1286
Clinical response rate and flares of hidradenitis suppurativa in the treatment with adalimumab. 62
31630436 2020
1287
Spironolactone therapy for hidradenitis suppurativa. 62
31602704 2020
1288
Chronic Pain in Hidradenitis Suppurativa Explained Through the Process of Central Sensitization. 62
32267476 2020
1289
Comprehensive approach to managing hidradenitis suppurativa patients. 62
32250448 2020
1290
Successful treatment of recalcitrant gluteal hidradenitis suppurativa with brodalumab after anti-TNF failure. 62
32012238 2020
1291
Identifying barriers to care and research in hidradenitis suppurativa: findings from a patient engagement event. 62
31883104 2020
1292
Evaluation of Hidradenitis Suppurativa Disease Course During Pregnancy and Postpartum. 62
32347884 2020
1293
Hidradenitis suppurativa in a long-lived patient with trisomy 13. 62
32490117 2020
1294
Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: Results of an open-label trial. 62
32044410 2020
1295
The contradictory inefficacy of methotrexate in hidradenitis suppurativa: a need to revise pathogenesis or acknowledge disease heterogeneity? 62
30945961 2020
1296
Integrated multidisciplinary approach to hidradenitis suppurativa in clinical practice,. 62
32637537 2020
1297
Development of New Lesions of Hidradenitis Suppurativa on a Caesarean Section Scar: A Manifestation of the Koebner Phenomenon? 62
32656234 2020
1298
LAight® Therapy Improves Hidradenitis Suppurativa in Patients Declining Surgical Intervention: Two Case Reports. 62
32516428 2020
1299
Clinical and Ultrasonographic Profile of Adalimumab-treated Hidradenitis Suppurativa Patients: A Real-life Monocentric Experience. 62
32421198 2020
1300
Reconstruction for axillary hidradenitis suppurativa using one-stage local tissue rearrangement: A retrospective analysis of 53 cases. 62
32067416 2020
1301
Photobiomodulation therapy is able to decrease IL1B gene expression in an in vitro cellular model of hidradenitis suppurativa. 62
31444612 2020
1302
Correction to: Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice. 62
32207072 2020
1303
Hidradenitis Suppurative: Our Experience with a Surgical Case Management Team. 62
32408974 2020
1304
[Painful nodules on the soles in a pediatric patient: A diagnostic challenge]. 62
32730522 2020
1305
Ultrasonographic assessment of fibrosis in hidradenitis suppurativa fistulae helps in addressing treatment. 62
31762109 2020
1306
Hidradenitis suppurativa associated with pazopanib. 62
32181980 2020
1307
Surgically resected hidradenitis suppurativa: a population-based cost analysis. 62
31774145 2020
1308
Could vascular endothelial growth factor inhibitors induce hidradenitis suppurativa? Report of three patients with renal cancer treated with sunitinib. 62
32181974 2020
1309
Atypical Hidradenitis Suppurativa on the Leg in a Psoriatic Patient. 62
32565572 2020
1310
The impact of hidradenitis suppurativa on work productivity and activity impairment. 62
31707731 2020
1311
Surgical and postsurgical wound care in hidradenitis suppurativa. 62
32083788 2020
1312
Hidradenitis suppurativa encounters in a national electronic health record database notable for low dermatology utilization, infrequent biologic prescriptions, and frequent opiate prescriptions. 62
31866261 2020
1313
Multiple SCCs arising in the gluteal area from patient with short disease duration of hidradenitis suppurativa (hurley I-II): Surgical approach with favorable outcome. 62
32157779 2020
1314
Hidradenitis suppurativa: Epidemiology, clinical presentation, and pathogenesis. 62
31604104 2020
1315
Successful treatment of Sapho syndrome and hidradenitis suppurativa: A therapeutic challenge. 62
32319137 2020
1316
Hidradenitis suppurativa: Current and emerging treatments. 62
31604100 2020
1317
Surgical Management of Pediatric Hidradenitis Suppurativa: A Case Series and Review of the Literature. 62
31913903 2020
1318
Provider landscape for hidradenitis suppurativa patients. 62
31736054 2020
1319
Beyond antibodies: B cells in Hidradenitis Suppurativa: Bystanders, contributors or therapeutic targets? 62
32145106 2020
1320
Enrichment of Plasma Cells in the Peripheral Blood and Skin of Patients with Hidradenitis Suppurativa. 62
31682839 2020
1321
Serum amyloid A and C-reactive protein levels and erythrocyte sedimentation rate are important indicators in hidradenitis suppurativa. 62
31729595 2020
1322
Seventy-MHz Ultrasound Detection of Early Signs Linked to the Severity, Patterns of Keratin Fragmentation, and Mechanisms of Generation of Collections and Tunnels in Hidradenitis Suppurativa. 62
31705709 2020
1323
Intralesional Triamcinolone May Not Be Beneficial for Treating Acute Hidradenitis Suppurativa Lesions: A Double-Blind, Randomized, Placebo-Controlled Trial. 62
31490300 2020
1324
The use of guselkumab 100 mg every 4 weeks on patients with hidradenitis suppurativa and a literature review. 62
32319172 2020
1325
Metformin use in hidradenitis suppurativa. 62
30893570 2020
1326
Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials. 62
31630445 2020
1327
The pharmacology of antibiotic therapy in hidradenitis suppurativa. 62
32364806 2020
1328
New onset vitiligo in a patient with hidradenitis suppurativa treated with adalimumab. 62
32239739 2020
1329
A case of hidradenitis suppurativa successfully treated with apremilast in a patient with psoriasis and SAMPUS. 62
32323441 2020
1330
Dowling-Degos Disease with Hidradenitis Suppurativa and Inflammatory Arthritis in Two Generations. 62
32695705 2020
1331
Patients with hidradenitis suppurativa may suffer from neuropathic pain: A Finnish multicenter study. 62
31730843 2020
1332
Weight counseling in pediatric hidradenitis suppurativa patients. 62
32124482 2020
1333
Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data. 62
31881294 2020
1334
High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. 62
31589948 2020
1335
Atypical Clinical Presentation of Hidradenitis Suppurativa in a Patient with Severe Mannose-Binding Lectin Deficiency. 62
32508615 2020
1336
Body Image Quality of Life in Patients with Hidradenitis Suppurativa Compared with Other Dermatological Disorders. 62
32201901 2020
1337
Sweet syndrome in a patient with Hidradenitis Suppurativa. 62
32274056 2020
1338
[Hidradenitis suppurativa/acne inversa in the genitoanal region]. 62
32077977 2020
1339
Serum IL-36α, IL-36β, and IL-36γ levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome. 62
31722038 2020
1340
IL-17 and its role in inflammatory, autoimmune, and oncological skin diseases: state of art. 62
31663126 2020
1341
Pediatric Endoscopic Hidradenitis Treatment: A New Minimally Invasive Treatment for Pediatric Patients with Hidradenitis Suppurativa. 62
32017645 2020
1342
Hidradenitis suppurativa and smoking: A systematic review and meta-analysis. 62
31678467 2020
1343
No evidence that impaired Notch signalling differentiates hidradenitis suppurativa from other inflammatory skin diseases. 62
31594026 2020
1344
Cryoinsufflation in the presurgical assessment of hidradenitis suppurativa. 62
31836560 2020
1345
Studies on the role of diet in the management of hidradenitis suppurativa are needed. 62
31836565 2020
1346
Reconstruction of bilateral inferomedial gluteal defects after resection of hidradenitis suppurativa with symmetrical keystone flaps designed parallel to relaxed skin-tension lines: A case report. 62
32243413 2020
1347
Efficacy and satisfaction of surgical treatment for hidradenitis suppurativa. 62
31799758 2020
1348
Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa. 62
32098513 2020
1349
Severity and Area Score for Hidradenitis (SASH): a novel outcome measurement for hidradenitis suppurativa. 62
31233623 2020
1350
Alterations in innate immunity and epithelial cell differentiation are the molecular pillars of hidradenitis suppurativa. 62
31838778 2020
1351
Skin Microbiota Perturbations Are Distinct and Disease Severity-Dependent in Hidradenitis Suppurativa. 62
31539533 2020
1352
SAPHO Syndrome from Hidradenitis Suppurativa. 62
32076984 2020
1353
Adalimumab-Induced Neutropenia in a Man With Hidradenitis Suppurativa. 62
31980127 2020
1354
Interleukin 17C is elevated in lesional tissue of hidradenitis suppurativa. 62
31556100 2020
1355
Reply to: "Studies on the role of diet in the management of hidradenitis suppurativa are needed". 62
31837346 2020
1356
Putting nodule counts behind us: hidradenitis suppurativa outcome measures independent of descriptive semantics. 62
31486069 2020
1357
Mammillary Fistula as a Possible Manifestation of Hidradenitis Suppurativa. 62
31902443 2020
1358
[Management of surgical therapy for advanced hidradenitis suppurativa with special consideration of perioperative antibiotic treatment - a questionnaire study]. 62
32259857 2020
1359
Laser and Light-Based Treatment Modalities for the Management of Hidradenitis Suppurativa. 62
31845121 2020
1360
Frequency of circulating subpopulations of T-regulatory cells in patients with hidradenitis suppurativa. 62
31721309 2020
1361
Laser hair reduction for hidradenitis suppurativa warrants insurance coverage. 62
32621692 2020
1362
Factors Affecting Healing in the Treatment of Hidradenitis Suppurativa. 62
31688123 2020
1363
Hyperbaric oxygen therapy (HBOT )can improve the effectiveness of adalimumab in hidradenitis suppurativa. 62
29683280 2020
1364
The International Hidradenitis Suppurativa Severity Score System (IHS4) is a valuable tool to assess gender-associated differences. 62
32281935 2020
1365
[Acne inversa (hidradenitis suppurativa)]. 62
31915870 2020
1366
Exploring the EQ-5D Dimension of Pain/Discomfort in Dermatology Outpatients from a Multicentre Study in 13 European Countries. 62
32250441 2020
1367
[Fake hidradenitis after pregnancy]. 62
31937445 2020
1368
Phagocytosis of Wnt inhibitor SFRP4 by late wound macrophages drives chronic Wnt activity for fibrotic skin healing. 62
32219160 2020
1369
Anti-tumor necrosis factor (TNF)-induced lupus in a patient with hidradenitis suppurativa. 62
31633193 2020
1370
Hidradenitis suppurativa. 62
32165632 2020
1371
Psychiatric diseases from the psychotic spectrum in hidradenitis suppurativa patients: An under-recognized comorbidity. 62
32112616 2020
1372
Flares in hidradenitis suppurativa in treatment with adalimumab. 62
31736161 2020
1373
Lessons learned from the development of a hidradenitis suppurativa xenograft mouse model. 62
31322280 2020
1374
Fatal outcome of malignant transformation of hidradenitis suppurativa: A case report and literature review. 62
32185045 2020
1375
Systematic Review of Light-Based Treatments for Hidradenitis Suppurativa. 62
31870491 2020
1376
Knowledge about and determinants for diagnosing hidradenitis suppurativa by ministry of health primary healthcare physicians in Jeddah city 2019: An analytical cross-sectional study. 62
32509631 2020
1377
Is there an association between hidradenitis suppurativa and fibromyalgia? 62
32352448 2020
1378
Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy-Reply. 62
31913415 2020
1379
Creation of a Registry to Address Knowledge Gaps in Hidradenitis Suppurativa and Pregnancy. 62
31913434 2020
1380
Hidradenitis suppurativa. 62
32165620 2020
1381
Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital-based cohort study. 62
31442338 2020
1382
Case of miliaria rubra histologically showing neutrophilic eccrine hidradenitis due to hyperhidrosis induced by a catecholamine-producing neuroblastoma. 62
31912533 2020
1383
Identification of bacterial DNA in the peripheral blood of patients with active hidradenitis suppurativa. 62
31422449 2020
1384
Loss of Skin Microbial Diversity and Alteration of Bacterial Metabolic Function in Hidradenitis Suppurativa. 62
31465743 2020
1385
A Genetic Variant in the BCL2 Gene Associates with Adalimumab Response in Hidradenitis Suppurativa Clinical Trials and Regulates Expression of BCL2. 62
31465739 2020
1386
Investigating race and gender in age at onset of hidradenitis suppurativa. 62
31736152 2020
1387
A concise clinician's guide to therapy for hidradenitis suppurativa. 62
32258336 2020
1388
Hyperhidrosis affects quality of life in hidradenitis suppurativa: A prospective analysis. 62
31449904 2020
1389
Risk of Inflammatory Arthritis After a New Diagnosis of Hidradenitis Suppurativa. 62
31968066 2020
1390
Special considerations for women with hidradenitis suppurativa. 62
32258337 2020
1391
Relationship between fecal calprotectin level and disease activity in patients with hidradenitis suppurativa. 62
31985885 2020
1392
Work productivity and activity impairment in patients with hidradenitis suppurativa: a cross-sectional study. 62
31736064 2020
1393
Complementary and Alternative Medicine Use in Patients With Hidradenitis Suppurativa. 62
31995122 2020
1394
Umbilical hidradenitis suppurativa symptoms: a case series and review of the literature. 62
32206815 2020
1395
A case of new-onset vitiligo in a patient on tofacitinib and brief review of paradoxical presentations with other novel targeted therapies. 62
32609446 2020
1396
Treatment of lichen planopilaris with adalimumab in a patient with hidradenitis suppurativa and rheumatoid arthritis. 62
32123715 2020
1397
Hidradenitis suppurativa and schizophrenia: a nationwide cohort study. 62
31587377 2020
1398
PsAPASH: a rare and recent autoinflammatory syndrome associated with hidradenitis suppurativa. 62
32063421 2020
1399
Off-label studies on apremilast in dermatology: a review. 62
30935262 2020
1400
Comment on 'The effects of isotretinoin therapy on serum homocysteine, folate and vitamin B12 levels in patients with acne': may retinoids be useful to treat hyperhomocysteinemia found in patients affected by hidradenitis suppurativa? 62
31660646 2020
1401
Biologics for chronic inflammatory skin diseases: an update for the clinician. 62
30827126 2020
1402
Role of the Complement Pathway in Inflammatory Skin Diseases: A Focus on Hidradenitis Suppurativa. 62
31870626 2020
1403
Photobiomodulation as potential novel third line tool for non-invasive treatment of hidradenitis suppurativa. 62
31042851 2020
1404
Associations of cutaneous and extracutaneous infections with hidradenitis suppurativa in U.S. children and adults. 62
31049925 2020
1405
Effects of Zinc Supplementation on Inflammatory Skin Diseases: A Systematic Review of the Clinical Evidence. 62
31745908 2020
1406
Prevalence of inflammatory bowel disease (IBD) in hidradenitis suppurativa (HS): systematic review and adjusted meta-analysis. 62
31631340 2020
1407
Remission of severe hidradenitis suppurativa following chemotherapy for Hodgkin lymphoma. 62
31396947 2020
1408
Follicular occlusion triad: an isotopic response or adverse effect of rituximab? 62
32239887 2020
1409
Review of Comorbidities of Hidradenitis Suppurativa: Implications for Daily Clinical Practice. 62
31955366 2020
1410
A novel NCSTN missense mutation in the signal peptide domain causes hidradenitis suppurativa, which has features characteristic of an autoinflammatory keratinization disease. 62
31421058 2020
1411
Type 2 diabetes mellitus in a cohort of Finnish patients with hidradenitis suppurativa. 62
31596976 2020
1412
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo. 62
31905036 2020
1413
A gene dysfunction module reveals the underlying pathogenesis of hidradenitis suppurativa: An update. 62
31266094 2020
1414
The Role of the Cutaneous Microbiome in Hidradenitis Suppurativa-Light at the End of the Microbiological Tunnel. 62
32054085 2020
1415
Psoriasis as a comorbidity of hidradenitis suppurativa. 62
31591714 2020
1416
Characterizing inpatient hospitalizations for hidradenitis suppurativa in the United States. 62
31541745 2020
1417
Clinical, microbiological, immunological and imaging characteristics of tunnels and fistulas in hidradenitis suppurativa and Crohn's disease. 62
31519056 2020
1418
Low-dose methotrexate as rescue therapy in patients with hidradenitis suppurativa and pyoderma gangrenosum developing human antichimeric antibodies to infliximab: A retrospective chart review. 62
31541746 2020
1419
Association between obesity and hidradenitis suppurativa among children and adolescents: A population-based analysis in the United States. 62
31442534 2020
1420
Factors influencing the local cure rate of hidradenitis suppurativa following wide local excision. 62
31680472 2020
1421
A qualitative analysis of psychological distress in hidradenitis suppurativa. 62
31099891 2020
1422
Hidradenitis suppurativa and polycystic ovarian syndrome: Systematic review and meta-analysis. 62
31261440 2020
1423
Evaluating patients' unmet needs in hidradenitis suppurativa: Results from the Global Survey Of Impact and Healthcare Needs (VOICE) Project. 62
31279015 2020
1424
Dietary and metabolic factors in the pathogenesis of hidradenitis suppurativa: a systematic review. 62
31651051 2020
1425
AKT-dependent hyperproliferation of keratinocytes in familial hidradenitis suppurativa with a NCSTN mutation: a potential role of defective miR-100-5p. 62
31448409 2020
1426
Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. 62
31993474 2020
1427
Hidradenitis suppurativa and infections. 62
31885072 2020
1428
Hidradenitis suppurativa, a rare skin disease. 62
32063633 2020
1429
Concordance of severity scores for photographic assessment of hidradenitis suppurativa. 62
31494929 2020
1430
Complementary and alternative medicine use in hidradenitis suppurativa. 62
31396946 2020
1431
An association between hidradenitis suppurativa and HIV. 62
31407315 2020
1432
The surgeon’s perspective: a retrospective study of wide local excisions taken to healthy subcutaneous fat in the management of advanced hidradenitis suppurativa 62
32109015 2020
1433
Thyroid disorders in patients with hidradenitis suppurativa: A systematic review and meta-analysis. 62
31310843 2020
1434
Standing up together to the shame and stigma associated with hidradenitis suppurativa. 62
31789426 2020
1435
The role of hypothalamus-pituitary-adrenal (HPA)-like axis in inflammatory pilosebaceous disorders. 62
32239884 2020
1436
[Suppurative Hidradenitis]. 62
32108134 2020
1437
Chemotherapy Associated Neutrophilic Eccrine Hidradenitis, an Unusual Case with Eccrine Squamous Syringometaplasia. 62
32064208 2020
1438
Consensus definitions of disease activity in hidradenitis suppurativa: crossing the semantic gap. 62
31583685 2020
1439
Periodic worsening, or flare, in hidradenitis suppurativa: the perspective of people with hidradenitis. 62
31168883 2020
1440
Clinical Characteristics of Hidradenitis Suppurativa Patients from a Reference Centre in Kaunas, Lithuania. 62
31940646 2020
1441
Hidradenitis Suppurativa and Bipolar Disorders: A Role for Lithium Therapy? 62
32036365 2020
1442
Hidradenitis Suppurativa Influences Tattooing Practice in Women. 62
31958793 2020
1443
The pain of hidradenitis suppurativa: 'We only see what we know'. 62
31403175 2020
1444
Could Residents Adequately Assess the Severity of Hidradenitis Suppurativa? Interrater and Intrarater Reliability Assessment of Major Scoring Systems. 62
31487719 2020
1445
Miscarriage as a Complication of Hidradenitis Suppurativa of the Vulva. 62
33149704 2020
1446
A narrative review of the definition of 'flare' in hidradenitis suppurativa. 62
31025310 2020
1447
Clinical Pearls for Managing Hidradenitis Suppurativa Patients of Low Socioeconomic Status. 62
31927547 2020
1448
Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study. 62
31935718 2020
1449
Dietary Intervention: An Essential Part of the Management of Patients Affected by Hidradenitis Suppurativa. 62
31805559 2020
1450
Hidradenitis Suppurativa: The Disease Which Stimulates Researchers and Clinicians. 62
31955165 2020
1451
Hidradenitis Suppurativa Recurrence in a Caesarean Scar. 62
32566337 2020
1452
Leflunomide-Induced Hidradenitis Suppurativa. 62
32148994 2020
1453
The Efficacy and Effectiveness of Non-ablative Light-Based Devices in Hidradenitis Suppurativa: A Systematic Review and Meta-Analysis. 62
33224966 2020
1454
Reply to "Hidradenitis Suppurativa Influences Tattooing Practice in Women". 62
32348983 2020
1455
Surgical treatment of extensive perianal hidradenitis. 62
33242970 2020
1456
Ustekinumab with Intravenous Infusion: Results in Hidradenitis Suppurativa. 62
31288233 2020
1457
Hidradenitis Suppurativa Area and Severity Index (HASI): a pilot study to develop a novel instrument to measure the physical signs of hidradenitis suppurativa. 62
31286486 2020
1458
Pruritus and Malodour in Patients with Hidradenitis Suppurativa: Impact on Quality of Life and Clinical Features Associated with Symptom Severity. 62
31466061 2020
1459
Epidemiology of hidradenitis suppurativa in Germany - an observational cohort study based on a multisource approach. 62
31494987 2020
1460
Hidradenitis Suppurativa: Current Understanding of Pathogenic Mechanisms and Suggestion for Treatment Algorithm. 62
32195261 2020
1461
An Update on Health-Related Quality of Life and Patient-Reported Outcomes in Hidradenitis Suppurativa. 62
32104123 2020
1462
Pain perception in patients with hidradenitis suppurativa. 62
30919930 2020
1463
Integrating complement into the molecular pathogenesis of Hidradenitis Suppurativa. 62
31688984 2020
1464
Rifampin-moxifloxacin-metronidazole combination therapy for severe Hurley Stage 1 Hidradenitis Suppurativa: prospective short-term trial and one-year follow-up in 28 consecutive patients. 62
31931082 2020
1465
Hidradenitis Suppurativa and Thyroid Disease: Systematic Review and Meta-Analysis. 62
31994934 2020
1466
Delayed Diagnosis of Hidradenitis Suppurativa and Its Effect on Patients and Healthcare System. 62
32610312 2020
1467
Hidradenitis Suppurativa or Hidradenitis Suppurativa-Like Lesions Located on Amputation Stumps? Description of 2 Cases. 62
32021860 2020
1468
Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. 62
32408306 2020
1469
Review of imaging technologies used in Hidradenitis Suppurativa. 62
31595571 2020
1470
Hidradenitis Suppurativa and Bipolar Disorders: A Population-Based Study. 62
31910425 2020
1471
Deranged Iron Status Evidenced by Iron Deficiency Characterizes Patients with Hidradenitis Suppurativa. 62
31927542 2020
1472
Intralesional Triamcinolone for Fistulous Tracts in Hidradenitis Suppurativa: An Uncontrolled Prospective Trial with Clinical and Ultrasonographic Follow-Up. 62
31141811 2020
1473
Infrared thermography and color Doppler: Two combined tools for assessing inflammation in hidradenitis suppurativa. 62
31342563 2020
1474
Hidradenitis Suppurativa in Sweden: A Registry-Based Cross-Sectional Study of 13,538 Patients. 62
32015234 2020
1475
Hidradenitis suppurativa has an enormous impact on patients' lives. 62
31302191 2020
1476
Paradoxical Hidradenitis Suppurativa in Patients Receiving TNF-α Inhibitors: Case Series, Systematic Review, and Case Meta-Analysis. 62
32135533 2020
1477
The most recent advances in understanding and managing hidradenitis suppurativa. 62
32884675 2020
1478
Prevalence and Impact of Dietary Avoidance among Individuals with Hidradenitis Suppurativa. 62
31678977 2020
1479
Weight Loss and Dietary Interventions for Hidradenitis Suppurativa: A Systematic Review. 62
31502868 2020
1480
Hidradenitis suppurativa: Current understanding, diagnostic and surgical challenges, and developments in ultrasound application. 62
31423654 2020
1481
Staphylococcus aureus Carriage Status in Patients with Hidradenitis Suppurativa: An Observational Cohort Study in a Tertiary Referral Hospital in Athens, Greece. 62
31801143 2020
1482
Evaluation of Cardiovascular Risk in Hidradenitis Suppurativa Patients Using Heart Rate Variability (HRV) Analysis. 62
32695226 2020
1483
Proposed Definitions of Typical Lesions in Hidradenitis Suppurativa. 62
32516781 2020
1484
Secukinumab-induced paradoxical hidradenitis suppurativa. 62
31670893 2020
1485
Demographic and Clinical Features of Hidradenitis Suppurativa in Turkey. 62
31698918 2020
1486
Which Factors Determine Affected Sites in Hidradenitis Suppurativa? 62
31905351 2020
1487
Paradoxical psoriasis induced by TNF-α blockade shows immunological features typical of the early phase of psoriasis development. 62
31577850 2020
1488
Follicular occlusion disorders in Down syndrome patients. 62
31626333 2020
1489
The IL-23/IL-17 Pathway in Inflammatory Skin Diseases: From Bench to Bedside. 62
33281823 2020
1490
Hidradenitis Suppurativa as a Potential Subtype of Autoinflammatory Keratinization Disease. 62
32508815 2020
1491
Long-Term Safety of Adalimumab in 29,967 Adult Patients From Global Clinical Trials Across Multiple Indications: An Updated Analysis. 62
31748904 2020
1492
Ancient friends, revisited: Systematic review and case report of pyoderma gangrenosum-associated autoinflammatory syndromes. 62
33305249 2020
1493
Skin manifestations in spondyloarthritis. 62
33343725 2020
1494
Apremilast for the treatment of hidradenitis suppurativa associated with psoriatic arthritis in multimorbid patients: Case report and review of literature. 62
32000436 2020
1495
Novel variants of MEFV and NOD2 genes in familial hidradenitis suppurativa: A case report. 62
33029352 2020
1496
Spiky follicular mycosis fungoides and hidradenitis suppurativa-like lesions in a patient - complete remission with interferon alpha. 62
31899065 2020
1497
Comparison of Split Thickness Skin Grafts and Flaps in Bilateral Chronic Axillary Hidradenitis Suppurativa. 62
32190593 2020
1498
Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review. 62
31150716 2020
1499
Hidradenitis Suppurativa and 1-Carbon Metabolism: Role of Gut Microbiome, Matrix Metalloproteinases, and Hyperhomocysteinemia. 62
32973741 2020
1500
Cutaneous Effects of Notch Inhibitor Therapy: A Report of Two Cases. 62
32695530 2020
1501
Identifying anaemia in a cohort of patients with hidradenitis suppurativa. 62
31374127 2020
1502
Adalimumab Dose Intensification in Recalcitrant Hidradenitis Suppurativa/Acne Inversa. 62
31630144 2020
1503
Hidradenitis suppurativa in a patient with Warkany syndrome: Sustainability of adalimumab treatment. 62
31705612 2020
1504
The Important Role of Leptin in Modulating the Risk of Dermatological Diseases. 62
33597945 2020
1505
Incidence of Myocardial Infarction and Cerebrovascular Accident in Patients With Hidradenitis Suppurativa. 62
31721983 2020
1506
Hidradenitis Suppurativa: a lesser-known cause of AA amyloidosis. 62
33364737 2020
1507
Risk Factors of Sexual Dysfunction in Patients with Hidradenitis Suppurativa: A Cross-Sectional Study. 62
31434072 2020
1508
Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn's Disease? 62
32943900 2020
1509
Two cases of hidradenitis suppurativa exacerbated by ambulatory aides for myelomeningocele. 62
31788527 2019
1510
Lobular neutrophilic panniculitis associated with DNA methyltransferase inhibitors in the treatment of myeloid disease. 62
31254406 2019
1511
Comorbidities of hidradenitis suppurativa: A review of the literature. 62
31909152 2019
1512
Sleep quality among adult patients with chronic dermatoses. 62
31997991 2019
1513
Pilonidal sinus disease: an intergluteal localization of hidradenitis suppurativa/acne inversa: a cross-sectional study among 2465 patients. 62
30919434 2019
1514
Ustekinumab treatment for hidradenitis suppurativa. 62
31638283 2019
1515
Squamous carcinoma over perineal hidradenitis suppurativa. 62
30825999 2019
1516
Isotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. 62
31455984 2019
1517
Defining lesional, perilesional and unaffected skin in hidradenitis suppurativa: proposed recommendations for clinical trials and translational research studies. 62
31269228 2019
1518
Transcriptome patterns in hidradenitis suppurativa: support for the role of antimicrobial peptides and interferon pathways in disease pathogenesis. 62
30828847 2019
1519
5-ALA PDT successfully treats facial hidradenitis suppurativa-induced severe hypertrophic scar. 62
31614224 2019
1520
High-dosage ustekinumab for the treatment of severe hidradenitis suppurativa. 62
31903963 2019
1521
Is substance use disorder more prevalent in patients with hidradenitis suppurativa? 62
31909153 2019
1522
Increased risk of alopecia areata for people with hidradenitis suppurativa in a cross-sectional study. 62
31582196 2019
1523
Photodynamic therapy combined with surgery for hidradenitis suppurativa: A case report. 62
31362110 2019
1524
Uncommon pretibial bilateral manifestation of Hidradenitis suppurativa (Hurley III) after discontinuation of systemic treatment with adalimumab: a serious reason to prefer surgery as a primary approach? 62
31273867 2019
1525
The Thin bilateral and bipedicled DIEAP flap for axillary reconstruction in hidradenitis suppurativa. 62
31307106 2019
1526
Into the (gluteal) fold: pilonidal disease and hidradenitis suppurativa - association or continuum? 62
31386167 2019
1527
Errata: Review article: Hidradenitis suppurativa: A systematic review and meta-analysis of therapeutic interventions. 62
31512583 2019
1528
Extensive hidradenitis suppurativa with dorsal foot involvement: a case report. 62
31803468 2019
1529
Depression in hidradenitis suppurativa. 62
31099413 2019
1530
Expert Commentary on Hidradenitis Suppurativa. 62
31596760 2019
1531
[Case Report of Pseudomonas Hot-Foot Syndrome in Uppsala, Sweden]. 62
31742652 2019
1532
Hidradenitis Suppurativa. 62
31596759 2019
1533
Improving health literacy and treatment understanding of hidradenitis suppurativa using group educational interventions. 62
30582391 2019
1534
Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review. 62
31290151 2019
1535
Earwax of patients with hidradenitis suppurativa: A retrospective study. 62
31775210 2019
1536
Continued weekly adalimumab is an effective strategy in patients with hidradenitis suppurativa who show at least partial response to therapy at week 12. 62
31494923 2019
1537
Staphylococcus aureus and host interaction in the flare-ups of hidradenitis suppurativa. 62
31403170 2019
1538
Presence of arthralgia exacerbates decreased quality of life in hidradenitis suppurativa patients. 62
32045157 2019
1539
Emotional Well-Being Is Impaired in Hidradenitis Suppurativa Patients. 62
31799265 2019
1540
A new T helper 17 cytokine in hidradenitis suppurativa: antimicrobial and proinflammatory role of interleukin-26. 62
30829398 2019
1541
Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials. 62
30916379 2019
1542
Vulvar squamous cell carcinoma complicating hidradenitis suppurativa in a young woman. 62
31720350 2019
1543
Ultrasound as a diagnostic and management tool in hidradenitis suppurativa patients: a multicentre study. 62
31124183 2019
1544
Long-term therapy with anakinra in hidradenitis suppurativa in three patients. 62
31353451 2019
1545
Don't forget these 5 things when treating hidradenitis suppurativa. 62
31886798 2019
1546
Thalidomide in Severe Hidradenitis Suppurativa: A Therapeutic Option. 62
31314122 2019
1547
Topical timolol for treatment of persistent granulation tissue in the setting of severe hidradenitis suppurativa. 62
32045154 2019
1548
Diet in hidradenitis suppurativa: a review of published and lay literature. 62
31006861 2019
1549
Mass Spectrometry Imaging of Lipids in Human Skin Disease Model Hidradenitis Suppurativa by Laser Desorption Ionization from Silicon Nanopost Arrays. 62
31767918 2019
1550
Color Doppler as a tool for correlating vascularization and pain in hidradenitis suppurativa lesions. 62
31140660 2019
1551
Hidradenitis suppurativa for the dermatologic hospitalist. 62
31886786 2019
1552
Incidence of Long-term Opioid Use Among Opioid-Naive Patients With Hidradenitis Suppurativa in the United States. 62
31509172 2019
1553
Coexistence of steatocystoma multiplex and hidradenitis suppurativa: Assessment of this unique association by means of ultrasonography and Color Doppler. 62
31353757 2019
1554
One drug and two diseases: A case of multidrug-resistant hidradenitis suppurativa and psoriasis treated with apremilast. 62
31577864 2019
1555